{"PMC7396958": [["Seventy years ago, Susan's 92-year-old father's first teaching job was in a one-room schoolhouse in Fayetteville, Maine.", [["father", "ORGANISM", 39, 45]]]], "4a9bdf497f276c36abac9da179a0bb1488617a40": [["Avian oviduct in biomedical researchAvian species are excellent biological models in reproduction and tumorigenesis [1] as well as efficient source of secreting cells for use in bioreactors [2] [3] [4] .", [["oviduct", "ANATOMY", 6, 13], ["cells", "ANATOMY", 161, 166], ["Avian", "ORGANISM", 0, 5], ["oviduct", "ORGAN", 6, 13], ["cells", "CELL", 161, 166], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 190, 201], ["secreting cells", "CELL_TYPE", 151, 166], ["Avian", "SPECIES", 0, 5], ["Avian oviduct in biomedical researchAvian species", "TREATMENT", 0, 49], ["secreting cells", "PROBLEM", 151, 166]]], ["Both hen and quail oviduct cells secrete human therapeutic proteins after genetic modification [3] .", [["oviduct cells", "ANATOMY", 19, 32], ["hen", "ORGANISM", 5, 8], ["quail", "ORGANISM", 13, 18], ["oviduct cells", "CELL", 19, 32], ["human", "ORGANISM", 41, 46], ["hen and quail oviduct cells", "CELL_TYPE", 5, 32], ["human therapeutic proteins", "PROTEIN", 41, 67], ["hen", "SPECIES", 5, 8], ["quail", "SPECIES", 13, 18], ["human", "SPECIES", 41, 46], ["hen", "SPECIES", 5, 8], ["quail", "SPECIES", 13, 18], ["human", "SPECIES", 41, 46], ["Both hen and quail oviduct cells", "TREATMENT", 0, 32], ["human therapeutic proteins", "TREATMENT", 41, 67], ["genetic modification", "TREATMENT", 74, 94]]], ["Therefore the oviduct epithelium is a useful and fast in vitro model to test for the efficiency of viral [5] and nonviral genetic constructs [6] to study the modified secretome.", [["oviduct epithelium", "ANATOMY", 14, 32], ["oviduct epithelium", "TISSUE", 14, 32], ["nonviral genetic constructs", "TREATMENT", 113, 140]]], ["Both quail and hen produce cellular substrates for the development of vaccines [7] .", [["cellular", "ANATOMY", 27, 35], ["quail", "ORGANISM", 5, 10], ["hen", "ORGANISM", 15, 18], ["cellular", "CELL", 27, 35], ["quail", "SPECIES", 5, 10], ["quail", "SPECIES", 5, 10], ["cellular substrates", "TREATMENT", 27, 46]]], ["Genetic markers, including markers of stemness, are useful to identify mechanisms of malignant changes in a fallopian tube, because the somatic stem cells contribute to a population of tumorinitiating cells [8] .", [["fallopian tube", "ANATOMY", 108, 122], ["somatic stem cells", "ANATOMY", 136, 154], ["cells", "ANATOMY", 201, 206], ["fallopian tube", "TISSUE", 108, 122], ["somatic stem cells", "CELL", 136, 154], ["tumorinitiating cells", "CELL", 185, 206], ["somatic stem cells", "CELL_TYPE", 136, 154], ["tumorinitiating cells", "CELL_TYPE", 185, 206], ["Genetic markers", "TEST", 0, 15], ["malignant changes", "PROBLEM", 85, 102], ["a fallopian tube", "TREATMENT", 106, 122], ["the somatic stem cells", "PROBLEM", 132, 154], ["tumorinitiating cells", "PROBLEM", 185, 206], ["malignant", "OBSERVATION", 85, 94], ["fallopian tube", "OBSERVATION", 108, 122], ["stem cells", "OBSERVATION", 144, 154]]], ["Recently, the knowledge about cell differentiation, physiology, and cancerogenic changes in avian oviduct has been extrapolated to women fallopian tube and uterine tract [9, 10] .", [["cell", "ANATOMY", 30, 34], ["oviduct", "ANATOMY", 98, 105], ["fallopian tube", "ANATOMY", 137, 151], ["uterine tract", "ANATOMY", 156, 169], ["cell", "CELL", 30, 34], ["avian", "ORGANISM", 92, 97], ["oviduct", "ORGAN", 98, 105], ["women", "ORGANISM", 131, 136], ["fallopian tube", "MULTI-TISSUE_STRUCTURE", 137, 151], ["uterine tract", "MULTI-TISSUE_STRUCTURE", 156, 169], ["women", "SPECIES", 131, 136], ["cancerogenic changes in avian oviduct", "PROBLEM", 68, 105], ["cell differentiation", "OBSERVATION", 30, 50], ["cancerogenic", "OBSERVATION_MODIFIER", 68, 80], ["oviduct", "ANATOMY", 98, 105], ["uterine tract", "ANATOMY", 156, 169]]], ["However, in avian species, markers of stemness in oviduct cells have not been reported yet.", [["oviduct cells", "ANATOMY", 50, 63], ["oviduct cells", "CELL", 50, 63], ["oviduct cells", "CELL_TYPE", 50, 63], ["stemness in oviduct cells", "PROBLEM", 38, 63], ["stemness", "OBSERVATION", 38, 46], ["oviduct cells", "OBSERVATION", 50, 63]]], ["There is a knowledge gap regarding distinctive features of the epithelial cells in in vitro conditions vs. their status in tissue, which limits full understanding and characterization of this cellular model.", [["epithelial cells", "ANATOMY", 63, 79], ["tissue", "ANATOMY", 123, 129], ["cellular", "ANATOMY", 192, 200], ["epithelial cells", "CELL", 63, 79], ["tissue", "TISSUE", 123, 129], ["cellular", "CELL", 192, 200], ["epithelial cells", "CELL_TYPE", 63, 79], ["the epithelial cells", "PROBLEM", 59, 79], ["epithelial cells", "OBSERVATION", 63, 79]]], ["In this paper, we have made initial attempts to confirm progenitor molecular signatures in oviducts of laying hen (Gallus gallus domesticus) and quail (Coturnix japonica), both in tissue and in cultured oviduct epithelial cells (in vitro assay).", [["progenitor", "ANATOMY", 56, 66], ["oviducts", "ANATOMY", 91, 99], ["tissue", "ANATOMY", 180, 186], ["oviduct epithelial cells", "ANATOMY", 203, 227], ["progenitor", "CELL", 56, 66], ["oviducts", "ORGANISM_SUBDIVISION", 91, 99], ["hen", "ORGANISM_SUBDIVISION", 110, 113], ["Gallus gallus domesticus", "ORGANISM", 115, 139], ["quail", "ORGANISM", 145, 150], ["Coturnix japonica", "ORGANISM", 152, 169], ["tissue", "TISSUE", 180, 186], ["oviduct epithelial cells", "CELL", 203, 227], ["cultured oviduct epithelial cells", "CELL_LINE", 194, 227], ["hen", "SPECIES", 110, 113], ["Gallus gallus", "SPECIES", 115, 128], ["domesticus", "SPECIES", 129, 139], ["quail", "SPECIES", 145, 150], ["Coturnix japonica", "SPECIES", 152, 169], ["hen", "SPECIES", 110, 113], ["Gallus gallus domesticus", "SPECIES", 115, 139], ["quail", "SPECIES", 145, 150], ["Coturnix japonica", "SPECIES", 152, 169], ["progenitor molecular signatures", "PROBLEM", 56, 87], ["laying hen (Gallus gallus domesticus", "TREATMENT", 103, 139], ["quail (Coturnix japonica", "TREATMENT", 145, 169], ["vitro assay", "TEST", 232, 243], ["tissue", "ANATOMY", 180, 186], ["epithelial cells", "OBSERVATION", 211, 227]]], ["We have addressed the following questions: What is the location of progenitor cells in avian oviduct tissue?", [["progenitor cells", "ANATOMY", 67, 83], ["oviduct tissue", "ANATOMY", 93, 107], ["progenitor cells", "CELL", 67, 83], ["avian", "ORGANISM", 87, 92], ["oviduct tissue", "TISSUE", 93, 107], ["progenitor cells", "CELL_TYPE", 67, 83], ["progenitor cells", "TREATMENT", 67, 83], ["progenitor cells", "OBSERVATION", 67, 83], ["oviduct", "ANATOMY", 93, 100]]], ["What is an individual molecular characteristic of distal oviduct tissue compartments?", [["oviduct tissue compartments", "ANATOMY", 57, 84], ["oviduct tissue", "TISSUE", 57, 71], ["distal", "ANATOMY_MODIFIER", 50, 56], ["oviduct tissue", "OBSERVATION", 57, 71]]], ["Is this distinctive characteristic stable once the cells are plated in in vitro condition?", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["stable", "OBSERVATION_MODIFIER", 35, 41]]], ["Is the molecular pattern shared between these two model species (laying hen and quail) used for oviduct studies?", [["oviduct", "ANATOMY", 96, 103], ["hen", "ORGANISM_SUBDIVISION", 72, 75], ["quail", "ORGANISM", 80, 85], ["oviduct", "ORGAN", 96, 103], ["hen", "SPECIES", 72, 75], ["quail", "SPECIES", 80, 85], ["these two model species", "PROBLEM", 40, 63], ["oviduct studies", "TEST", 96, 111], ["molecular pattern", "OBSERVATION", 7, 24], ["two", "OBSERVATION_MODIFIER", 46, 49], ["model species", "OBSERVATION", 50, 63]]], ["Altogether, this study aims to provide a new understanding of molecular characteristic of oviduct epithelial cells in avian species.Adult epithelial cells in the oviductIn adult tissue, epithelial progenitor cells have limited potential to divide and they can develop only into few differentiated cell types.", [["oviduct epithelial cells", "ANATOMY", 90, 114], ["epithelial cells", "ANATOMY", 138, 154], ["oviduct", "ANATOMY", 162, 169], ["adult tissue", "ANATOMY", 172, 184], ["epithelial progenitor cells", "ANATOMY", 186, 213], ["cell", "ANATOMY", 297, 301], ["oviduct epithelial cells", "CELL", 90, 114], ["epithelial cells", "CELL", 138, 154], ["oviduct", "ORGAN", 162, 169], ["tissue", "TISSUE", 178, 184], ["epithelial progenitor cells", "CELL", 186, 213], ["cell", "CELL", 297, 301], ["oviduct epithelial cells", "CELL_TYPE", 90, 114], ["Adult epithelial cells", "CELL_TYPE", 132, 154], ["epithelial progenitor cells", "CELL_TYPE", 186, 213], ["differentiated cell types", "CELL_TYPE", 282, 307], ["this study", "TEST", 12, 22], ["oviduct epithelial cells in avian species", "PROBLEM", 90, 131], ["Adult epithelial cells in the oviduct", "PROBLEM", 132, 169], ["epithelial progenitor cells", "PROBLEM", 186, 213], ["oviduct epithelial cells", "OBSERVATION", 90, 114], ["avian species", "OBSERVATION", 118, 131], ["epithelial cells", "OBSERVATION", 138, 154], ["oviduct", "ANATOMY", 162, 169], ["adult tissue", "OBSERVATION_MODIFIER", 172, 184], ["epithelial progenitor cells", "OBSERVATION", 186, 213], ["few", "OBSERVATION_MODIFIER", 278, 281], ["differentiated cell types", "OBSERVATION", 282, 307]]], ["They express stem cell markers and can differentiate into epithelial cells with various phenotypes.Adult epithelial cells in the oviductMucous epithelium of an avian oviduct is composed of simple columnar cells equipped with cilia to move the ovum from distal to proximal oviduct and of nonciliated secreting cells.", [["stem cell", "ANATOMY", 13, 22], ["epithelial cells", "ANATOMY", 58, 74], ["epithelial cells", "ANATOMY", 105, 121], ["oviduct", "ANATOMY", 129, 136], ["Mucous epithelium", "ANATOMY", 136, 153], ["oviduct", "ANATOMY", 166, 173], ["columnar cells", "ANATOMY", 196, 210], ["cilia", "ANATOMY", 225, 230], ["ovum", "ANATOMY", 243, 247], ["oviduct", "ANATOMY", 272, 279], ["cells", "ANATOMY", 309, 314], ["stem cell", "CELL", 13, 22], ["epithelial cells", "CELL", 58, 74], ["epithelial cells", "CELL", 105, 121], ["oviduct", "ORGAN", 129, 136], ["Mucous epithelium", "TISSUE", 136, 153], ["oviduct", "ORGAN", 166, 173], ["columnar cells", "CELL", 196, 210], ["cilia", "CELLULAR_COMPONENT", 225, 230], ["oviduct", "ORGAN", 272, 279], ["cells", "CELL", 309, 314], ["stem cell markers", "PROTEIN", 13, 30], ["epithelial cells", "CELL_TYPE", 58, 74], ["Adult epithelial cells", "CELL_TYPE", 99, 121], ["simple columnar cells", "CELL_TYPE", 189, 210], ["nonciliated secreting cells", "CELL_TYPE", 287, 314], ["avian", "SPECIES", 160, 165], ["stem cell markers", "TEST", 13, 30], ["various phenotypes", "PROBLEM", 80, 98], ["Adult epithelial cells in the oviduct", "PROBLEM", 99, 136], ["Mucous epithelium of an avian oviduct", "PROBLEM", 136, 173], ["simple columnar cells", "PROBLEM", 189, 210], ["cilia", "TREATMENT", 225, 230], ["nonciliated secreting cells", "PROBLEM", 287, 314], ["stem cell markers", "OBSERVATION", 13, 30], ["epithelial cells", "OBSERVATION", 58, 74], ["various phenotypes", "OBSERVATION", 80, 98], ["epithelial cells", "OBSERVATION", 105, 121], ["oviduct", "ANATOMY", 129, 136], ["epithelium", "ANATOMY_MODIFIER", 143, 153], ["avian oviduct", "OBSERVATION", 160, 173], ["simple", "OBSERVATION_MODIFIER", 189, 195], ["columnar cells", "OBSERVATION", 196, 210], ["ovum", "ANATOMY", 243, 247], ["distal", "ANATOMY_MODIFIER", 253, 259], ["proximal", "ANATOMY_MODIFIER", 263, 271], ["oviduct", "ANATOMY", 272, 279], ["nonciliated", "OBSERVATION_MODIFIER", 287, 298], ["secreting cells", "OBSERVATION", 299, 314]]], ["Both cell types require sustained renewal from the stem cell compartment and a high proliferation and maturation activity from the progenitor compartment.", [["cell", "ANATOMY", 5, 9], ["stem cell compartment", "ANATOMY", 51, 72], ["progenitor compartment", "ANATOMY", 131, 153], ["cell", "CELL", 5, 9], ["stem cell", "CELL", 51, 60], ["progenitor compartment", "CELLULAR_COMPONENT", 131, 153], ["a high proliferation", "PROBLEM", 77, 97], ["cell types", "OBSERVATION", 5, 15], ["stem cell compartment", "OBSERVATION", 51, 72], ["high proliferation", "OBSERVATION", 79, 97], ["progenitor compartment", "OBSERVATION", 131, 153]]], ["Those compartments are putatively based under the luminal epithelium as cellular niches [11] .", [["compartments", "ANATOMY", 6, 18], ["luminal epithelium", "ANATOMY", 50, 68], ["cellular", "ANATOMY", 72, 80], ["luminal", "CHEMICAL", 50, 57], ["luminal epithelium", "TISSUE", 50, 68], ["cellular", "CELL", 72, 80], ["luminal", "ANATOMY_MODIFIER", 50, 57], ["epithelium", "ANATOMY_MODIFIER", 58, 68]]], ["In a mammalian fallopian tube, stem cells niches were tracked using antibodies and genetic markers and were found to be localized in the distal fallopian tube [8, 12] .", [["fallopian tube", "ANATOMY", 15, 29], ["stem cells", "ANATOMY", 31, 41], ["distal fallopian tube", "ANATOMY", 137, 158], ["fallopian tube", "TISSUE", 15, 29], ["stem cells", "CELL", 31, 41], ["fallopian tube", "TISSUE", 144, 158], ["stem cells", "CELL_TYPE", 31, 41], ["antibodies", "PROTEIN", 68, 78], ["a mammalian fallopian tube", "TREATMENT", 3, 29], ["stem cells niches", "TREATMENT", 31, 48], ["antibodies", "TEST", 68, 78], ["genetic markers", "TEST", 83, 98], ["fallopian tube", "OBSERVATION", 15, 29], ["stem cells", "OBSERVATION", 31, 41], ["distal", "ANATOMY_MODIFIER", 137, 143], ["fallopian tube", "OBSERVATION", 144, 158]]], ["In our earlier research, we determined faster proliferation of cultivated hen oviduct cells derived from infundibulum/ distal magnum compared to the cells that were sourced from a proximal magnum.", [["oviduct cells", "ANATOMY", 78, 91], ["infundibulum/ distal magnum", "ANATOMY", 105, 132], ["cells", "ANATOMY", 149, 154], ["hen", "ORGANISM", 74, 77], ["oviduct cells", "CELL", 78, 91], ["infundibulum", "ORGAN", 105, 117], ["distal magnum", "MULTI-TISSUE_STRUCTURE", 119, 132], ["cells", "CELL", 149, 154], ["magnum", "MULTI-TISSUE_STRUCTURE", 189, 195], ["cultivated hen oviduct cells", "CELL_LINE", 63, 91], ["hen", "SPECIES", 74, 77], ["hen", "SPECIES", 74, 77], ["faster proliferation of cultivated hen oviduct cells", "PROBLEM", 39, 91], ["infundibulum/ distal magnum", "PROBLEM", 105, 132], ["cultivated hen oviduct cells", "OBSERVATION", 63, 91], ["infundibulum", "ANATOMY_MODIFIER", 105, 117], ["distal", "ANATOMY_MODIFIER", 119, 125], ["magnum", "ANATOMY", 126, 132], ["proximal", "ANATOMY_MODIFIER", 180, 188], ["magnum", "ANATOMY", 189, 195]]], ["We have also determined that distal oviduct compartments were positively immunostained against CD44 and p63, which are known to be epithelial stem/progenitor markers [13] .", [["oviduct compartments", "ANATOMY", 36, 56], ["epithelial stem", "ANATOMY", 131, 146], ["progenitor", "ANATOMY", 147, 157], ["oviduct compartments", "MULTI-TISSUE_STRUCTURE", 36, 56], ["CD44", "GENE_OR_GENE_PRODUCT", 95, 99], ["p63", "GENE_OR_GENE_PRODUCT", 104, 107], ["epithelial stem", "CELL", 131, 146], ["progenitor", "CELL", 147, 157], ["CD44", "PROTEIN", 95, 99], ["p63", "PROTEIN", 104, 107], ["epithelial stem/progenitor markers", "CELL_TYPE", 131, 165], ["distal oviduct compartments", "TEST", 29, 56], ["CD44", "TEST", 95, 99], ["p63", "TEST", 104, 107], ["distal", "ANATOMY_MODIFIER", 29, 35], ["oviduct", "ANATOMY", 36, 43], ["known to be", "UNCERTAINTY", 119, 130], ["epithelial stem", "OBSERVATION", 131, 146]]], ["Thereby, we have hypothesized that distal segments of avian oviduct contain progenitor gene expression signatures.Genetic markers of distinctive signatures in avian oviduct epitheliumCharacterization of oviduct cells using molecular markers for epithelial progenitors contributes to the understanding of differentiation and regeneration processes, which occur in the oviduct epithelium.", [["distal segments", "ANATOMY", 35, 50], ["oviduct", "ANATOMY", 60, 67], ["progenitor", "ANATOMY", 76, 86], ["oviduct", "ANATOMY", 165, 172], ["oviduct cells", "ANATOMY", 203, 216], ["epithelial progenitors", "ANATOMY", 245, 267], ["oviduct epithelium", "ANATOMY", 367, 385], ["avian", "ORGANISM", 54, 59], ["oviduct", "ORGAN", 60, 67], ["progenitor", "CELL", 76, 86], ["avian", "ORGANISM", 159, 164], ["oviduct", "DEVELOPING_ANATOMICAL_STRUCTURE", 165, 172], ["oviduct cells", "CELL", 203, 216], ["epithelial progenitors", "CELL", 245, 267], ["oviduct epithelium", "TISSUE", 367, 385], ["oviduct cells", "CELL_TYPE", 203, 216], ["epithelial progenitors", "CELL_TYPE", 245, 267], ["distal segments of avian oviduct", "PROBLEM", 35, 67], ["Genetic markers", "TEST", 114, 129], ["distinctive signatures", "PROBLEM", 133, 155], ["oviduct cells", "PROBLEM", 203, 216], ["molecular markers", "TEST", 223, 240], ["epithelial progenitors", "PROBLEM", 245, 267], ["regeneration processes", "PROBLEM", 324, 346], ["distal", "ANATOMY_MODIFIER", 35, 41], ["segments", "ANATOMY_MODIFIER", 42, 50], ["avian oviduct", "ANATOMY", 54, 67], ["progenitor gene", "OBSERVATION", 76, 91], ["expression signatures", "OBSERVATION", 92, 113], ["distinctive signatures", "OBSERVATION", 133, 155], ["avian oviduct", "OBSERVATION", 159, 172], ["oviduct cells", "OBSERVATION", 203, 216], ["epithelial progenitors", "OBSERVATION", 245, 267], ["regeneration processes", "OBSERVATION", 324, 346], ["oviduct", "ANATOMY", 367, 374], ["epithelium", "ANATOMY_MODIFIER", 375, 385]]], ["As reported earlier, the self-renewal activity of cells in the fallopian tube occurs in its distal part [14, 15] .", [["cells", "ANATOMY", 50, 55], ["fallopian tube", "ANATOMY", 63, 77], ["cells", "CELL", 50, 55], ["fallopian tube", "MULTI-TISSUE_STRUCTURE", 63, 77], ["the fallopian tube", "TREATMENT", 59, 77], ["fallopian tube", "OBSERVATION", 63, 77], ["distal", "ANATOMY_MODIFIER", 92, 98]]], ["Thereby, in this paper, we have focused on distal parts of the oviduct (the closest to ovaries and abdomen) to follow the molecular characteristics of the cells in tissue and in vitro.", [["distal parts", "ANATOMY", 43, 55], ["oviduct", "ANATOMY", 63, 70], ["ovaries", "ANATOMY", 87, 94], ["abdomen", "ANATOMY", 99, 106], ["cells", "ANATOMY", 155, 160], ["tissue", "ANATOMY", 164, 170], ["oviduct", "ORGAN", 63, 70], ["ovaries", "ORGAN", 87, 94], ["abdomen", "ORGAN", 99, 106], ["cells", "CELL", 155, 160], ["tissue", "TISSUE", 164, 170], ["distal", "ANATOMY_MODIFIER", 43, 49], ["oviduct", "ANATOMY", 63, 70], ["ovaries", "ANATOMY", 87, 94], ["abdomen", "ANATOMY", 99, 106]]], ["We propose a panel of epithelial genetic markers to determine the progenitor/epithelial cell pattern in selected compartments of the oviduct (Fig. 1) .", [["epithelial", "ANATOMY", 22, 32], ["progenitor", "ANATOMY", 66, 76], ["epithelial cell", "ANATOMY", 77, 92], ["compartments", "ANATOMY", 113, 125], ["oviduct", "ANATOMY", 133, 140], ["epithelial", "TISSUE", 22, 32], ["progenitor", "CELL", 66, 76], ["epithelial cell", "CELL", 77, 92], ["oviduct", "ORGAN", 133, 140], ["epithelial genetic markers", "TEST", 22, 48], ["the progenitor/epithelial cell pattern", "TEST", 62, 100], ["epithelial cell pattern", "OBSERVATION", 77, 100], ["oviduct", "ANATOMY", 133, 140]]], ["In particular, we have aimed to reveal which of the avian oviduct compartments (infundibulum (INF), distal magnum (DM), or proximal magnum (PM)) carry known progenitor signatures.Isolation of the oviduct tissueIn this study, all the procedures involving experimental animals were approved by the Local Ethics Committee for Animal Research (http://lke.utp.edu.pl) located at the Faculty of Animal Breeding and Biology, UTP University of Science and Technology in Bydgoszcz (study approval reference number 35/2012, in accordance with the 2010_63_UE_PL Directive).", [["oviduct compartments", "ANATOMY", 58, 78], ["infundibulum", "ANATOMY", 80, 92], ["distal magnum", "ANATOMY", 100, 113], ["DM", "ANATOMY", 115, 117], ["proximal magnum", "ANATOMY", 123, 138], ["PM", "ANATOMY", 140, 142], ["progenitor", "ANATOMY", 157, 167], ["oviduct", "ANATOMY", 196, 203], ["UTP", "CHEMICAL", 418, 421], ["avian", "ORGANISM", 52, 57], ["oviduct compartments", "MULTI-TISSUE_STRUCTURE", 58, 78], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 80, 92], ["distal magnum", "MULTI-TISSUE_STRUCTURE", 100, 113], ["progenitor", "CELL", 157, 167], ["oviduct tissueIn", "MULTI-TISSUE_STRUCTURE", 196, 212], ["infundibulum (INF), distal magnum (DM)", "PROBLEM", 80, 118], ["this study", "TEST", 213, 223], ["avian oviduct", "ANATOMY", 52, 65], ["infundibulum", "ANATOMY_MODIFIER", 80, 92], ["INF", "ANATOMY", 94, 97], ["distal", "ANATOMY_MODIFIER", 100, 106], ["magnum", "ANATOMY", 107, 113], ["proximal", "ANATOMY_MODIFIER", 123, 131], ["magnum", "ANATOMY", 132, 138], ["progenitor signatures", "OBSERVATION", 157, 178], ["oviduct", "ANATOMY", 196, 203]]], ["The Hybrid Tetra SL laying hens (n = 6, 40 weeks old) were obtained from a commercial farm (Nowosc, Pradocin, Poland).", [["The Hybrid Tetra SL laying", "TREATMENT", 0, 26]]], ["Laying Japanese quails (n = 6, 10 weeks old) were obtained from a commercial producer (K. Drazek, Wyzne, Poland).", [["quails", "ORGANISM", 16, 22], ["quails", "SPECIES", 16, 22], ["Japanese quails", "SPECIES", 7, 22]]], ["All birds laid eggs at a daily rate and no hormonal stimulation was applied for this study.", [["eggs", "ANATOMY", 15, 19], ["birds", "ORGANISM", 4, 9], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 15, 19], ["hormonal stimulation", "TREATMENT", 43, 63], ["this study", "TEST", 80, 90]]], ["Immediately upon transportation, the animals were sacrificed by cervical dislocation.", [["cervical", "ANATOMY", 64, 72], ["cervical dislocation", "DISEASE", 64, 84], ["animals", "ORGANISM", 37, 44], ["cervical", "ORGANISM_SUBDIVISION", 64, 72], ["cervical dislocation", "PROBLEM", 64, 84], ["cervical", "ANATOMY", 64, 72], ["dislocation", "OBSERVATION", 73, 84]]], ["Only the oviducts after egg passage, with ovum position in a shell gland, were used for the experiments.", [["oviducts", "ANATOMY", 9, 17], ["egg", "ANATOMY", 24, 27], ["ovum", "ANATOMY", 42, 46], ["shell gland", "ANATOMY", 61, 72], ["oviducts", "MULTI-TISSUE_STRUCTURE", 9, 17], ["gland", "ORGAN", 67, 72], ["egg passage", "TREATMENT", 24, 35], ["ovum position in a shell gland", "TREATMENT", 42, 72], ["egg passage", "OBSERVATION", 24, 35], ["shell gland", "ANATOMY", 61, 72]]], ["Each oviduct was rinsed twice in tube filled out with 25 mL physiological buffered saline (PBS) w/o Mg, w/o Ca (Lonza Biosciences, Celllab, Warszawa, Poland), which was gently mixed with Penicillin-Streptomycin solution at 1:100 (v:v; Life Technologies, Warszawa, Poland).In vitro culture of oviduct epithelial cellsThe epithelial cells were isolated from the oviduct tissue using the methodology described earlier [16] .", [["oviduct", "ANATOMY", 5, 12], ["tube", "ANATOMY", 33, 37], ["oviduct epithelial cells", "ANATOMY", 292, 316], ["epithelial cells", "ANATOMY", 320, 336], ["oviduct tissue", "ANATOMY", 360, 374], ["Mg", "CHEMICAL", 100, 102], ["Ca", "CHEMICAL", 108, 110], ["Penicillin", "CHEMICAL", 187, 197], ["Streptomycin", "CHEMICAL", 198, 210], ["Mg", "CHEMICAL", 100, 102], ["Ca", "CHEMICAL", 108, 110], ["Penicillin", "CHEMICAL", 187, 197], ["Streptomycin", "CHEMICAL", 198, 210], ["oviduct", "ORGAN", 5, 12], ["tube", "TISSUE", 33, 37], ["saline", "SIMPLE_CHEMICAL", 83, 89], ["Penicillin-Streptomycin", "SIMPLE_CHEMICAL", 187, 210], ["oviduct epithelial cells", "CELL", 292, 316], ["epithelial cells", "CELL", 320, 336], ["oviduct tissue", "TISSUE", 360, 374], ["oviduct epithelial cells", "CELL_TYPE", 292, 316], ["epithelial cells", "CELL_TYPE", 320, 336], ["physiological buffered saline (PBS", "TREATMENT", 60, 94], ["Ca", "TEST", 108, 110], ["Celllab", "TEST", 131, 138], ["Penicillin-Streptomycin solution", "TREATMENT", 187, 219], ["vitro culture", "TEST", 275, 288], ["oviduct epithelial cells", "PROBLEM", 292, 316], ["The epithelial cells", "PROBLEM", 316, 336], ["oviduct epithelial cells", "OBSERVATION", 292, 316], ["epithelial cells", "OBSERVATION", 320, 336], ["oviduct tissue", "OBSERVATION", 360, 374]]], ["Immediately after tissue collection, three oviduct fragments were dissected: infundibulum, distal magnum, and proximal magnum, each 3 cm long.", [["tissue", "ANATOMY", 18, 24], ["oviduct fragments", "ANATOMY", 43, 60], ["infundibulum", "ANATOMY", 77, 89], ["distal magnum", "ANATOMY", 91, 104], ["proximal magnum", "ANATOMY", 110, 125], ["tissue", "TISSUE", 18, 24], ["oviduct fragments", "MULTI-TISSUE_STRUCTURE", 43, 60], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 77, 89], ["distal magnum", "MULTI-TISSUE_STRUCTURE", 91, 104], ["magnum", "MULTI-TISSUE_STRUCTURE", 119, 125], ["tissue collection", "PROBLEM", 18, 35], ["three oviduct fragments", "PROBLEM", 37, 60], ["infundibulum, distal magnum, and proximal magnum", "PROBLEM", 77, 125], ["tissue", "ANATOMY", 18, 24], ["collection", "OBSERVATION", 25, 35], ["three", "OBSERVATION_MODIFIER", 37, 42], ["oviduct", "OBSERVATION_MODIFIER", 43, 50], ["fragments", "OBSERVATION_MODIFIER", 51, 60], ["infundibulum", "ANATOMY_MODIFIER", 77, 89], ["distal", "ANATOMY_MODIFIER", 91, 97], ["magnum", "ANATOMY", 98, 104], ["proximal", "ANATOMY_MODIFIER", 110, 118], ["magnum", "ANATOMY", 119, 125], ["3 cm", "OBSERVATION_MODIFIER", 132, 136], ["long", "OBSERVATION_MODIFIER", 137, 141]]], ["Each fragment was cleaned off the mesentery tissue and minced with a scalpel blade on a Petri dish.", [["mesentery tissue", "ANATOMY", 34, 50], ["mesentery tissue", "TISSUE", 34, 50], ["Each fragment", "PROBLEM", 0, 13], ["a scalpel blade", "TREATMENT", 67, 82], ["a Petri dish", "TREATMENT", 86, 98], ["fragment", "OBSERVATION", 5, 13], ["mesentery tissue", "ANATOMY", 34, 50], ["scalpel blade", "OBSERVATION", 69, 82], ["Petri dish", "OBSERVATION", 88, 98]]], ["The minced fragments were digested in a solution of 1 mg/mL collagenase P (Sigma-Aldrich, Poznan, Poland) in Advanced Dulbecco's Modified Eagles Medium-F12 (DMEM/F-12; Life Technologies, Warszawa, Poland) for 30 min at 37\u00b0C, on a shaker.", [["fragments", "ANATOMY", 11, 20], ["collagenase", "GENE_OR_GENE_PRODUCT", 60, 71], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 75, 88], ["The minced fragments", "TREATMENT", 0, 20], ["a solution", "TREATMENT", 38, 48], ["minced", "OBSERVATION_MODIFIER", 4, 10], ["fragments", "OBSERVATION", 11, 20]]], ["Due to the size of oviductal tubes, the amount of minced tissue was~50% less in quail than in hen.", [["oviductal tubes", "ANATOMY", 19, 34], ["tissue", "ANATOMY", 57, 63], ["oviductal tubes", "MULTI-TISSUE_STRUCTURE", 19, 34], ["tissue", "TISSUE", 57, 63], ["quail", "ORGANISM", 80, 85], ["hen", "ORGANISM", 94, 97], ["quail", "SPECIES", 80, 85], ["hen", "SPECIES", 94, 97], ["quail", "SPECIES", 80, 85], ["hen", "SPECIES", 94, 97], ["oviductal tubes", "TREATMENT", 19, 34], ["minced tissue", "PROBLEM", 50, 63], ["size", "OBSERVATION_MODIFIER", 11, 15], ["oviductal tubes", "OBSERVATION", 19, 34], ["amount", "OBSERVATION_MODIFIER", 40, 46], ["minced tissue", "OBSERVATION", 50, 63]]], ["Thus, adequately lower volumes of digestion solution were applied to process the quail oviduct tissue.", [["oviduct tissue", "ANATOMY", 87, 101], ["quail", "ORGANISM", 81, 86], ["oviduct tissue", "TISSUE", 87, 101], ["quail", "SPECIES", 81, 86], ["quail", "SPECIES", 81, 86], ["digestion solution", "TREATMENT", 34, 52], ["lower", "OBSERVATION_MODIFIER", 17, 22], ["volumes", "OBSERVATION_MODIFIER", 23, 30], ["quail oviduct tissue", "OBSERVATION", 81, 101]]], ["The cells were counted manually using Neubauer hemocytometer and seeded at a density of 4 \u00d7 10 4 cells/cm 2 into 25 cm 2 vented BD type Primaria flasks (Becton Dickinson, Diagmed, Warszawa, Poland).", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 97, 102], ["cells", "CELL", 4, 9], ["Neubauer hemocytometer", "TEST", 38, 60], ["25 cm", "OBSERVATION_MODIFIER", 113, 118], ["Primaria flasks", "OBSERVATION", 136, 151]]], ["The cells were incubated in 7% CO 2 atmosphere at 37\u00b0C. The oviduct cells were maintained in DMEM-F12 supplemented with 5% (v/v) fetal bovine serum (FBS; Life Technologies, cat.", [["cells", "ANATOMY", 4, 9], ["oviduct cells", "ANATOMY", 60, 73], ["fetal bovine serum", "ANATOMY", 129, 147], ["FBS", "ANATOMY", 149, 152], ["CO", "CHEMICAL", 31, 33], ["cells", "CELL", 4, 9], ["oviduct cells", "CELL", 60, 73], ["DMEM-F12", "CELL", 93, 101], ["bovine", "ORGANISM", 135, 141], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["FBS", "ORGANISM_SUBSTANCE", 149, 152], ["cat", "ORGANISM", 173, 176], ["oviduct cells", "CELL_TYPE", 60, 73], ["bovine", "SPECIES", 135, 141], ["bovine", "SPECIES", 135, 141], ["The oviduct cells", "TREATMENT", 56, 73], ["fetal bovine serum", "TEST", 129, 147]]], ["16,140-063, batch No. 41G4541K, Warszawa, Poland), 1% (v/v) nonessential amino acids (Sigma-Aldrich, Poznan, Poland), 20 mM L-glutamine (Sigma-Aldrich, Poznan, Poland), 10 ng/mL human epidermal growth factor (human EGF; R&D Bioscience, Biokom, Janki, Poland), 1% (v/v) antibioticantimycotic solution (Life Technologies, Warszawa, Poland), 0.5 \u03bcg/mL hydrocortisone (Sigma Aldrich, Poznan, Poland) and 5 \u03bcg/mL insulin-transferrinselenium (ITS; Sigma-Aldrich, Poznan, Poland).", [["amino acids", "CHEMICAL", 73, 84], ["L-glutamine", "CHEMICAL", 124, 135], ["hydrocortisone", "CHEMICAL", 349, 363], ["insulin-transferrinselenium", "CHEMICAL", 408, 435], ["amino acids", "CHEMICAL", 73, 84], ["L-glutamine", "CHEMICAL", 124, 135], ["hydrocortisone", "CHEMICAL", 349, 363], ["transferrinselenium", "CHEMICAL", 416, 435], ["amino acids", "AMINO_ACID", 73, 84], ["L-glutamine", "SIMPLE_CHEMICAL", 124, 135], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 137, 150], ["human", "ORGANISM", 178, 183], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 184, 207], ["human", "ORGANISM", 209, 214], ["EGF", "GENE_OR_GENE_PRODUCT", 215, 218], ["hydrocortisone", "SIMPLE_CHEMICAL", 349, 363], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 365, 378], ["insulin-transferrinselenium", "SIMPLE_CHEMICAL", 408, 435], ["human epidermal growth factor", "PROTEIN", 178, 207], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 209, 214], ["batch", "TEST", 12, 17], ["nonessential amino acids", "TREATMENT", 60, 84], ["20 mM L-glutamine", "TREATMENT", 118, 135], ["human epidermal growth factor (human EGF", "TREATMENT", 178, 218], ["R&D Bioscience", "TREATMENT", 220, 234], ["Biokom, Janki, Poland)", "TREATMENT", 236, 258], ["antibioticantimycotic solution (Life Technologies", "TREATMENT", 269, 318], ["hydrocortisone", "TREATMENT", 349, 363], ["insulin", "TREATMENT", 408, 415]]], ["The viability and the proliferation of oviduct cells were measured by a real-time cell analyzer (RTCA) supplied by xCELLigence system (Roche Applied Science, Basel, Switzerland).", [["oviduct cells", "ANATOMY", 39, 52], ["cell", "ANATOMY", 82, 86], ["oviduct cells", "CELL", 39, 52], ["cell", "CELL", 82, 86], ["oviduct cells", "CELL_TYPE", 39, 52], ["the proliferation of oviduct cells", "PROBLEM", 18, 52], ["viability", "OBSERVATION_MODIFIER", 4, 13], ["proliferation", "OBSERVATION_MODIFIER", 22, 35], ["oviduct cells", "OBSERVATION", 39, 52]]], ["The measurements of proliferating cells were conducted at 3.1 h intervals through 287 h post seeding, in accordance with the producer's manual.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["proliferating cells", "CELL_TYPE", 20, 39], ["proliferating cells", "PROBLEM", 20, 39], ["proliferating cells", "OBSERVATION", 20, 39]]], ["The cells intended for sampling were cultivated for 5-7 days prior to harvesting and analysis.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["sampling", "TEST", 23, 31], ["harvesting", "TREATMENT", 70, 80], ["analysis", "TEST", 85, 93]]], ["Every second day, the epithelial colonies were counted and photographed under an objective with phase contrast (Zeiss Axiovert 40) equipped with a digital camera (Canon EOS 600).", [["epithelial colonies", "ANATOMY", 22, 41], ["epithelial colonies", "CELL", 22, 41], ["epithelial colonies", "CELL_LINE", 22, 41], ["the epithelial colonies", "TEST", 18, 41], ["phase contrast (Zeiss Axiovert", "TREATMENT", 96, 126], ["epithelial", "ANATOMY", 22, 32], ["colonies", "OBSERVATION", 33, 41]]], ["The cells were harvested upon reaching 80% of growth confluence.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9], ["growth", "OBSERVATION_MODIFIER", 46, 52], ["confluence", "OBSERVATION_MODIFIER", 53, 63]]], ["Cultured oviduct epithelial cells were referred as chicken oviduct epithelial cells (COEC) or quail oviduct epithelial cells (QOEC) in further parts of this paper.In vitro culture of oviduct epithelial cellsRNA isolation from oviduct tissue, COEC, and QOEC RNA was isolated from three different sections of the oviduct tube (INF, DM, and PM) and cultivated oviduct cells, derived from the respective birds.", [["oviduct epithelial cells", "ANATOMY", 9, 33], ["oviduct epithelial cells", "ANATOMY", 59, 83], ["COEC", "ANATOMY", 85, 89], ["oviduct epithelial cells", "ANATOMY", 100, 124], ["QOEC", "ANATOMY", 126, 130], ["oviduct epithelial", "ANATOMY", 183, 201], ["oviduct tissue", "ANATOMY", 226, 240], ["COEC", "ANATOMY", 242, 246], ["sections", "ANATOMY", 295, 303], ["oviduct tube", "ANATOMY", 311, 323], ["PM", "ANATOMY", 338, 340], ["oviduct cells", "ANATOMY", 357, 370], ["oviduct epithelial cells", "CELL", 9, 33], ["chicken", "ORGANISM", 51, 58], ["oviduct epithelial cells", "CELL", 59, 83], ["COEC", "CELL", 85, 89], ["quail oviduct epithelial cells", "CELL", 94, 124], ["QOEC", "CELL", 126, 130], ["oviduct epithelial cellsRNA", "CELL", 183, 210], ["oviduct tissue", "TISSUE", 226, 240], ["COEC", "CELL", 242, 246], ["oviduct tube", "TISSUE", 311, 323], ["oviduct cells", "CELL", 357, 370], ["birds", "ORGANISM", 400, 405], ["Cultured oviduct epithelial cells", "CELL_TYPE", 0, 33], ["chicken oviduct epithelial cells", "CELL_TYPE", 51, 83], ["COEC", "CELL_TYPE", 85, 89], ["quail oviduct epithelial cells", "CELL_TYPE", 94, 124], ["QOEC", "CELL_TYPE", 126, 130], ["QOEC RNA", "RNA", 252, 260], ["oviduct cells", "CELL_TYPE", 357, 370], ["chicken", "SPECIES", 51, 58], ["quail", "SPECIES", 94, 99], ["chicken", "SPECIES", 51, 58], ["quail", "SPECIES", 94, 99], ["Cultured oviduct epithelial cells", "PROBLEM", 0, 33], ["chicken oviduct epithelial cells", "TEST", 51, 83], ["COEC", "TEST", 85, 89], ["quail oviduct epithelial cells", "TEST", 94, 124], ["vitro culture", "TEST", 166, 179], ["oviduct epithelial cellsRNA isolation", "PROBLEM", 183, 220], ["oviduct tissue", "PROBLEM", 226, 240], ["COEC", "TEST", 242, 246], ["QOEC RNA", "PROBLEM", 252, 260], ["the oviduct tube", "TREATMENT", 307, 323], ["DM", "PROBLEM", 330, 332], ["cultivated oviduct cells", "PROBLEM", 346, 370], ["epithelial cells", "OBSERVATION", 17, 33], ["epithelial cells", "OBSERVATION", 108, 124], ["oviduct epithelial cellsRNA", "OBSERVATION", 183, 210], ["oviduct tissue", "ANATOMY", 226, 240], ["oviduct", "ANATOMY", 311, 318], ["tube", "OBSERVATION", 319, 323], ["oviduct cells", "OBSERVATION", 357, 370]]], ["For in vivo assay, INF, DM, and PM fragments, each 1 cm long, were cut off aseptically and put separately into Eppendorf tubes containing 3.0 mL RNAfix (EURx, Gdansk, Poland).", [["PM fragments", "ANATOMY", 32, 44], ["vivo assay", "TEST", 7, 17], ["DM", "PROBLEM", 24, 26], ["PM fragments", "PROBLEM", 32, 44], ["Eppendorf tubes", "TREATMENT", 111, 126], ["INF", "ANATOMY", 19, 22], ["DM", "OBSERVATION", 24, 26], ["PM fragments", "OBSERVATION_MODIFIER", 32, 44]]], ["Tissue samples were kept for 24 h at 4\u00b0C and subsequently stored at \u2212 20\u00b0C until isolation of RNA.", [["Tissue samples", "ANATOMY", 0, 14], ["Tissue samples", "CANCER", 0, 14], ["C", "GENE_OR_GENE_PRODUCT", 73, 74], ["RNA", "RNA", 94, 97], ["Tissue samples", "TEST", 0, 14], ["isolation of RNA", "PROBLEM", 81, 97], ["RNA", "OBSERVATION", 94, 97]]], ["For RNA isolation from COEC, confluent cells were detached using Accutase\u00ae solution (A&E Life Sciences, Gentaur, Sopot, Poland) and centrifuged at 220\u00d7g for 5 min at room temperature (RT).", [["COEC", "ANATOMY", 23, 27], ["cells", "ANATOMY", 39, 44], ["COEC", "CELL", 23, 27], ["cells", "CELL", 39, 44], ["COEC", "CELL_LINE", 23, 27], ["confluent cells", "CELL_LINE", 29, 44], ["RNA isolation", "PROBLEM", 4, 17], ["confluent cells", "PROBLEM", 29, 44], ["Accutase\u00ae solution", "TREATMENT", 65, 83], ["confluent cells", "OBSERVATION", 29, 44]]], ["Cell pellets were resuspended in 0.5 mL RNAfix (EURx, Gdansk, Poland) to preserve cells prior to RNA isolation.", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 82, 87], ["Cell", "CELL", 0, 4], ["cells", "CELL", 82, 87], ["Cell pellets", "TREATMENT", 0, 12], ["RNA isolation", "TREATMENT", 97, 110]]], ["RNA was extracted using the universal RNA purification kit (EURx, Gdansk, Poland) according to manufacturer's recommendation.", [["RNA", "RNA", 0, 3]]], ["RNA was quantified using spectrophotometry and RNA quality by gel electrophoresis.RT-qPCR analysisReverse transcription was performed with Maxima First Strand cDNA synthesis kit for RT-qPCR (Thermo Scientific/Fermentas, Vilnius, Lithuania). cDNA was diluted to a final concentration of 70 ng/\u03bcL and stored at \u221220\u00b0C. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed in a total volume of 10 \u03bcL, which included Maxima SYBR Green qPCR Master Mix (Thermo Scientific/Fermentas, Vilnius, Lithuania), 1 \u03bcM of each primer (forward and reverse), and 2 \u03bcL of diluted cDNA (140 ng).", [["RNA", "RNA", 0, 3], ["cDNA", "DNA", 241, 245], ["diluted cDNA", "DNA", 584, 596], ["spectrophotometry", "TEST", 25, 42], ["gel electrophoresis", "TEST", 62, 81], ["RT-qPCR analysis", "TEST", 82, 98], ["Reverse transcription", "TREATMENT", 98, 119], ["RT", "TEST", 182, 184], ["Reverse transcription", "TREATMENT", 316, 337], ["quantitative polymerase chain reaction", "PROBLEM", 338, 376], ["diluted cDNA", "TREATMENT", 584, 596]]], ["Primer sequences (Table 1) were derived from the literature or designed with NCBI Primer Blast, based on cDNA reference sequences [17] .", [["Primer sequences", "DNA", 0, 16], ["NCBI Primer Blast", "DNA", 77, 94], ["cDNA reference sequences", "DNA", 105, 129], ["Primer sequences", "TEST", 0, 16], ["cDNA reference sequences", "TEST", 105, 129]]], ["Thermal cycling was conducted in LightCycler II 480 (Roche Applied Science, Basel, Switzerland). qPCR thermal profile consisted of initial denaturation at 95\u00b0C for 20 min, followed by 40 cycles of amplification including 15 s of denaturation at 95\u00b0C, 20 s of annealing at 58\u00b0C, and 20 s of elongation at 72\u00b0C. After completion of the amplification reaction, a melting curve was generated to test for the specificity of RT-qPCR.", [["qPCR thermal profile", "TEST", 97, 117], ["initial denaturation", "PROBLEM", 131, 151], ["amplification", "TREATMENT", 197, 210], ["denaturation", "TREATMENT", 229, 241], ["the amplification reaction", "PROBLEM", 330, 356], ["a melting curve", "TEST", 358, 373], ["initial", "OBSERVATION_MODIFIER", 131, 138], ["denaturation", "OBSERVATION", 139, 151]]], ["For this purpose, the temperature was gradually increased to 98\u00b0C with continuous fluorescence measurement.Relative quantification of gene expressionRelative gene expression analysis was performed for each experimental group with \u0394\u0394Ct method [18] , using Primer sequences reported in this study were designed based on the cDNA reference sequence and NCBI Primer Blast [17] .", [["Primer sequences", "DNA", 255, 271], ["cDNA reference sequence", "DNA", 322, 345], ["the temperature", "TEST", 18, 33], ["continuous fluorescence measurement", "TEST", 71, 106], ["gene expressionRelative gene expression analysis", "TEST", 134, 182], ["Primer sequences", "TEST", 255, 271], ["this study", "TEST", 284, 294]]], ["Oligonucleotide primers spanned exon-exon boundaries to avoid unspecific gDNA amplification.", [["Oligonucleotide primers", "TREATMENT", 0, 23], ["unspecific gDNA amplification", "PROBLEM", 62, 91]]], ["Genome Achicken (G. gallus), Bquail (C. japonica)Relative quantification of gene expressionUbiqutin C (UB) and \u03b2-actin (ACTB) as reference housekeeping genes.", [["G. gallus", "ORGANISM", 17, 26], ["C. japonica", "ORGANISM", 37, 48], ["gene expressionUbiqutin C", "GENE_OR_GENE_PRODUCT", 76, 101], ["UB", "GENE_OR_GENE_PRODUCT", 103, 105], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 111, 118], ["ACTB", "GENE_OR_GENE_PRODUCT", 120, 124], ["gene expressionUbiqutin C", "DNA", 76, 101], ["UB", "DNA", 103, 105], ["\u03b2-actin", "DNA", 111, 118], ["ACTB", "DNA", 120, 124], ["reference housekeeping genes", "DNA", 129, 157], ["G. gallus", "SPECIES", 17, 26], ["C. japonica", "SPECIES", 37, 48], ["G. gallus", "SPECIES", 17, 26], ["C. japonica", "SPECIES", 37, 48], ["Bquail (C. japonica", "TREATMENT", 29, 48], ["gene expressionUbiqutin C (UB)", "TREATMENT", 76, 106], ["\u03b2-actin (ACTB)", "TREATMENT", 111, 125]]], ["Geometric means of Ct value of both reference genes was used in calculations.", [["Ct value", "TEST", 19, 27]]], ["For tested samples, \u0394Ct was calculated by subtracting mean Ct values of the reference genes from Ct values of the target gene.", [["samples", "ANATOMY", 11, 18], ["reference genes", "DNA", 76, 91], ["target gene", "DNA", 114, 125], ["tested samples", "TEST", 4, 18], ["\u0394Ct", "TEST", 20, 23], ["Ct values", "TEST", 59, 68], ["Ct values", "TEST", 97, 106]]], ["A base sample (calibrator) was defined by an origin different from the reproductive system.", [["sample", "ANATOMY", 7, 13], ["A base sample (calibrator", "TREATMENT", 0, 25]]], ["For in tissue study, muscle samples from the same birds were used.", [["tissue", "ANATOMY", 7, 13], ["muscle samples", "ANATOMY", 21, 35], ["tissue", "TISSUE", 7, 13], ["muscle samples", "CANCER", 21, 35], ["birds", "ORGANISM", 50, 55], ["tissue study", "TEST", 7, 19], ["muscle samples", "TEST", 21, 35], ["muscle", "ANATOMY", 21, 27]]], ["For in vitro study, the chicken macrophage-like cell line [19] was used as a calibrator.", [["macrophage-like cell line", "ANATOMY", 32, 57], ["chicken", "ORGANISM", 24, 31], ["macrophage-like cell line [19]", "CELL", 32, 62], ["chicken macrophage-like cell line", "CELL_LINE", 24, 57], ["chicken", "SPECIES", 24, 31], ["chicken", "SPECIES", 24, 31], ["vitro study", "TEST", 7, 18], ["the chicken macrophage-like cell line", "TREATMENT", 20, 57], ["a calibrator", "TREATMENT", 75, 87], ["cell line", "OBSERVATION", 48, 57]]], ["\u0394\u0394Ct was then calculated using the equation: \u0394Ct sample -\u0394Ct calibrator.", [["\u0394Ct sample", "TEST", 45, 55], ["\u0394Ct calibrator", "TREATMENT", 57, 71]]], ["Fold change of the gene expression was calculated as: R = 2 -\u0394\u0394Ct .Statistical analysisRT-qPCR results were statistically analyzed using SAS Enterprise Guide 6.1 (SAS Institute, Cary, NC, USA).", [["Statistical analysisRT", "TEST", 67, 89]]], ["All tests were conducted on \u0394Ct values.", [["All tests", "TEST", 0, 9], ["\u0394Ct values", "TEST", 28, 38]]], ["First, Shapiro-Wilk test was used to assess the normality of data distribution.Statistical analysisThen the significance of changes in the gene expression (in comparison to calibrator samples) was conducted by Student's t-test (P < 0.05).", [["Shapiro-Wilk test", "TEST", 7, 24], ["Statistical analysis", "TEST", 79, 99], ["calibrator samples", "TEST", 173, 191], ["Student's t-test", "TEST", 210, 226]]], ["Finally, multiple comparisons for all pairs (e.g., oviduct fragments or donor species) were performed with one-way ANOVA followed by Tukey's HSD post hoc test.", [["oviduct fragments", "ANATOMY", 51, 68], ["oviduct fragments", "DNA", 51, 68], ["all pairs (e.g., oviduct fragments", "PROBLEM", 34, 68], ["hoc test", "TEST", 150, 158]]], ["Standard error of the mean (SEM) was used as a parameter of variability within the group.Primary cultures of hen and quail oviduct epithelial cellsCultivated oviduct cells of hen (COEC) and quail (QOEC) reached the confluence after 5-7 days after seeding.", [["Primary cultures", "ANATOMY", 89, 105], ["oviduct epithelial cells", "ANATOMY", 123, 147], ["oviduct cells", "ANATOMY", 158, 171], ["COEC", "ANATOMY", 180, 184], ["hen", "ORGANISM", 109, 112], ["quail oviduct epithelial cells", "CELL", 117, 147], ["oviduct cells", "CELL", 158, 171], ["hen", "ORGANISM", 175, 178], ["COEC", "CELL", 180, 184], ["quail", "ORGANISM", 190, 195], ["QOEC", "CELL", 197, 201], ["hen and quail oviduct epithelial cells", "CELL_TYPE", 109, 147], ["Cultivated oviduct cells", "CELL_TYPE", 147, 171], ["hen", "SPECIES", 109, 112], ["quail", "SPECIES", 117, 122], ["hen", "SPECIES", 175, 178], ["quail", "SPECIES", 190, 195], ["hen", "SPECIES", 109, 112], ["quail", "SPECIES", 117, 122], ["hen", "SPECIES", 175, 178], ["quail", "SPECIES", 190, 195], ["Primary cultures", "TEST", 89, 105], ["quail oviduct epithelial cells", "TEST", 117, 147], ["Cultivated oviduct cells", "TEST", 147, 171], ["seeding", "PROBLEM", 247, 254], ["epithelial cells", "OBSERVATION", 131, 147], ["oviduct cells", "OBSERVATION", 158, 171], ["confluence", "OBSERVATION_MODIFIER", 215, 225]]], ["The COEC and QOEC isolated from the infundibulum region typically occurred as cellular spheres, which attached to the polystyrene culture vessel after 3 days post seeding and were consequently creating epithelial-like colonies, which spread on the surface of the culture vessel.", [["infundibulum region", "ANATOMY", 36, 55], ["cellular spheres", "ANATOMY", 78, 94], ["culture vessel", "ANATOMY", 130, 144], ["epithelial", "ANATOMY", 202, 212], ["colonies", "ANATOMY", 218, 226], ["surface", "ANATOMY", 248, 255], ["culture vessel", "ANATOMY", 263, 277], ["polystyrene", "CHEMICAL", 118, 129], ["COEC", "CANCER", 4, 8], ["infundibulum", "ORGAN", 36, 48], ["cellular spheres", "CELL", 78, 94], ["vessel", "MULTI-TISSUE_STRUCTURE", 138, 144], ["epithelial-like colonies", "CELL", 202, 226], ["surface", "CELLULAR_COMPONENT", 248, 255], ["culture vessel", "MULTI-TISSUE_STRUCTURE", 263, 277], ["COEC", "CELL_LINE", 4, 8], ["QOEC", "DNA", 13, 17], ["epithelial-like colonies", "CELL_LINE", 202, 226], ["The COEC", "TEST", 0, 8], ["cellular spheres", "PROBLEM", 78, 94], ["the polystyrene culture vessel", "TREATMENT", 114, 144], ["seeding", "PROBLEM", 163, 170], ["epithelial-like colonies", "PROBLEM", 202, 226], ["infundibulum", "ANATOMY_MODIFIER", 36, 48], ["cellular spheres", "OBSERVATION", 78, 94], ["vessel", "ANATOMY", 138, 144], ["epithelial", "ANATOMY", 202, 212], ["like colonies", "OBSERVATION", 213, 226], ["culture vessel", "OBSERVATION", 263, 277]]], ["Once the small epithelial colonies appeared beneath the spheres, they enter a high proliferation phase to rapidly form a confluent monolayer.", [["epithelial colonies", "ANATOMY", 15, 34], ["monolayer", "ANATOMY", 131, 140], ["epithelial colonies", "CELL", 15, 34], ["monolayer", "CELL", 131, 140], ["small epithelial colonies", "CELL_LINE", 9, 34], ["confluent monolayer", "CELL_LINE", 121, 140], ["the small epithelial colonies", "PROBLEM", 5, 34], ["a high proliferation phase", "PROBLEM", 76, 102], ["a confluent monolayer", "PROBLEM", 119, 140], ["small", "OBSERVATION_MODIFIER", 9, 14], ["epithelial colonies", "OBSERVATION", 15, 34], ["spheres", "OBSERVATION_MODIFIER", 56, 63], ["high proliferation phase", "OBSERVATION", 78, 102], ["confluent", "OBSERVATION_MODIFIER", 121, 130], ["monolayer", "OBSERVATION_MODIFIER", 131, 140]]], ["Typical cultures from the infundibulum region were characterized by numerous compact epithelial islands, oval in shape, surrounded by elongated cells of mesenchymal or fibroblast-like phenotype (Fig. 2a, b) .", [["cultures", "ANATOMY", 8, 16], ["infundibulum region", "ANATOMY", 26, 45], ["epithelial islands", "ANATOMY", 85, 103], ["cells", "ANATOMY", 144, 149], ["mesenchymal", "ANATOMY", 153, 164], ["fibroblast", "ANATOMY", 168, 178], ["infundibulum region", "MULTI-TISSUE_STRUCTURE", 26, 45], ["epithelial islands", "TISSUE", 85, 103], ["cells", "CELL", 144, 149], ["mesenchymal", "CELL", 153, 164], ["fibroblast", "CELL", 168, 178], ["elongated cells", "CELL_TYPE", 134, 149], ["mesenchymal or fibroblast-like phenotype", "CELL_TYPE", 153, 193], ["Typical cultures from the infundibulum region", "TEST", 0, 45], ["numerous compact epithelial islands", "PROBLEM", 68, 103], ["oval in shape", "PROBLEM", 105, 118], ["mesenchymal or fibroblast-like phenotype", "PROBLEM", 153, 193], ["infundibulum", "ANATOMY_MODIFIER", 26, 38], ["numerous", "OBSERVATION_MODIFIER", 68, 76], ["compact", "OBSERVATION_MODIFIER", 77, 84], ["epithelial islands", "OBSERVATION", 85, 103], ["oval", "OBSERVATION_MODIFIER", 105, 109], ["shape", "OBSERVATION_MODIFIER", 113, 118], ["elongated cells", "OBSERVATION", 134, 149], ["mesenchymal", "OBSERVATION_MODIFIER", 153, 164], ["fibroblast", "OBSERVATION_MODIFIER", 168, 178]]], ["Epithelial cells isolated from the region of distal magnum (a transition region between infundibulum and proximal magnum) formed visible epithelial islands 3 days after seeding, which was sooner compared to the infundibulum region.", [["Epithelial cells", "ANATOMY", 0, 16], ["distal magnum", "ANATOMY", 45, 58], ["infundibulum", "ANATOMY", 88, 100], ["proximal magnum", "ANATOMY", 105, 120], ["epithelial islands", "ANATOMY", 137, 155], ["infundibulum region", "ANATOMY", 211, 230], ["Epithelial cells", "CELL", 0, 16], ["distal magnum", "MULTI-TISSUE_STRUCTURE", 45, 58], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 88, 100], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 211, 223], ["Epithelial cells", "CELL_TYPE", 0, 16], ["Epithelial cells", "PROBLEM", 0, 16], ["a transition region between infundibulum and proximal magnum)", "PROBLEM", 60, 121], ["visible epithelial islands", "PROBLEM", 129, 155], ["seeding", "PROBLEM", 169, 176], ["cells", "OBSERVATION", 11, 16], ["region", "ANATOMY_MODIFIER", 35, 41], ["distal", "ANATOMY_MODIFIER", 45, 51], ["magnum", "ANATOMY", 52, 58], ["infundibulum", "ANATOMY_MODIFIER", 88, 100], ["proximal", "ANATOMY_MODIFIER", 105, 113], ["magnum", "ANATOMY", 114, 120], ["visible", "OBSERVATION_MODIFIER", 129, 136], ["epithelial islands", "OBSERVATION", 137, 155], ["infundibulum", "ANATOMY_MODIFIER", 211, 223]]], ["In the case of distal magnum, spheres that formed epithelial-like colonies in vitro were half the size of those isolated from the infundibulum and about two times less colonies were initiated, compared to those from the infundibulum region on day 3 (Fig. 2c, d) .", [["distal magnum", "ANATOMY", 15, 28], ["spheres", "ANATOMY", 30, 37], ["epithelial", "ANATOMY", 50, 60], ["colonies", "ANATOMY", 66, 74], ["infundibulum", "ANATOMY", 130, 142], ["colonies", "ANATOMY", 168, 176], ["infundibulum region", "ANATOMY", 220, 239], ["epithelial-like colonies", "CELL", 50, 74], ["infundibulum", "ORGAN", 130, 142], ["epithelial-like colonies", "CELL_LINE", 50, 74], ["epithelial-like colonies", "PROBLEM", 50, 74], ["distal", "ANATOMY_MODIFIER", 15, 21], ["magnum", "ANATOMY", 22, 28], ["epithelial", "ANATOMY_MODIFIER", 50, 60], ["like colonies", "OBSERVATION", 61, 74], ["size", "OBSERVATION_MODIFIER", 98, 102], ["infundibulum", "ANATOMY_MODIFIER", 130, 142], ["colonies", "OBSERVATION", 168, 176], ["infundibulum", "ANATOMY_MODIFIER", 220, 232]]], ["In most cases, the epithelial colonies from the distal magnum proliferated fast and were ready for passage by 6-7 days after seeding.", [["epithelial colonies", "ANATOMY", 19, 38], ["distal magnum", "ANATOMY", 48, 61], ["epithelial colonies", "CELL", 19, 38], ["magnum", "ORGAN", 55, 61], ["epithelial colonies", "CELL_LINE", 19, 38], ["the epithelial colonies", "TEST", 15, 38], ["seeding", "PROBLEM", 125, 132], ["epithelial colonies", "OBSERVATION", 19, 38], ["distal", "ANATOMY_MODIFIER", 48, 54], ["magnum", "ANATOMY", 55, 61]]], ["The cells from the region of proximal magnum usually did not form spheres in the beginning of the cultivation (Fig. 2e, f ) .", [["cells", "ANATOMY", 4, 9], ["proximal magnum", "ANATOMY", 29, 44], ["cells", "CELL", 4, 9], ["region", "ANATOMY_MODIFIER", 19, 25], ["proximal", "ANATOMY_MODIFIER", 29, 37], ["magnum", "ANATOMY", 38, 44], ["spheres", "OBSERVATION", 66, 73]]], ["Typically, in proximal magnum, the proliferating epithelial colonies were observed in 3-5 days post seeding.", [["proximal magnum", "ANATOMY", 14, 29], ["epithelial colonies", "ANATOMY", 49, 68], ["epithelial colonies", "CELL", 49, 68], ["proliferating epithelial colonies", "CELL_LINE", 35, 68], ["the proliferating epithelial colonies", "PROBLEM", 31, 68], ["seeding", "PROBLEM", 100, 107], ["proximal", "ANATOMY_MODIFIER", 14, 22], ["magnum", "ANATOMY", 23, 29], ["proliferating", "OBSERVATION_MODIFIER", 35, 48], ["epithelial colonies", "OBSERVATION", 49, 68]]], ["The microscopic observations of growing colonies were in line with the measurements acquired from the xCELLigence real-time cell monitoring system.", [["colonies", "ANATOMY", 40, 48], ["cell", "ANATOMY", 124, 128], ["cell", "CELL", 124, 128], ["growing colonies", "PROBLEM", 32, 48], ["the measurements", "TEST", 67, 83], ["growing", "OBSERVATION_MODIFIER", 32, 39], ["colonies", "OBSERVATION", 40, 48]]], ["The peak of the proliferation was determined for the cells from all oviduct compartments after 3 days post seeding: at 78.", [["cells", "ANATOMY", 53, 58], ["oviduct compartments", "ANATOMY", 68, 88], ["cells", "CELL", 53, 58], ["oviduct compartments", "MULTI-TISSUE_STRUCTURE", 68, 88], ["the cells", "PROBLEM", 49, 58], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["proliferation", "OBSERVATION", 16, 29]]], ["Motile cilia, which are characteristic for oviduct ciliated cells, were observed in the cultivated primary colonies, but only until the first passage.", [["cilia", "ANATOMY", 7, 12], ["oviduct ciliated cells", "ANATOMY", 43, 65], ["colonies", "ANATOMY", 107, 115], ["Motile cilia", "CELLULAR_COMPONENT", 0, 12], ["oviduct ciliated cells", "CELL", 43, 65], ["oviduct ciliated cells", "CELL_TYPE", 43, 65], ["cultivated primary colonies", "CELL_LINE", 88, 115], ["Motile cilia", "PROBLEM", 0, 12], ["oviduct ciliated cells", "PROBLEM", 43, 65], ["cilia", "ANATOMY_MODIFIER", 7, 12], ["characteristic for", "UNCERTAINTY", 24, 42], ["oviduct", "OBSERVATION", 43, 50], ["ciliated cells", "OBSERVATION", 51, 65], ["cultivated", "OBSERVATION_MODIFIER", 88, 98], ["primary colonies", "OBSERVATION", 99, 115]]], ["A movie file shows this in more detail (Additional file 1).Gene expression analysisIn this study, we have used three gene panels to characterize oviduct fragments of hen and quail, and the respective primary epithelial cell cultures that were derived from them.", [["oviduct fragments", "ANATOMY", 145, 162], ["epithelial cell cultures", "ANATOMY", 208, 232], ["oviduct", "MULTI-TISSUE_STRUCTURE", 145, 152], ["hen", "ORGANISM", 166, 169], ["quail", "ORGANISM", 174, 179], ["epithelial cell cultures", "CELL", 208, 232], ["oviduct fragments", "DNA", 145, 162], ["primary epithelial cell cultures", "CELL_LINE", 200, 232], ["hen", "SPECIES", 166, 169], ["quail", "SPECIES", 174, 179], ["hen", "SPECIES", 166, 169], ["quail", "SPECIES", 174, 179], ["A movie file", "TEST", 0, 12], ["Gene expression analysis", "TEST", 59, 83], ["this study", "TEST", 86, 96], ["three gene panels", "TREATMENT", 111, 128], ["oviduct fragments", "PROBLEM", 145, 162], ["the respective primary epithelial cell cultures", "TEST", 185, 232], ["epithelial cell", "OBSERVATION", 208, 223]]], ["Those panels were comprised of oviduct (ESR1, OVAL, and OVM), epithelial (KRT5, KRT14, and OCLN), and stem-like/progenitor (LGR5, MSI1, SOX9, NANOG, and OCT4/cPOUV) gene expression signatures.", [["oviduct", "ANATOMY", 31, 38], ["epithelial", "ANATOMY", 62, 72], ["stem-like/progenitor", "ANATOMY", 102, 122], ["oviduct", "MULTI-TISSUE_STRUCTURE", 31, 38], ["ESR1", "GENE_OR_GENE_PRODUCT", 40, 44], ["OVAL", "GENE_OR_GENE_PRODUCT", 46, 50], ["OVM", "GENE_OR_GENE_PRODUCT", 56, 59], ["epithelial", "TISSUE", 62, 72], ["KRT5", "GENE_OR_GENE_PRODUCT", 74, 78], ["KRT14", "GENE_OR_GENE_PRODUCT", 80, 85], ["OCLN", "GENE_OR_GENE_PRODUCT", 91, 95], ["progenitor", "CELL", 112, 122], ["LGR5", "GENE_OR_GENE_PRODUCT", 124, 128], ["MSI1", "GENE_OR_GENE_PRODUCT", 130, 134], ["SOX9", "GENE_OR_GENE_PRODUCT", 136, 140], ["NANOG", "GENE_OR_GENE_PRODUCT", 142, 147], ["OCT4", "GENE_OR_GENE_PRODUCT", 153, 157], ["cPOUV", "GENE_OR_GENE_PRODUCT", 158, 163], ["ESR1", "DNA", 40, 44], ["KRT5", "DNA", 74, 78], ["KRT14", "DNA", 80, 85], ["OCLN", "DNA", 91, 95], ["stem-like/progenitor (LGR5, MSI1, SOX9, NANOG, and OCT4/cPOUV) gene expression signatures", "DNA", 102, 191], ["Those panels", "TEST", 0, 12], ["ESR1", "TEST", 40, 44], ["OVAL", "TEST", 46, 50], ["OVM", "TEST", 56, 59], ["epithelial", "TEST", 62, 72], ["KRT5", "TEST", 74, 78], ["KRT14", "TEST", 80, 85], ["OCLN", "TEST", 91, 95], ["stem", "TEST", 102, 106], ["LGR5", "TEST", 124, 128], ["MSI1", "TEST", 130, 134], ["SOX9", "TEST", 136, 140], ["NANOG", "TEST", 142, 147], ["OCT4", "TEST", 153, 157], ["epithelial", "ANATOMY_MODIFIER", 62, 72], ["stem", "ANATOMY", 102, 106]]], ["Table 2 presents the overview of the gene function and the sequence similarity between a hen and a quail.", [["quail", "ORGANISM", 99, 104], ["hen", "SPECIES", 89, 92], ["quail", "SPECIES", 99, 104]]], ["The overall gene expression of the markers analyzed in both species (hen and quail) and sample types (tissue and in vitro) is presented in Table 3 .", [["sample", "ANATOMY", 88, 94], ["tissue", "ANATOMY", 102, 108], ["hen", "ORGANISM_SUBDIVISION", 69, 72], ["quail", "ORGANISM", 77, 82], ["tissue", "TISSUE", 102, 108], ["hen", "SPECIES", 69, 72], ["quail", "SPECIES", 77, 82], ["hen", "SPECIES", 69, 72], ["quail", "SPECIES", 77, 82], ["the markers", "TEST", 31, 42]]], ["All twelve genes were expressed only in COEC.", [["COEC", "ANATOMY", 40, 44], ["COEC", "CANCER", 40, 44], ["COEC", "CELL_LINE", 40, 44], ["twelve genes", "OBSERVATION", 4, 16]]], ["Ten out of twelve genes were expressed in oviduct tissues-sourced from both hen and quail.", [["oviduct tissues", "ANATOMY", 42, 57], ["oviduct tissues", "TISSUE", 42, 57], ["hen", "ORGANISM", 76, 79], ["quail", "ORGANISM", 84, 89], ["hen", "SPECIES", 76, 79], ["quail", "SPECIES", 84, 89], ["hen", "SPECIES", 76, 79], ["quail", "SPECIES", 84, 89]]], ["In the hen tissue, two progenitor markers (LGR5 and OCT4/cPOUV) were at a level too low to be detected.", [["hen tissue", "ANATOMY", 7, 17], ["progenitor", "ANATOMY", 23, 33], ["hen", "ORGANISM", 7, 10], ["tissue", "TISSUE", 11, 17], ["progenitor", "CELL", 23, 33], ["LGR5", "GENE_OR_GENE_PRODUCT", 43, 47], ["OCT4", "GENE_OR_GENE_PRODUCT", 52, 56], ["cPOUV", "GENE_OR_GENE_PRODUCT", 57, 62], ["progenitor markers", "PROTEIN", 23, 41], ["LGR5", "PROTEIN", 43, 47], ["OCT4", "PROTEIN", 52, 56], ["cPOUV", "PROTEIN", 57, 62], ["hen", "SPECIES", 7, 10], ["hen", "SPECIES", 7, 10], ["two progenitor markers", "TEST", 19, 41], ["LGR5 and OCT4/cPOUV)", "TEST", 43, 63]]], ["In the quail tissue, one epithelial marker (OCLN) and one progenitor marker (LGR5) were not detected.", [["quail tissue", "ANATOMY", 7, 19], ["epithelial", "ANATOMY", 25, 35], ["progenitor", "ANATOMY", 58, 68], ["quail", "ORGANISM", 7, 12], ["tissue", "TISSUE", 13, 19], ["epithelial", "TISSUE", 25, 35], ["OCLN", "GENE_OR_GENE_PRODUCT", 44, 48], ["LGR5", "GENE_OR_GENE_PRODUCT", 77, 81], ["epithelial marker", "PROTEIN", 25, 42], ["OCLN", "PROTEIN", 44, 48], ["progenitor marker", "PROTEIN", 58, 75], ["LGR5", "PROTEIN", 77, 81], ["quail", "SPECIES", 7, 12], ["quail", "SPECIES", 7, 12], ["quail tissue", "ANATOMY", 7, 19], ["one", "OBSERVATION_MODIFIER", 21, 24], ["epithelial marker", "OBSERVATION", 25, 42], ["progenitor", "OBSERVATION_MODIFIER", 58, 68], ["marker", "OBSERVATION_MODIFIER", 69, 75], ["not detected", "UNCERTAINTY", 88, 100]]], ["In QOEC, OVAL and OVM (oviduct markers) were not expressed as well as OCLN (epithelial marker).", [["oviduct", "ANATOMY", 23, 30], ["epithelial", "ANATOMY", 76, 86], ["OVAL", "GENE_OR_GENE_PRODUCT", 9, 13], ["OVM", "GENE_OR_GENE_PRODUCT", 18, 21], ["oviduct", "ORGAN", 23, 30], ["OCLN", "GENE_OR_GENE_PRODUCT", 70, 74], ["epithelial", "TISSUE", 76, 86], ["QOEC", "PROTEIN", 3, 7], ["OVAL", "PROTEIN", 9, 13], ["OVM", "PROTEIN", 18, 21], ["oviduct markers", "PROTEIN", 23, 38], ["OCLN", "PROTEIN", 70, 74], ["OVAL and OVM (oviduct markers", "TREATMENT", 9, 38], ["OVAL", "OBSERVATION_MODIFIER", 9, 13]]], ["In both species, LGR5, a progenitor marker, was absent in the oviduct tissue, but then we detected it in the oviduct epithelial cell culture.", [["progenitor", "ANATOMY", 25, 35], ["oviduct tissue", "ANATOMY", 62, 76], ["oviduct epithelial cell culture", "ANATOMY", 109, 140], ["LGR5", "GENE_OR_GENE_PRODUCT", 17, 21], ["progenitor", "CELL", 25, 35], ["oviduct tissue", "TISSUE", 62, 76], ["oviduct epithelial cell culture", "CELL", 109, 140], ["LGR5", "PROTEIN", 17, 21], ["oviduct epithelial cell culture", "CELL_LINE", 109, 140], ["a progenitor marker", "TEST", 23, 42], ["the oviduct epithelial cell culture", "TEST", 105, 140], ["oviduct tissue", "ANATOMY", 62, 76], ["oviduct", "ANATOMY", 109, 116], ["epithelial cell", "OBSERVATION", 117, 132]]], ["OCLN was not expressed in quail oviduct-neither in the tissue, nor in the cell culture.Characterization of gene expression signatures in hen and quail oviduct tissueHereby we have characterized gene expression profile in different parts (INF, DM, and PM) of hen and quail oviduct tissue (Fig. 3) .", [["oviduct", "ANATOMY", 32, 39], ["tissue", "ANATOMY", 55, 61], ["cell culture", "ANATOMY", 74, 86], ["oviduct tissueHereby", "ANATOMY", 151, 171], ["PM", "ANATOMY", 251, 253], ["oviduct tissue", "ANATOMY", 272, 286], ["OCLN", "GENE_OR_GENE_PRODUCT", 0, 4], ["quail", "ORGANISM", 26, 31], ["oviduct", "ORGAN", 32, 39], ["tissue", "TISSUE", 55, 61], ["cell culture", "CELL", 74, 86], ["hen", "ORGANISM", 137, 140], ["quail", "ORGANISM", 145, 150], ["hen", "ORGANISM", 258, 261], ["quail", "ORGANISM", 266, 271], ["oviduct tissue", "TISSUE", 272, 286], ["OCLN", "PROTEIN", 0, 4], ["quail", "SPECIES", 26, 31], ["hen", "SPECIES", 137, 140], ["quail", "SPECIES", 145, 150], ["hen", "SPECIES", 258, 261], ["quail", "SPECIES", 266, 271], ["quail", "SPECIES", 26, 31], ["hen", "SPECIES", 137, 140], ["quail", "SPECIES", 145, 150], ["hen", "SPECIES", 258, 261], ["quail", "SPECIES", 266, 271], ["the cell culture", "TEST", 70, 86], ["gene expression signatures", "PROBLEM", 107, 133], ["gene expression profile", "PROBLEM", 194, 217], ["DM", "PROBLEM", 243, 245], ["quail oviduct", "ANATOMY", 266, 279]]], ["In hen oviduct (Fig. 3a) , the expression of oviduct markers (ESR1, OVAL and OVM) increased spatially, from distal to proximal part of the oviduct with a peak in PM (P < 0.05).", [["oviduct", "ANATOMY", 7, 14], ["oviduct", "ANATOMY", 45, 52], ["oviduct", "ANATOMY", 139, 146], ["hen", "ORGANISM", 3, 6], ["oviduct", "ORGAN", 7, 14], ["oviduct", "ORGAN", 45, 52], ["ESR1", "GENE_OR_GENE_PRODUCT", 62, 66], ["OVAL", "GENE_OR_GENE_PRODUCT", 68, 72], ["OVM", "GENE_OR_GENE_PRODUCT", 77, 80], ["oviduct", "ORGAN", 139, 146], ["oviduct markers", "PROTEIN", 45, 60], ["ESR1", "PROTEIN", 62, 66], ["OVAL", "PROTEIN", 68, 72], ["OVM", "PROTEIN", 77, 80], ["hen", "SPECIES", 3, 6], ["hen", "SPECIES", 3, 6], ["oviduct", "ANATOMY", 45, 52], ["OVAL", "OBSERVATION_MODIFIER", 68, 72], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["spatially", "OBSERVATION_MODIFIER", 92, 101], ["distal", "ANATOMY_MODIFIER", 108, 114], ["proximal", "ANATOMY_MODIFIER", 118, 126], ["oviduct", "ANATOMY", 139, 146], ["peak", "OBSERVATION_MODIFIER", 154, 158]]], ["Reversely, the expression of epithelial markers, KRT14 and OCLN, was high in INF and it decreased toward PM (P < 0.05).", [["epithelial", "ANATOMY", 29, 39], ["epithelial", "TISSUE", 29, 39], ["KRT14", "GENE_OR_GENE_PRODUCT", 49, 54], ["OCLN", "GENE_OR_GENE_PRODUCT", 59, 63], ["epithelial markers", "PROTEIN", 29, 47], ["KRT14", "PROTEIN", 49, 54], ["OCLN", "PROTEIN", 59, 63], ["INF", "PROTEIN", 77, 80], ["epithelial markers", "TEST", 29, 47], ["KRT14", "TEST", 49, 54], ["OCLN", "TEST", 59, 63], ["high in INF", "PROBLEM", 69, 80], ["epithelial markers", "OBSERVATION", 29, 47], ["high", "OBSERVATION_MODIFIER", 69, 73], ["decreased", "OBSERVATION_MODIFIER", 88, 97]]], ["KRT5 was expressed at much lower level and only in INF (P < 0.05).", [["KRT5", "GENE_OR_GENE_PRODUCT", 0, 4], ["KRT5", "PROTEIN", 0, 4], ["KRT5", "TREATMENT", 0, 4]]], ["As for progenitor markers, SOX9 was uniformly expressed at high level across all fragments of the oviduct in hen (P < 0.05).", [["progenitor", "ANATOMY", 7, 17], ["fragments", "ANATOMY", 81, 90], ["oviduct", "ANATOMY", 98, 105], ["progenitor", "CELL", 7, 17], ["SOX9", "GENE_OR_GENE_PRODUCT", 27, 31], ["oviduct", "ORGAN", 98, 105], ["progenitor markers", "PROTEIN", 7, 25], ["SOX9", "PROTEIN", 27, 31], ["progenitor markers", "TEST", 7, 25], ["all", "OBSERVATION_MODIFIER", 77, 80], ["fragments", "OBSERVATION", 81, 90], ["oviduct", "ANATOMY", 98, 105]]], ["Expression of MSI1 and CD44 was the highest in INF and it gradually decreased toward PM (P < 0.05).", [["MSI1", "GENE_OR_GENE_PRODUCT", 14, 18], ["CD44", "GENE_OR_GENE_PRODUCT", 23, 27], ["MSI1", "PROTEIN", 14, 18], ["CD44", "PROTEIN", 23, 27], ["MSI1", "TEST", 14, 18], ["CD44", "TEST", 23, 27], ["highest", "OBSERVATION_MODIFIER", 36, 43], ["decreased", "OBSERVATION_MODIFIER", 68, 77]]], ["Expression of NANOG was detected, but was not significant (P > 0.05).Characterization of gene expression signatures in hen and quail oviduct tissueIn quail oviduct (Fig. 3b) , we had to use chicken primer sequences to show the expression pattern of OVAL, OVM, KRT5, KRT14, and OCT4/cPOUV.", [["oviduct", "ANATOMY", 133, 140], ["oviduct", "ANATOMY", 156, 163], ["NANOG", "GENE_OR_GENE_PRODUCT", 14, 19], ["hen", "ORGANISM", 119, 122], ["quail", "ORGANISM", 127, 132], ["quail", "ORGANISM", 150, 155], ["oviduct", "ORGAN", 156, 163], ["Fig. 3b", "CELL", 165, 172], ["chicken", "ORGANISM", 190, 197], ["OVAL", "GENE_OR_GENE_PRODUCT", 249, 253], ["OVM", "GENE_OR_GENE_PRODUCT", 255, 258], ["KRT5", "GENE_OR_GENE_PRODUCT", 260, 264], ["KRT14", "GENE_OR_GENE_PRODUCT", 266, 271], ["OCT4", "GENE_OR_GENE_PRODUCT", 277, 281], ["cPOUV", "GENE_OR_GENE_PRODUCT", 282, 287], ["NANOG", "DNA", 14, 19], ["chicken primer sequences", "DNA", 190, 214], ["OVAL", "PROTEIN", 249, 253], ["OVM", "PROTEIN", 255, 258], ["KRT5", "PROTEIN", 260, 264], ["KRT14", "PROTEIN", 266, 271], ["OCT4", "PROTEIN", 277, 281], ["cPOUV", "PROTEIN", 282, 287], ["hen", "SPECIES", 119, 122], ["quail", "SPECIES", 127, 132], ["quail", "SPECIES", 150, 155], ["chicken", "SPECIES", 190, 197], ["hen", "SPECIES", 119, 122], ["quail oviduct tissueIn quail", "SPECIES", 127, 155], ["chicken", "SPECIES", 190, 197], ["NANOG", "TEST", 14, 19], ["gene expression signatures", "PROBLEM", 89, 115], ["chicken primer sequences", "TREATMENT", 190, 214], ["KRT5", "TEST", 260, 264], ["KRT14", "TEST", 266, 271], ["gene expression", "OBSERVATION", 89, 104], ["OCT4", "ANATOMY", 277, 281]]], ["We have determined a similar pattern of the gene expression for two oviduct markers OVAL and OVM, which were expressed in all the studied oviduct compartments (INF, DM and PM).", [["oviduct", "ANATOMY", 68, 75], ["oviduct compartments", "ANATOMY", 138, 158], ["OVAL", "GENE_OR_GENE_PRODUCT", 84, 88], ["OVM", "GENE_OR_GENE_PRODUCT", 93, 96], ["oviduct compartments", "MULTI-TISSUE_STRUCTURE", 138, 158], ["oviduct markers", "PROTEIN", 68, 83], ["OVAL", "PROTEIN", 84, 88], ["OVM", "PROTEIN", 93, 96]]], ["Whereas, oviduct marker for ESR1 was significantly expressed in INF and DM compartments of a quail oviduct (P < 0.05).", [["oviduct", "ANATOMY", 9, 16], ["DM compartments", "ANATOMY", 72, 87], ["quail oviduct", "ANATOMY", 93, 106], ["oviduct", "ORGAN", 9, 16], ["ESR1", "GENE_OR_GENE_PRODUCT", 28, 32], ["INF", "CELL", 64, 67], ["quail", "ORGANISM", 93, 98], ["oviduct", "ORGAN", 99, 106], ["ESR1", "PROTEIN", 28, 32], ["quail", "SPECIES", 93, 98], ["quail", "SPECIES", 93, 98], ["ESR1", "PROBLEM", 28, 32], ["a quail oviduct", "TREATMENT", 91, 106], ["quail oviduct", "ANATOMY", 93, 106]]], ["Among epithelial markers, the expression of KRT14 and KRT5 was high and increased toward INF, but expression of OCLN did not reach the significance threshold.", [["epithelial", "ANATOMY", 6, 16], ["epithelial", "TISSUE", 6, 16], ["KRT14", "GENE_OR_GENE_PRODUCT", 44, 49], ["KRT5", "GENE_OR_GENE_PRODUCT", 54, 58], ["INF", "GENE_OR_GENE_PRODUCT", 89, 92], ["OCLN", "GENE_OR_GENE_PRODUCT", 112, 116], ["epithelial markers", "PROTEIN", 6, 24], ["KRT14", "PROTEIN", 44, 49], ["KRT5", "PROTEIN", 54, 58], ["INF", "PROTEIN", 89, 92], ["OCLN", "PROTEIN", 112, 116], ["KRT14", "TEST", 44, 49], ["KRT5", "TEST", 54, 58], ["epithelial markers", "OBSERVATION", 6, 24], ["high", "OBSERVATION_MODIFIER", 63, 67], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["In quail, we found significant expression of as much as four progenitor markers (LGR5, OCT4/cPOUV, SOX9, and CD44) (P < 0.05).Characterization of gene expression signatures in hen and quail oviduct tissueLGR5 and OCT4/cPOUV were most abundant in INF and DM compartments of the quail oviduct.", [["progenitor", "ANATOMY", 61, 71], ["oviduct", "ANATOMY", 190, 197], ["DM compartments", "ANATOMY", 254, 269], ["quail oviduct", "ANATOMY", 277, 290], ["quail", "ORGANISM", 3, 8], ["progenitor", "CELL", 61, 71], ["LGR5", "GENE_OR_GENE_PRODUCT", 81, 85], ["OCT4", "GENE_OR_GENE_PRODUCT", 87, 91], ["cPOUV", "GENE_OR_GENE_PRODUCT", 92, 97], ["SOX9", "GENE_OR_GENE_PRODUCT", 99, 103], ["CD44", "GENE_OR_GENE_PRODUCT", 109, 113], ["hen", "ORGANISM", 176, 179], ["quail", "ORGANISM", 184, 189], ["oviduct", "ORGAN", 190, 197], ["tissueLGR5", "GENE_OR_GENE_PRODUCT", 198, 208], ["OCT4", "GENE_OR_GENE_PRODUCT", 213, 217], ["cPOUV", "GENE_OR_GENE_PRODUCT", 218, 223], ["INF", "CANCER", 246, 249], ["quail", "ORGANISM", 277, 282], ["oviduct", "ORGAN", 283, 290], ["progenitor markers", "PROTEIN", 61, 79], ["LGR5", "PROTEIN", 81, 85], ["OCT4", "PROTEIN", 87, 91], ["cPOUV", "PROTEIN", 92, 97], ["SOX9", "PROTEIN", 99, 103], ["CD44", "PROTEIN", 109, 113], ["OCT4", "DNA", 213, 217], ["cPOUV", "DNA", 218, 223], ["quail", "SPECIES", 3, 8], ["hen", "SPECIES", 176, 179], ["quail", "SPECIES", 184, 189], ["quail", "SPECIES", 277, 282], ["hen", "SPECIES", 176, 179], ["quail", "SPECIES", 184, 189], ["quail", "SPECIES", 277, 282], ["progenitor markers", "TEST", 61, 79], ["LGR5", "TEST", 81, 85], ["OCT4", "TEST", 87, 91], ["cPOUV", "TEST", 92, 97], ["SOX9", "TEST", 99, 103], ["CD44", "TEST", 109, 113], ["gene expression signatures", "PROBLEM", 146, 172], ["OCT4/cPOUV", "TEST", 213, 223], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["expression", "OBSERVATION", 31, 41], ["gene expression", "OBSERVATION", 146, 161], ["quail oviduct", "ANATOMY", 277, 290]]], ["Expression of NANOG was detected but it was not significant (P > 0.05). gallus sequence with human LGR5, but the same protein sequence shows 95% identity with human VAV3 GDP/GTP exchange factor.", [["GDP", "CHEMICAL", 170, 173], ["GTP", "CHEMICAL", 174, 177], ["GDP", "CHEMICAL", 170, 173], ["GTP", "CHEMICAL", 174, 177], ["NANOG", "GENE_OR_GENE_PRODUCT", 14, 19], ["gallus", "ORGANISM", 72, 78], ["human", "ORGANISM", 93, 98], ["LGR5", "GENE_OR_GENE_PRODUCT", 99, 103], ["human", "ORGANISM", 159, 164], ["VAV3", "GENE_OR_GENE_PRODUCT", 165, 169], ["GDP", "SIMPLE_CHEMICAL", 170, 173], ["GTP exchange factor", "GENE_OR_GENE_PRODUCT", 174, 193], ["NANOG", "DNA", 14, 19], ["human LGR5", "PROTEIN", 93, 103], ["human VAV3 GDP/GTP exchange factor", "PROTEIN", 159, 193], ["gallus", "SPECIES", 72, 78], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 159, 164], ["gallus", "SPECIES", 72, 78], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 159, 164], ["NANOG", "TEST", 14, 19], ["gallus sequence", "TEST", 72, 87], ["human LGR5", "TEST", 93, 103], ["the same protein sequence", "TEST", 109, 134], ["human VAV3 GDP", "TEST", 159, 173], ["GTP exchange factor", "TREATMENT", 174, 193]]], ["For a quail, only 900 proteins are annotated in existing UniProt databases.", [["quail", "ORGANISM", 6, 11], ["quail", "SPECIES", 6, 11], ["quail", "SPECIES", 6, 11]]], ["Thus, when a gap in quail database [22] limits the interpretation of a sequence, a relevant genomic alignment onto chicken was performed [23] .", [["quail", "ORGANISM", 20, 25], ["chicken", "ORGANISM", 115, 122], ["chicken", "SPECIES", 115, 122], ["chicken", "SPECIES", 115, 122], ["a sequence", "TEST", 69, 79]]], ["Depending on the database used (ENSEMBL, NCBI, and/or UniProt), sequences of the genes selected for this study had 89%-100% similarity.", [["this study", "TEST", 100, 110]]], ["Thereby, gene expression assays developed were comparable between both speciesGene profiling of the gene expression signatures in COEC and QOECAfter having determined gene expression signatures in three specific fragments of chicken and quail oviducts, we have established the respective cell cultures, which were analyzed for the presence of the same markers.", [["fragments", "ANATOMY", 212, 221], ["oviducts", "ANATOMY", 243, 251], ["cell cultures", "ANATOMY", 288, 301], ["COEC", "CANCER", 130, 134], ["chicken", "ORGANISM", 225, 232], ["quail", "ORGANISM", 237, 242], ["oviducts", "MULTI-TISSUE_STRUCTURE", 243, 251], ["cell cultures", "CELL", 288, 301], ["COEC", "CELL_LINE", 130, 134], ["QOECAfter", "DNA", 139, 148], ["cell cultures", "CELL_LINE", 288, 301], ["chicken", "SPECIES", 225, 232], ["quail", "SPECIES", 237, 242], ["chicken", "SPECIES", 225, 232], ["quail", "SPECIES", 237, 242], ["gene expression assays", "TEST", 9, 31], ["gene expression signatures", "PROBLEM", 167, 193], ["the respective cell cultures", "TEST", 273, 301]]], ["Results of the relative gene expression analysis in chicken and quail oviduct epithelial cells are presented in Fig. 4a .", [["oviduct epithelial cells", "ANATOMY", 70, 94], ["chicken", "ORGANISM", 52, 59], ["quail", "ORGANISM", 64, 69], ["oviduct epithelial cells", "CELL", 70, 94], ["chicken and quail oviduct epithelial cells", "CELL_TYPE", 52, 94], ["chicken", "SPECIES", 52, 59], ["quail", "SPECIES", 64, 69], ["chicken", "SPECIES", 52, 59], ["quail", "SPECIES", 64, 69], ["the relative gene expression analysis", "TEST", 11, 48], ["epithelial cells", "OBSERVATION", 78, 94]]], ["In COEC (Fig. 4a) only few markers were numerically and significantly upregulated, namely OVAL, OVM, KRT14, and SOX9 (P < 0.05).", [["OVAL", "GENE_OR_GENE_PRODUCT", 90, 94], ["OVM", "GENE_OR_GENE_PRODUCT", 96, 99], ["KRT14", "GENE_OR_GENE_PRODUCT", 101, 106], ["SOX9", "GENE_OR_GENE_PRODUCT", 112, 116], ["OVAL", "PROTEIN", 90, 94], ["OVM", "PROTEIN", 96, 99], ["KRT14", "PROTEIN", 101, 106], ["SOX9", "PROTEIN", 112, 116], ["KRT14", "TEST", 101, 106], ["SOX9", "TEST", 112, 116], ["OVAL", "OBSERVATION_MODIFIER", 90, 94]]], ["In the case of QOEC, we routinely found the abundance of ovalbumin in quail oviduct cell culture using antichicken OVA antibody and western blot detection.", [["oviduct cell", "ANATOMY", 76, 88], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 57, 66], ["quail", "ORGANISM", 70, 75], ["oviduct cell", "CELL", 76, 88], ["ovalbumin", "PROTEIN", 57, 66], ["quail oviduct cell culture", "CELL_LINE", 70, 96], ["antichicken OVA antibody", "PROTEIN", 103, 127], ["quail", "SPECIES", 70, 75], ["quail", "SPECIES", 70, 75], ["ovalbumin", "TREATMENT", 57, 66], ["quail oviduct cell culture", "TEST", 70, 96], ["antichicken OVA antibody", "TREATMENT", 103, 127], ["blot detection", "TEST", 140, 154]]], ["MSI1 was upregulated statistically (P < 0.05), though it did not have high numerical values of fold induction.", [["MSI1", "GENE_OR_GENE_PRODUCT", 0, 4], ["MSI1", "PROTEIN", 0, 4], ["MSI1", "TEST", 0, 4], ["fold induction", "TREATMENT", 95, 109]]], ["In both, COEC and QOEC, OCT4/cPOUV was significantly downregulated (P < 0.", [["COEC", "CELL", 9, 13], ["OCT4", "GENE_OR_GENE_PRODUCT", 24, 28], ["cPOUV", "GENE_OR_GENE_PRODUCT", 29, 34], ["COEC", "CELL_LINE", 9, 13], ["QOEC", "DNA", 18, 22], ["OCT4", "PROTEIN", 24, 28], ["cPOUV", "PROTEIN", 29, 34], ["OCT4/cPOUV", "TEST", 24, 34]]], ["We did not determine any significant differences between COEC derived from different fragments of the oviduct, apart from the expression of OCLN (epithelial marker) andGene profiling of the gene expression signatures in COEC and QOECLGR (progenitor marker) that was high in the INF compartment (P > 0.05).Gene profiling of the gene expression signatures in COEC and QOECIn QOEC, a similar significant expression, as in COEC, was found for progenitor markers SOX9 and MSI1 as well as epithelial marker KRT14.", [["fragments", "ANATOMY", 85, 94], ["oviduct", "ANATOMY", 102, 109], ["epithelial", "ANATOMY", 146, 156], ["COEC", "ANATOMY", 220, 224], ["progenitor", "ANATOMY", 238, 248], ["INF compartment", "ANATOMY", 278, 293], ["COEC", "ANATOMY", 357, 361], ["COEC", "ANATOMY", 419, 423], ["progenitor", "ANATOMY", 439, 449], ["epithelial", "ANATOMY", 483, 493], ["oviduct", "ORGAN", 102, 109], ["OCLN", "GENE_OR_GENE_PRODUCT", 140, 144], ["epithelial", "TISSUE", 146, 156], ["COEC", "CELL", 220, 224], ["progenitor", "CELL", 238, 248], ["COEC", "CELL", 357, 361], ["COEC", "CANCER", 419, 423], ["progenitor", "CELL", 439, 449], ["SOX9", "GENE_OR_GENE_PRODUCT", 458, 462], ["MSI1", "GENE_OR_GENE_PRODUCT", 467, 471], ["epithelial", "TISSUE", 483, 493], ["KRT14", "GENE_OR_GENE_PRODUCT", 501, 506], ["COEC", "CELL_LINE", 57, 61], ["OCLN", "PROTEIN", 140, 144], ["COEC", "CELL_LINE", 220, 224], ["QOECLGR", "CELL_LINE", 229, 236], ["COEC", "CELL_LINE", 357, 361], ["QOECIn QOEC", "CELL_LINE", 366, 377], ["COEC", "CELL_LINE", 419, 423], ["progenitor markers", "PROTEIN", 439, 457], ["SOX9", "PROTEIN", 458, 462], ["MSI1", "PROTEIN", 467, 471], ["epithelial marker KRT14", "PROTEIN", 483, 506], ["progenitor marker", "TEST", 238, 255], ["progenitor markers SOX9", "TEST", 439, 462], ["MSI1", "TEST", 467, 471], ["epithelial marker KRT14", "TEST", 483, 506], ["different", "OBSERVATION_MODIFIER", 75, 84], ["fragments", "OBSERVATION", 85, 94], ["oviduct", "ANATOMY", 102, 109], ["high", "OBSERVATION_MODIFIER", 266, 270], ["INF", "ANATOMY", 278, 281], ["significant", "OBSERVATION_MODIFIER", 389, 400], ["expression", "OBSERVATION", 401, 411]]], ["The remaining epithelial and stem-like/progenitor markers were significantly expressed in the cultivated quail cells derived from all studied compartments of oviduct (P > 0.05).DiscussionAmong avian species, laying hen (Gallus gallus domesticus) and Japanese quail (C. japonica) provide two excellent experimental oviduct models to study the immunology and reproductive biology [20] .", [["epithelial", "ANATOMY", 14, 24], ["stem-like/progenitor", "ANATOMY", 29, 49], ["quail cells", "ANATOMY", 105, 116], ["compartments", "ANATOMY", 142, 154], ["oviduct", "ANATOMY", 158, 165], ["oviduct", "ANATOMY", 314, 321], ["epithelial", "CELL", 14, 24], ["stem-like", "CELL", 29, 38], ["progenitor", "CELL", 39, 49], ["quail cells", "CELL", 105, 116], ["oviduct", "ORGAN", 158, 165], ["avian", "ORGANISM", 193, 198], ["laying hen", "ORGANISM", 208, 218], ["Gallus gallus domesticus", "ORGANISM", 220, 244], ["Japanese quail", "ORGANISM", 250, 264], ["C. japonica", "ORGANISM", 266, 277], ["oviduct", "MULTI-TISSUE_STRUCTURE", 314, 321], ["epithelial and stem-like/progenitor markers", "CELL_TYPE", 14, 57], ["cultivated quail cells", "CELL_LINE", 94, 116], ["quail", "SPECIES", 105, 110], ["hen", "SPECIES", 215, 218], ["Gallus gallus", "SPECIES", 220, 233], ["domesticus", "SPECIES", 234, 244], ["quail", "SPECIES", 259, 264], ["C. japonica", "SPECIES", 266, 277], ["quail", "SPECIES", 105, 110], ["hen", "SPECIES", 215, 218], ["Gallus gallus domesticus", "SPECIES", 220, 244], ["Japanese quail", "SPECIES", 250, 264], ["C. japonica", "SPECIES", 266, 277], ["laying hen (Gallus gallus domesticus", "TREATMENT", 208, 244], ["Japanese quail (C. japonica)", "TREATMENT", 250, 278], ["epithelial", "ANATOMY_MODIFIER", 14, 24], ["stem", "ANATOMY_MODIFIER", 29, 33], ["progenitor markers", "OBSERVATION", 39, 57], ["oviduct", "ANATOMY", 158, 165]]], ["Particular properties of oviductal cells include hormonal regulators as well as biosynthetic and secretive activity, which can be used for biomedical applications.", [["oviductal cells", "ANATOMY", 25, 40], ["oviductal cells", "CELL", 25, 40], ["oviductal cells", "CELL_TYPE", 25, 40], ["oviductal cells", "PROBLEM", 25, 40], ["hormonal regulators", "TREATMENT", 49, 68], ["biosynthetic and secretive activity", "TREATMENT", 80, 115], ["biomedical applications", "TREATMENT", 139, 162], ["oviductal cells", "OBSERVATION", 25, 40], ["hormonal regulators", "OBSERVATION", 49, 68], ["secretive activity", "OBSERVATION", 97, 115]]], ["Firstly, the secreting function of an oviduct epithelium makes it an ideal natural bioreactor to obtain human therapeutic proteins by using genetic manipulation of the oviduct secretome.", [["oviduct epithelium", "ANATOMY", 38, 56], ["oviduct secretome", "ANATOMY", 168, 185], ["oviduct epithelium", "TISSUE", 38, 56], ["human", "ORGANISM", 104, 109], ["oviduct", "ORGAN", 168, 175], ["human therapeutic proteins", "PROTEIN", 104, 130], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["an oviduct epithelium", "PROBLEM", 35, 56], ["human therapeutic proteins", "TREATMENT", 104, 130], ["genetic manipulation of the oviduct secretome", "TREATMENT", 140, 185], ["oviduct", "ANATOMY", 168, 175]]], ["The product is accumulated in the egg white and is easily harvested [3] .", [["egg white", "ANATOMY", 34, 43], ["accumulated", "OBSERVATION_MODIFIER", 15, 26], ["egg", "ANATOMY", 34, 37], ["harvested", "OBSERVATION", 58, 67]]], ["Secondly, both hen and quail are recognized to reflect the development and chemoprevention of spontaneous leiomyoma, also known as fibroids of the oviduct in relation to human cancer [21] .", [["leiomyoma", "ANATOMY", 106, 115], ["fibroids", "ANATOMY", 131, 139], ["oviduct", "ANATOMY", 147, 154], ["cancer", "ANATOMY", 176, 182], ["leiomyoma", "DISEASE", 106, 115], ["fibroids of the oviduct", "DISEASE", 131, 154], ["cancer", "DISEASE", 176, 182], ["hen", "ORGANISM", 15, 18], ["quail", "ORGANISM", 23, 28], ["leiomyoma", "CANCER", 106, 115], ["oviduct", "ORGAN", 147, 154], ["human", "ORGANISM", 170, 175], ["cancer", "CANCER", 176, 182], ["hen", "SPECIES", 15, 18], ["quail", "SPECIES", 23, 28], ["human", "SPECIES", 170, 175], ["hen", "SPECIES", 15, 18], ["quail", "SPECIES", 23, 28], ["human", "SPECIES", 170, 175], ["spontaneous leiomyoma", "PROBLEM", 94, 115], ["fibroids of the oviduct", "PROBLEM", 131, 154], ["human cancer", "PROBLEM", 170, 182], ["spontaneous", "OBSERVATION_MODIFIER", 94, 105], ["leiomyoma", "OBSERVATION", 106, 115], ["fibroids", "OBSERVATION", 131, 139], ["oviduct", "ANATOMY", 147, 154], ["human", "ANATOMY", 170, 175], ["cancer", "OBSERVATION", 176, 182]]], ["Thirdly, the development of new oviduct cell lines would allow selectively propagating and studying important pathogens including Campylobacter and Salmonella strains or influenza and Coronaviruses.", [["oviduct cell lines", "ANATOMY", 32, 50], ["influenza", "DISEASE", 170, 179], ["oviduct cell lines", "CELL", 32, 50], ["Salmonella strains", "ORGANISM", 148, 166], ["Coronaviruses", "CANCER", 184, 197], ["oviduct cell lines", "CELL_LINE", 32, 50], ["new oviduct cell lines", "TREATMENT", 28, 50], ["Campylobacter", "PROBLEM", 130, 143], ["Salmonella strains", "PROBLEM", 148, 166], ["influenza", "PROBLEM", 170, 179], ["Coronaviruses", "PROBLEM", 184, 197], ["new", "OBSERVATION_MODIFIER", 28, 31], ["oviduct cell lines", "OBSERVATION", 32, 50], ["Salmonella strains", "OBSERVATION", 148, 166]]], ["Such cell lines offer new in vitro substrates for pathogens originating from a reproductive tract.DiscussionFor this purpose, we have attempted to provide a utility set of molecular markers to characterize the avian oviduct tissue in hen and quail and in vitro-derived oviduct epithelial cell culture.", [["cell lines", "ANATOMY", 5, 15], ["reproductive tract", "ANATOMY", 79, 97], ["oviduct tissue", "ANATOMY", 216, 230], ["oviduct epithelial cell culture", "ANATOMY", 269, 300], ["cell lines", "CELL", 5, 15], ["reproductive tract", "ORGANISM_SUBDIVISION", 79, 97], ["avian", "ORGANISM", 210, 215], ["oviduct tissue", "TISSUE", 216, 230], ["hen", "ORGANISM", 234, 237], ["quail", "ORGANISM", 242, 247], ["oviduct epithelial cell culture", "CELL", 269, 300], ["cell lines", "CELL_LINE", 5, 15], ["oviduct epithelial cell culture", "CELL_LINE", 269, 300], ["hen", "SPECIES", 234, 237], ["quail", "SPECIES", 242, 247], ["hen", "SPECIES", 234, 237], ["quail", "SPECIES", 242, 247], ["Such cell lines", "TREATMENT", 0, 15], ["new in vitro substrates", "TREATMENT", 22, 45], ["pathogens", "PROBLEM", 50, 59], ["a reproductive tract", "PROBLEM", 77, 97], ["molecular markers", "TEST", 172, 189], ["the avian oviduct tissue", "PROBLEM", 206, 230], ["epithelial cell culture", "TEST", 277, 300], ["cell lines", "OBSERVATION", 5, 15], ["epithelial cell", "OBSERVATION", 277, 292]]], ["For a quail, only 900 proteins are annotated in the existing UniProt databases.", [["quail", "ORGANISM", 6, 11], ["quail", "SPECIES", 6, 11], ["quail", "SPECIES", 6, 11]]], ["Thus, when a gap in quail database [22] limits the interpretation of a sequence, a relevant genomic alignment onto the chicken is performed [23] .", [["quail", "ORGANISM", 20, 25], ["chicken", "ORGANISM", 119, 126], ["chicken", "SPECIES", 119, 126], ["quail", "SPECIES", 20, 25], ["chicken", "SPECIES", 119, 126], ["a sequence", "TEST", 69, 79]]], ["Depending on the database used (ENSEMBL, NCBi, and/or UniProt), sequences of the genes selected for this study had 89%-100% similarity.", [["NCBi", "DNA", 41, 45], ["this study", "TEST", 100, 110]]], ["Thereby, gene expression assays developed were comparable between both species.DiscussionIn our study, all 12 analyzed genes were expressed in both hen and quail.", [["hen", "ORGANISM", 148, 151], ["quail", "ORGANISM", 156, 161], ["hen", "SPECIES", 148, 151], ["quail", "SPECIES", 156, 161], ["hen", "SPECIES", 148, 151], ["quail", "SPECIES", 156, 161], ["gene expression assays", "TEST", 9, 31], ["our study", "TEST", 92, 101]]], ["In the first part, we have characterized gene expression signatures in three compartments of the oviduct tissue in hen and quail.", [["compartments", "ANATOMY", 77, 89], ["oviduct tissue", "ANATOMY", 97, 111], ["oviduct tissue", "TISSUE", 97, 111], ["hen", "ORGANISM", 115, 118], ["quail", "ORGANISM", 123, 128], ["hen", "SPECIES", 115, 118], ["quail", "SPECIES", 123, 128], ["hen", "SPECIES", 115, 118], ["quail", "SPECIES", 123, 128], ["gene expression signatures", "PROBLEM", 41, 67], ["gene", "OBSERVATION", 41, 45], ["expression signatures", "OBSERVATION", 46, 67], ["oviduct tissue", "ANATOMY", 97, 111]]], ["The mRNA abundance of the oviduct markers (ESR1, OVAL, and OVM) increased toward proximal parts of the oviduct.", [["oviduct", "ANATOMY", 26, 33], ["proximal parts", "ANATOMY", 81, 95], ["oviduct", "ANATOMY", 103, 110], ["oviduct", "MULTI-TISSUE_STRUCTURE", 26, 33], ["ESR1", "GENE_OR_GENE_PRODUCT", 43, 47], ["OVAL", "GENE_OR_GENE_PRODUCT", 49, 53], ["OVM", "GENE_OR_GENE_PRODUCT", 59, 62], ["oviduct", "ORGAN", 103, 110], ["oviduct markers", "PROTEIN", 26, 41], ["ESR1", "PROTEIN", 43, 47], ["OVAL", "PROTEIN", 49, 53], ["OVM", "PROTEIN", 59, 62], ["the oviduct markers", "TEST", 22, 41], ["ESR1", "TEST", 43, 47], ["abundance", "OBSERVATION_MODIFIER", 9, 18], ["oviduct", "ANATOMY", 26, 33], ["OVAL", "OBSERVATION_MODIFIER", 49, 53], ["proximal", "ANATOMY_MODIFIER", 81, 89], ["parts", "ANATOMY_MODIFIER", 90, 95], ["oviduct", "ANATOMY", 103, 110]]], ["Those differences between infundibulum and magnum compartments were significant only in hen earlier, but we have determined a clear numerical pattern also in quail.", [["infundibulum", "ANATOMY", 26, 38], ["magnum compartments", "ANATOMY", 43, 62], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 26, 38], ["magnum compartments", "MULTI-TISSUE_STRUCTURE", 43, 62], ["quail", "ORGANISM", 158, 163], ["quail", "SPECIES", 158, 163], ["quail", "SPECIES", 158, 163], ["Those differences between infundibulum and magnum compartments", "PROBLEM", 0, 62], ["infundibulum", "ANATOMY_MODIFIER", 26, 38], ["magnum", "ANATOMY", 43, 49], ["significant", "OBSERVATION_MODIFIER", 68, 79]]], ["Such a pattern of the oviduct markers reflects physiological functions of distinct compartments, e.g., oocyte transport and sperm storage in the infundibulum vs. egg white protein production in the magnum.", [["oviduct", "ANATOMY", 22, 29], ["compartments", "ANATOMY", 83, 95], ["oocyte", "ANATOMY", 103, 109], ["sperm", "ANATOMY", 124, 129], ["infundibulum", "ANATOMY", 145, 157], ["magnum", "ANATOMY", 198, 204], ["oviduct", "MULTI-TISSUE_STRUCTURE", 22, 29], ["oocyte", "CELLULAR_COMPONENT", 103, 109], ["sperm", "CELLULAR_COMPONENT", 124, 129], ["infundibulum", "ORGAN", 145, 157], ["magnum", "ORGAN", 198, 204], ["oviduct markers", "PROTEIN", 22, 37], ["sperm", "CELL_TYPE", 124, 129], ["the oviduct markers", "TEST", 18, 37], ["oocyte transport", "TREATMENT", 103, 119], ["sperm storage in the infundibulum", "PROBLEM", 124, 157], ["egg white protein production in the magnum", "PROBLEM", 162, 204], ["oviduct", "ANATOMY", 22, 29], ["physiological functions", "OBSERVATION", 47, 70], ["distinct", "OBSERVATION_MODIFIER", 74, 82], ["compartments", "OBSERVATION_MODIFIER", 83, 95], ["infundibulum", "ANATOMY_MODIFIER", 145, 157], ["magnum", "ANATOMY", 198, 204]]], ["For this reason, ESR1, which encodes the estrogen receptor 1, whose major function is binding estradiol-a major sex hormone of laying birds, was expressed in all parts of the oviduct.", [["oviduct", "ANATOMY", 175, 182], ["estrogen", "CHEMICAL", 41, 49], ["estradiol", "CHEMICAL", 94, 103], ["estrogen", "CHEMICAL", 41, 49], ["estradiol", "CHEMICAL", 94, 103], ["ESR1", "GENE_OR_GENE_PRODUCT", 17, 21], ["estrogen receptor 1", "GENE_OR_GENE_PRODUCT", 41, 60], ["estradiol", "SIMPLE_CHEMICAL", 94, 103], ["birds", "ORGANISM", 134, 139], ["oviduct", "ORGAN", 175, 182], ["ESR1", "PROTEIN", 17, 21], ["estrogen receptor 1", "PROTEIN", 41, 60], ["the estrogen receptor", "TREATMENT", 37, 58], ["oviduct", "ANATOMY", 175, 182]]], ["On the other hand, OVAL and OVM, which encode major egg white proteins, were expressed only in the magnum.", [["magnum", "ANATOMY", 99, 105], ["OVAL", "GENE_OR_GENE_PRODUCT", 19, 23], ["OVM", "GENE_OR_GENE_PRODUCT", 28, 31], ["egg white proteins", "GENE_OR_GENE_PRODUCT", 52, 70], ["magnum", "ORGAN", 99, 105], ["OVAL", "PROTEIN", 19, 23], ["OVM", "PROTEIN", 28, 31], ["major egg white proteins", "PROTEIN", 46, 70], ["OVAL and OVM", "TREATMENT", 19, 31], ["magnum", "ANATOMY", 99, 105]]], ["Such a pattern of the gene expression across the avian oviduct has been widely reported in the literature [24, 25] and it validates the functional setup of this experiment.", [["oviduct", "ANATOMY", 55, 62], ["oviduct", "ORGAN", 55, 62]]], ["In a panel of epithelial markers characterized in tissue, we have determined a reverse pattern, i.e., decrease of mRNA abundance from distal toward proximal parts of oviduct, in particular of KRT14, which was strongly expressed in the infundibulum of both, hen and quail.", [["epithelial", "ANATOMY", 14, 24], ["tissue", "ANATOMY", 50, 56], ["proximal parts", "ANATOMY", 148, 162], ["oviduct", "ANATOMY", 166, 173], ["infundibulum", "ANATOMY", 235, 247], ["epithelial", "CELL", 14, 24], ["tissue", "TISSUE", 50, 56], ["oviduct", "ORGAN", 166, 173], ["KRT14", "GENE_OR_GENE_PRODUCT", 192, 197], ["infundibulum", "ORGAN", 235, 247], ["hen", "ORGANISM", 257, 260], ["quail", "ORGANISM", 265, 270], ["epithelial markers", "PROTEIN", 14, 32], ["KRT14", "PROTEIN", 192, 197], ["hen", "SPECIES", 257, 260], ["quail", "SPECIES", 265, 270], ["hen", "SPECIES", 257, 260], ["quail", "SPECIES", 265, 270], ["epithelial markers", "TEST", 14, 32], ["mRNA abundance", "PROBLEM", 114, 128], ["epithelial markers", "OBSERVATION", 14, 32], ["decrease", "OBSERVATION_MODIFIER", 102, 110], ["mRNA abundance", "OBSERVATION", 114, 128], ["distal", "ANATOMY_MODIFIER", 134, 140], ["proximal", "ANATOMY_MODIFIER", 148, 156], ["parts", "ANATOMY_MODIFIER", 157, 162], ["oviduct", "ANATOMY", 166, 173], ["infundibulum", "ANATOMY_MODIFIER", 235, 247], ["both", "ANATOMY_MODIFIER", 251, 255]]], ["KRT5 appeared to be more abundant in quail and OCLN was significantly expressed in chicken oviduct.", [["quail", "ANATOMY", 37, 42], ["oviduct", "ANATOMY", 91, 98], ["KRT5", "GENE_OR_GENE_PRODUCT", 0, 4], ["quail", "ORGANISM", 37, 42], ["OCLN", "GENE_OR_GENE_PRODUCT", 47, 51], ["chicken", "ORGANISM", 83, 90], ["oviduct", "ORGAN", 91, 98], ["KRT5", "PROTEIN", 0, 4], ["quail", "SPECIES", 37, 42], ["chicken", "SPECIES", 83, 90], ["quail", "SPECIES", 37, 42], ["chicken", "SPECIES", 83, 90], ["more", "OBSERVATION_MODIFIER", 20, 24], ["abundant", "OBSERVATION", 25, 33], ["chicken oviduct", "OBSERVATION", 83, 98]]], ["Keratins encode for cytoskeletal proteins of highly proliferating basal epithelial cells [26] .", [["cytoskeletal", "ANATOMY", 20, 32], ["basal epithelial cells", "ANATOMY", 66, 88], ["Keratins", "GENE_OR_GENE_PRODUCT", 0, 8], ["basal epithelial cells", "CELL", 66, 88], ["Keratins", "PROTEIN", 0, 8], ["cytoskeletal proteins", "PROTEIN", 20, 41], ["highly proliferating basal epithelial cells", "CELL_TYPE", 45, 88], ["cytoskeletal proteins", "TEST", 20, 41], ["highly proliferating basal epithelial cells", "PROBLEM", 45, 88], ["highly", "OBSERVATION_MODIFIER", 45, 51], ["proliferating", "OBSERVATION_MODIFIER", 52, 65], ["basal epithelial cells", "OBSERVATION", 66, 88]]], ["Infundibulum is lined with ciliated epithelia, which are highly used by the frequent transportation of the oocyte and protein secretion.", [["ciliated epithelia", "ANATOMY", 27, 45], ["oocyte", "ANATOMY", 107, 113], ["ciliated epithelia", "TISSUE", 27, 45], ["oocyte", "CELLULAR_COMPONENT", 107, 113], ["ciliated epithelia", "PROBLEM", 27, 45], ["lined", "OBSERVATION", 16, 21], ["ciliated epithelia", "OBSERVATION", 27, 45]]], ["They require constant renewal from the basal epithelium, which is intensively proliferating.", [["basal epithelium", "ANATOMY", 39, 55], ["basal epithelium", "TISSUE", 39, 55], ["basal", "ANATOMY_MODIFIER", 39, 44], ["epithelium", "ANATOMY", 45, 55], ["proliferating", "OBSERVATION_MODIFIER", 78, 91]]], ["Strong induction of keratin genes is related with this function of the infundibulum.", [["infundibulum", "ANATOMY", 71, 83], ["keratin", "GENE_OR_GENE_PRODUCT", 20, 27], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 71, 83], ["keratin genes", "DNA", 20, 33], ["keratin genes", "PROBLEM", 20, 33], ["keratin genes", "OBSERVATION", 20, 33], ["infundibulum", "ANATOMY_MODIFIER", 71, 83]]], ["Previously, we have detected cytokeratins in chicken infundibulum by using immunohistochemistry technique, both in tissue and in vitro [6] , which is in line with the results of the current study.DiscussionAs for stem-like/progenitor markers analyzed in tissue, chicken expressed high mRNA abundance of CD44 and SOX9; moderate abundance of MSI1 and low of NANOG.", [["infundibulum", "ANATOMY", 53, 65], ["tissue", "ANATOMY", 115, 121], ["stem-like/progenitor", "ANATOMY", 213, 233], ["tissue", "ANATOMY", 254, 260], ["cytokeratins", "GENE_OR_GENE_PRODUCT", 29, 41], ["chicken", "ORGANISM", 45, 52], ["infundibulum", "ORGAN", 53, 65], ["tissue", "TISSUE", 115, 121], ["stem-like", "CELL", 213, 222], ["progenitor", "CELL", 223, 233], ["tissue", "TISSUE", 254, 260], ["chicken", "ORGANISM", 262, 269], ["CD44", "GENE_OR_GENE_PRODUCT", 303, 307], ["SOX9", "GENE_OR_GENE_PRODUCT", 312, 316], ["MSI1", "GENE_OR_GENE_PRODUCT", 340, 344], ["NANOG", "GENE_OR_GENE_PRODUCT", 356, 361], ["cytokeratins", "PROTEIN", 29, 41], ["stem-like/progenitor markers", "PROTEIN", 213, 241], ["CD44", "PROTEIN", 303, 307], ["SOX9", "PROTEIN", 312, 316], ["MSI1", "PROTEIN", 340, 344], ["NANOG", "PROTEIN", 356, 361], ["chicken", "SPECIES", 45, 52], ["chicken", "SPECIES", 262, 269], ["chicken", "SPECIES", 45, 52], ["chicken", "SPECIES", 262, 269], ["cytokeratins in chicken infundibulum", "PROBLEM", 29, 65], ["immunohistochemistry technique", "TEST", 75, 105], ["the current study", "TEST", 178, 195], ["stem-like/progenitor markers", "PROBLEM", 213, 241], ["SOX9", "TEST", 312, 316], ["moderate abundance of MSI1", "PROBLEM", 318, 344], ["low of NANOG", "PROBLEM", 349, 361], ["chicken infundibulum", "OBSERVATION_MODIFIER", 45, 65], ["moderate", "OBSERVATION_MODIFIER", 318, 326]]], ["OCT4/cPOUV and LGR5 were not expressed in the chicken oviduct tissue.", [["oviduct tissue", "ANATOMY", 54, 68], ["OCT4", "GENE_OR_GENE_PRODUCT", 0, 4], ["cPOUV", "GENE_OR_GENE_PRODUCT", 5, 10], ["LGR5", "GENE_OR_GENE_PRODUCT", 15, 19], ["chicken", "ORGANISM", 46, 53], ["oviduct tissue", "TISSUE", 54, 68], ["OCT4", "PROTEIN", 0, 4], ["cPOUV", "PROTEIN", 5, 10], ["LGR5", "PROTEIN", 15, 19], ["chicken", "SPECIES", 46, 53], ["chicken", "SPECIES", 46, 53], ["LGR5", "TREATMENT", 15, 19]]], ["In quail, we determined a high-fold induction of LGR5 and OCT4/cPOUV and a moderate abundance of CD44 and SOX9.", [["quail", "ORGANISM", 3, 8], ["LGR5", "GENE_OR_GENE_PRODUCT", 49, 53], ["OCT4", "GENE_OR_GENE_PRODUCT", 58, 62], ["cPOUV", "GENE_OR_GENE_PRODUCT", 63, 68], ["CD44", "GENE_OR_GENE_PRODUCT", 97, 101], ["SOX9", "GENE_OR_GENE_PRODUCT", 106, 110], ["LGR5", "PROTEIN", 49, 53], ["OCT4", "PROTEIN", 58, 62], ["cPOUV", "PROTEIN", 63, 68], ["CD44", "PROTEIN", 97, 101], ["SOX9", "PROTEIN", 106, 110], ["quail", "SPECIES", 3, 8], ["a high-fold induction", "TREATMENT", 24, 45], ["LGR5 and OCT4/cPOUV", "TEST", 49, 68], ["moderate", "OBSERVATION_MODIFIER", 75, 83], ["abundance", "OBSERVATION_MODIFIER", 84, 93], ["CD44", "OBSERVATION", 97, 101]]], ["CD44 is a cell surface glycoprotein and an established progenitor/stemlike cell marker in fallopian tube in mammals.", [["cell surface", "ANATOMY", 10, 22], ["progenitor/stemlike cell", "ANATOMY", 55, 79], ["fallopian tube", "ANATOMY", 90, 104], ["CD44", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 10, 14], ["progenitor", "CELL", 55, 65], ["stemlike cell", "CELL", 66, 79], ["fallopian tube", "TISSUE", 90, 104], ["CD44", "PROTEIN", 0, 4], ["cell surface glycoprotein", "PROTEIN", 10, 35], ["progenitor/stemlike cell marker", "CELL_TYPE", 55, 86], ["a cell surface glycoprotein", "TREATMENT", 8, 35], ["an established progenitor/stemlike cell marker", "TREATMENT", 40, 86], ["fallopian tube", "TREATMENT", 90, 104], ["stemlike cell marker", "OBSERVATION", 66, 86], ["fallopian tube", "OBSERVATION", 90, 104]]], ["CD44positive cell population showed the capacity for clonal growth and differentiation into tubal epithelial cells, particularly in the distal region of the tube [15, 27] .", [["CD44positive cell", "ANATOMY", 0, 17], ["tubal epithelial cells", "ANATOMY", 92, 114], ["distal region", "ANATOMY", 136, 149], ["tube", "ANATOMY", 157, 161], ["CD44positive cell", "CELL", 0, 17], ["clonal", "CELL", 53, 59], ["tubal epithelial cells", "CELL", 92, 114], ["tube", "TISSUE", 157, 161], ["CD44positive cell population", "CELL_LINE", 0, 28], ["tubal epithelial cells", "CELL_TYPE", 92, 114], ["CD44positive cell population", "TEST", 0, 28], ["the capacity", "TEST", 36, 48], ["clonal growth and differentiation into tubal epithelial cells", "PROBLEM", 53, 114], ["cell population", "OBSERVATION", 13, 28], ["growth", "OBSERVATION_MODIFIER", 60, 66], ["tubal epithelial cells", "OBSERVATION", 92, 114], ["distal", "ANATOMY_MODIFIER", 136, 142], ["region", "ANATOMY_MODIFIER", 143, 149], ["tube", "OBSERVATION", 157, 161]]], ["We Pairwise t-test was conducted to determine the significant modulation of the gene expression in the oviduct as compared to the external calibrator (breast muscle) (P < 0.05).", [["oviduct", "ANATOMY", 103, 110], ["breast muscle", "ANATOMY", 151, 164], ["oviduct", "ORGAN", 103, 110], ["breast muscle", "TISSUE", 151, 164], ["Pairwise t-test", "TEST", 3, 18], ["the gene expression in the oviduct", "PROBLEM", 76, 110], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["gene expression", "OBSERVATION", 80, 95], ["oviduct", "ANATOMY", 103, 110], ["external calibrator", "ANATOMY", 130, 149], ["breast muscle", "ANATOMY", 151, 164]]], ["Letters A, B, and C in brackets indicate results of one-way ANOVA multiple comparisons between different fragments of the oviduct (P < 0.05) stimulated with the estrogen prior to tissue harvesting, nor the cultivated cells were treated with estrogen, which might explain the lack of ESR-1 mRNA in the cultivated COEC.", [["fragments", "ANATOMY", 105, 114], ["oviduct", "ANATOMY", 122, 129], ["tissue", "ANATOMY", 179, 185], ["cells", "ANATOMY", 217, 222], ["COEC", "ANATOMY", 312, 316], ["estrogen", "CHEMICAL", 161, 169], ["estrogen", "CHEMICAL", 241, 249], ["estrogen", "CHEMICAL", 161, 169], ["estrogen", "CHEMICAL", 241, 249], ["B", "CELL", 11, 12], ["oviduct", "ORGAN", 122, 129], ["estrogen", "SIMPLE_CHEMICAL", 161, 169], ["tissue", "TISSUE", 179, 185], ["cells", "CELL", 217, 222], ["estrogen", "SIMPLE_CHEMICAL", 241, 249], ["ESR-1", "GENE_OR_GENE_PRODUCT", 283, 288], ["COEC", "CELL", 312, 316], ["cultivated cells", "CELL_LINE", 206, 222], ["ESR-1 mRNA", "RNA", 283, 293], ["COEC", "CELL_LINE", 312, 316], ["C in brackets", "TREATMENT", 18, 31], ["the estrogen", "TREATMENT", 157, 169], ["tissue harvesting", "TREATMENT", 179, 196], ["the cultivated cells", "PROBLEM", 202, 222], ["estrogen", "TREATMENT", 241, 249], ["ESR", "TEST", 283, 286], ["oviduct", "ANATOMY", 122, 129]]], ["Epithelial character of both COEC and QOEC was maintained, especially in KRT14 (COEC) and other epithelial markers (QOEC) mRNA abundance.DiscussionExpression of progenitor markers of early epithelial lineage (SOX9, MSI1, and LGR5) in both oviduct epithelial cultures was determined.DiscussionLGR5 was significantly upregulated in cultivated cells, and has been proven to mark the stem cells in murine oviduct/fimbria [14] .", [["Epithelial", "ANATOMY", 0, 10], ["COEC", "ANATOMY", 29, 33], ["epithelial", "ANATOMY", 96, 106], ["progenitor", "ANATOMY", 161, 171], ["epithelial lineage", "ANATOMY", 189, 207], ["oviduct epithelial cultures", "ANATOMY", 239, 266], ["cells", "ANATOMY", 341, 346], ["stem cells", "ANATOMY", 380, 390], ["oviduct", "ANATOMY", 401, 408], ["Epithelial", "TISSUE", 0, 10], ["COEC", "CELL", 29, 33], ["KRT14", "GENE_OR_GENE_PRODUCT", 73, 78], ["epithelial", "TISSUE", 96, 106], ["QOEC", "GENE_OR_GENE_PRODUCT", 116, 120], ["progenitor", "CELL", 161, 171], ["epithelial lineage", "CELL", 189, 207], ["SOX9", "GENE_OR_GENE_PRODUCT", 209, 213], ["MSI1", "GENE_OR_GENE_PRODUCT", 215, 219], ["LGR5", "GENE_OR_GENE_PRODUCT", 225, 229], ["oviduct epithelial cultures", "CELL", 239, 266], ["DiscussionLGR5", "GENE_OR_GENE_PRODUCT", 282, 296], ["cells", "CELL", 341, 346], ["stem cells", "CELL", 380, 390], ["murine", "ORGANISM", 394, 400], ["oviduct", "DEVELOPING_ANATOMICAL_STRUCTURE", 401, 408], ["COEC", "CELL_LINE", 29, 33], ["KRT14", "CELL_LINE", 73, 78], ["COEC", "CELL_LINE", 80, 84], ["epithelial markers (QOEC) mRNA", "RNA", 96, 126], ["progenitor markers", "PROTEIN", 161, 179], ["early epithelial lineage", "CELL_TYPE", 183, 207], ["SOX9", "DNA", 209, 213], ["MSI1", "PROTEIN", 215, 219], ["LGR5", "PROTEIN", 225, 229], ["oviduct epithelial cultures", "CELL_LINE", 239, 266], ["DiscussionLGR5", "PROTEIN", 282, 296], ["cultivated cells", "CELL_LINE", 330, 346], ["stem cells", "CELL_TYPE", 380, 390], ["murine", "SPECIES", 394, 400], ["Epithelial character", "TEST", 0, 20], ["other epithelial markers", "TEST", 90, 114], ["progenitor markers", "TEST", 161, 179], ["MSI1", "TEST", 215, 219], ["both oviduct epithelial cultures", "TEST", 234, 266], ["both", "ANATOMY_MODIFIER", 24, 28], ["COEC", "ANATOMY", 29, 33], ["epithelial markers", "OBSERVATION", 96, 114], ["epithelial lineage", "OBSERVATION", 189, 207], ["both", "ANATOMY_MODIFIER", 234, 238], ["oviduct", "ANATOMY", 239, 246], ["epithelial", "ANATOMY_MODIFIER", 247, 257], ["cultivated cells", "OBSERVATION", 330, 346], ["stem cells", "OBSERVATION", 380, 390]]], ["Precursor character of certain populations of cultured cells allowed for their proliferation and differentiation in vitro.", [["cells", "ANATOMY", 55, 60], ["cells", "CELL", 55, 60], ["cultured cells", "CELL_LINE", 46, 60], ["cultured cells", "PROBLEM", 46, 60], ["their proliferation", "PROBLEM", 73, 92]]], ["INF-derived COEC gained gene expression signatures of oviduct secretive cells (OVM and OVAL).", [["oviduct secretive cells", "ANATOMY", 54, 77], ["OVM", "ANATOMY", 79, 82], ["OVAL", "ANATOMY", 87, 91], ["INF", "GENE_OR_GENE_PRODUCT", 0, 3], ["COEC", "CELL", 12, 16], ["oviduct secretive cells", "CELL", 54, 77], ["OVM", "CELL", 79, 82], ["INF", "PROTEIN", 0, 3], ["COEC", "DNA", 12, 16], ["oviduct secretive cells", "CELL_TYPE", 54, 77], ["OVM", "CELL_TYPE", 79, 82], ["OVAL", "CELL_TYPE", 87, 91]]], ["Population of progenitor cells is required for the establishment of a primary cell culture [35] .", [["progenitor cells", "ANATOMY", 14, 30], ["cell", "ANATOMY", 78, 82], ["progenitor cells", "CELL", 14, 30], ["cell", "CELL", 78, 82], ["progenitor cells", "CELL_TYPE", 14, 30], ["progenitor cells", "PROBLEM", 14, 30], ["a primary cell culture", "TEST", 68, 90], ["progenitor cells", "OBSERVATION", 14, 30]]], ["In our study, we have confirmed progenitor gene expression signatures in proliferating cultures.", [["progenitor", "ANATOMY", 32, 42], ["cultures", "ANATOMY", 87, 95], ["progenitor", "CELL", 32, 42], ["proliferating cultures", "CELL_LINE", 73, 95], ["our study", "TEST", 3, 12], ["progenitor gene expression signatures", "PROBLEM", 32, 69], ["proliferating cultures", "TEST", 73, 95]]], ["Based on the morphological assessment, a subpopulation of the cultured cells displayed epithelial character of ciliated and secreting cells.", [["cells", "ANATOMY", 71, 76], ["epithelial", "ANATOMY", 87, 97], ["ciliated", "ANATOMY", 111, 119], ["cells", "ANATOMY", 134, 139], ["cells", "CELL", 71, 76], ["epithelial", "CELL", 87, 97], ["cells", "CELL", 134, 139], ["cultured cells", "CELL_LINE", 62, 76], ["ciliated and secreting cells", "CELL_TYPE", 111, 139], ["the morphological assessment", "TEST", 9, 37], ["the cultured cells", "TEST", 58, 76], ["epithelial character of ciliated and secreting cells", "PROBLEM", 87, 139], ["epithelial character", "OBSERVATION", 87, 107], ["ciliated", "ANATOMY_MODIFIER", 111, 119], ["secreting cells", "OBSERVATION", 124, 139]]], ["But there was also a large subpopulation of differentiated mesenchymal and fibroblast-like forms in both COEC and QOEC, after passaging.", [["mesenchymal", "ANATOMY", 59, 70], ["fibroblast", "ANATOMY", 75, 85], ["COEC", "ANATOMY", 105, 109], ["QOEC", "ANATOMY", 114, 118], ["mesenchymal", "CELL", 59, 70], ["fibroblast", "CELL", 75, 85], ["COEC", "CELL", 105, 109], ["differentiated mesenchymal and fibroblast-like forms", "CELL_LINE", 44, 96], ["COEC", "CELL_LINE", 105, 109], ["QOEC", "CELL_LINE", 114, 118], ["large", "OBSERVATION_MODIFIER", 21, 26], ["subpopulation", "OBSERVATION_MODIFIER", 27, 40], ["differentiated", "OBSERVATION_MODIFIER", 44, 58], ["mesenchymal", "OBSERVATION", 59, 70], ["fibroblast-like forms", "OBSERVATION_MODIFIER", 75, 96], ["both", "ANATOMY_MODIFIER", 100, 104], ["COEC", "ANATOMY", 105, 109]]], ["With these observations, a stable oviduct epithelial cell line could be probably established from both in vitro models, with the prior purification of progenitor cells from the heterogeneous starting cell populations.ConclusionIn this study, we have characterized the expression of oviduct, epithelial, and stem/progenitor markers in the oviduct tissue and cell culture of two avian species, the hen and the quail.", [["oviduct epithelial cell line", "ANATOMY", 34, 62], ["progenitor cells", "ANATOMY", 151, 167], ["cell", "ANATOMY", 200, 204], ["oviduct", "ANATOMY", 282, 289], ["epithelial", "ANATOMY", 291, 301], ["stem/progenitor", "ANATOMY", 307, 322], ["oviduct tissue", "ANATOMY", 338, 352], ["cell culture", "ANATOMY", 357, 369], ["oviduct epithelial cell line", "CELL", 34, 62], ["progenitor cells", "CELL", 151, 167], ["cell populations", "CELL", 200, 216], ["oviduct", "TISSUE", 282, 289], ["epithelial", "CELL", 291, 301], ["stem", "CELL", 307, 311], ["progenitor", "CELL", 312, 322], ["oviduct tissue", "TISSUE", 338, 352], ["cell culture", "CELL", 357, 369], ["avian", "ORGANISM", 377, 382], ["hen", "ORGANISM", 396, 399], ["quail", "ORGANISM", 408, 413], ["oviduct epithelial cell line", "CELL_LINE", 34, 62], ["progenitor cells", "CELL_TYPE", 151, 167], ["heterogeneous starting cell populations", "CELL_TYPE", 177, 216], ["oviduct, epithelial, and stem/progenitor markers", "PROTEIN", 282, 330], ["hen", "SPECIES", 396, 399], ["quail", "SPECIES", 408, 413], ["hen", "SPECIES", 396, 399], ["quail", "SPECIES", 408, 413], ["a stable oviduct epithelial cell line", "TREATMENT", 25, 62], ["progenitor cells", "PROBLEM", 151, 167], ["the heterogeneous starting cell populations", "PROBLEM", 173, 216], ["this study", "TEST", 230, 240], ["epithelial, and stem/progenitor markers", "PROBLEM", 291, 330], ["cell culture", "TEST", 357, 369], ["stable", "OBSERVATION_MODIFIER", 27, 33], ["epithelial cell line", "OBSERVATION", 42, 62], ["could be probably", "UNCERTAINTY", 63, 80], ["progenitor cells", "OBSERVATION", 151, 167], ["heterogeneous", "OBSERVATION_MODIFIER", 177, 190], ["starting cell populations", "OBSERVATION", 191, 216], ["oviduct", "ANATOMY", 282, 289], ["epithelial", "ANATOMY", 291, 301], ["stem", "ANATOMY", 307, 311], ["oviduct tissue", "ANATOMY", 338, 352]]], ["Analysis of the oviduct tissue and cultured cells allowed for characterizing the molecular makeup of those cells in tissue, in relation to the source of the oviduct compartment (infundibulum, distal magnum, and proximal magnum).", [["oviduct tissue", "ANATOMY", 16, 30], ["cells", "ANATOMY", 44, 49], ["cells", "ANATOMY", 107, 112], ["tissue", "ANATOMY", 116, 122], ["oviduct compartment", "ANATOMY", 157, 176], ["infundibulum", "ANATOMY", 178, 190], ["distal magnum", "ANATOMY", 192, 205], ["proximal magnum", "ANATOMY", 211, 226], ["oviduct tissue", "TISSUE", 16, 30], ["cells", "CELL", 44, 49], ["cells", "CELL", 107, 112], ["tissue", "TISSUE", 116, 122], ["oviduct compartment", "MULTI-TISSUE_STRUCTURE", 157, 176], ["infundibulum", "MULTI-TISSUE_STRUCTURE", 178, 190], ["distal magnum", "MULTI-TISSUE_STRUCTURE", 192, 205], ["magnum", "MULTI-TISSUE_STRUCTURE", 220, 226], ["cultured cells", "CELL_LINE", 35, 49], ["the oviduct tissue", "TEST", 12, 30], ["cultured cells", "TEST", 35, 49], ["those cells in tissue", "PROBLEM", 101, 122], ["oviduct tissue", "ANATOMY", 16, 30], ["those cells", "OBSERVATION", 101, 112], ["oviduct", "ANATOMY", 157, 164], ["compartment", "ANATOMY_MODIFIER", 165, 176], ["infundibulum", "ANATOMY_MODIFIER", 178, 190], ["distal", "ANATOMY_MODIFIER", 192, 198], ["magnum", "ANATOMY", 199, 205], ["proximal", "ANATOMY_MODIFIER", 211, 219], ["magnum", "ANATOMY", 220, 226]]], ["Further analysis from in vitro-cultivated cells showed molecular pattern that was different from noncultivated oviduct cells.", [["cells", "ANATOMY", 42, 47], ["oviduct cells", "ANATOMY", 111, 124], ["cells", "CELL", 42, 47], ["noncultivated oviduct cells", "CELL", 97, 124], ["in vitro-cultivated cells", "CELL_LINE", 22, 47], ["noncultivated oviduct cells", "CELL_TYPE", 97, 124], ["Further analysis", "TEST", 0, 16], ["vitro-cultivated cells", "TEST", 25, 47], ["molecular pattern", "PROBLEM", 55, 72], ["noncultivated oviduct cells", "PROBLEM", 97, 124], ["molecular pattern", "OBSERVATION", 55, 72], ["oviduct cells", "OBSERVATION", 111, 124]]], ["In conclusion, the analysis of tissue material revealed a gradual increase/decrease pattern in majority of the markers in both species.", [["tissue material", "ANATOMY", 31, 46], ["tissue material", "TISSUE", 31, 46], ["the analysis of tissue material", "TEST", 15, 46], ["a gradual increase/decrease pattern", "PROBLEM", 56, 91], ["gradual", "OBSERVATION_MODIFIER", 58, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["decrease", "OBSERVATION_MODIFIER", 75, 83], ["pattern", "OBSERVATION_MODIFIER", 84, 91], ["majority", "OBSERVATION_MODIFIER", 95, 103], ["both species", "OBSERVATION", 122, 134]]], ["This pattern changed after those cells had been cultured in vitro.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["those cells", "PROBLEM", 27, 38]]], ["A progenitor marker, OCT4/ cPOUV was strongly downregulated in both in vitro models, whereas the expression of SOX9 and the epithelial marker KRT14 were not changed compared to the calibrator (FC~1).", [["progenitor", "ANATOMY", 2, 12], ["epithelial", "ANATOMY", 124, 134], ["progenitor", "CELL", 2, 12], ["OCT4", "GENE_OR_GENE_PRODUCT", 21, 25], ["cPOUV", "GENE_OR_GENE_PRODUCT", 27, 32], ["SOX9", "GENE_OR_GENE_PRODUCT", 111, 115], ["epithelial", "TISSUE", 124, 134], ["KRT14", "GENE_OR_GENE_PRODUCT", 142, 147], ["OCT4", "PROTEIN", 21, 25], ["cPOUV", "PROTEIN", 27, 32], ["SOX9", "PROTEIN", 111, 115], ["KRT14", "PROTEIN", 142, 147], ["A progenitor marker", "TEST", 0, 19], ["OCT4/ cPOUV", "TEST", 21, 32], ["SOX9", "PROBLEM", 111, 115], ["the epithelial marker KRT14", "TEST", 120, 147], ["the calibrator (FC", "TEST", 177, 195], ["progenitor marker", "OBSERVATION", 2, 19], ["epithelial", "ANATOMY_MODIFIER", 124, 134]]], ["Cultivated hen cells (COEC) gained the expression of LGR5 progenitor marker, which could indicate a shift toward a more specific epithelial progenitor cell type.", [["hen cells", "ANATOMY", 11, 20], ["COEC", "ANATOMY", 22, 26], ["LGR5 progenitor", "ANATOMY", 53, 68], ["epithelial progenitor cell", "ANATOMY", 129, 155], ["hen cells", "CELL", 11, 20], ["COEC", "CELL", 22, 26], ["LGR5 progenitor", "CELL", 53, 68], ["epithelial progenitor cell type", "CELL", 129, 160], ["Cultivated hen cells", "CELL_LINE", 0, 20], ["COEC", "CELL_LINE", 22, 26], ["LGR5", "PROTEIN", 53, 57], ["epithelial progenitor cell type", "CELL_TYPE", 129, 160], ["hen", "SPECIES", 11, 14], ["Cultivated hen cells", "TEST", 0, 20], ["LGR5 progenitor marker", "TEST", 53, 75], ["LGR5 progenitor marker", "OBSERVATION", 53, 75], ["epithelial progenitor cell type", "OBSERVATION", 129, 160]]], ["These results can contribute to further research on creating new biological models from reproductive tissue and the characterization required to develop new avian cell lines.Additional fileAdditional file 1: Visualization of a typical phenotype of cultivated oviductal epithelial cells.", [["tissue", "ANATOMY", 101, 107], ["cell lines", "ANATOMY", 163, 173], ["oviductal epithelial cells", "ANATOMY", 259, 285], ["reproductive tissue", "TISSUE", 88, 107], ["avian", "ORGANISM", 157, 162], ["cell lines", "CELL", 163, 173], ["oviductal epithelial cells", "CELL", 259, 285], ["avian cell lines", "CELL_LINE", 157, 173], ["cultivated oviductal epithelial cells", "CELL_LINE", 248, 285], ["the characterization", "TEST", 112, 132], ["new avian cell lines", "TREATMENT", 153, 173], ["a typical phenotype of cultivated oviductal epithelial cells", "PROBLEM", 225, 285], ["new", "OBSERVATION_MODIFIER", 153, 156], ["avian cell lines", "OBSERVATION", 157, 173], ["cultivated oviductal epithelial cells", "OBSERVATION", 248, 285]]], ["The recording of the cultivated oviduct epithelial cells allows one to follow the typical cobble-like structure of lining epithelial cells and the rotatory movement of cilia on the nonsecreting ciliated cells, which are coisolated with the secreting tubular gland cells.", [["oviduct epithelial cells", "ANATOMY", 32, 56], ["lining epithelial cells", "ANATOMY", 115, 138], ["cilia", "ANATOMY", 168, 173], ["ciliated cells", "ANATOMY", 194, 208], ["tubular gland cells", "ANATOMY", 250, 269], ["oviduct epithelial cells", "CELL", 32, 56], ["lining epithelial cells", "CELL", 115, 138], ["cilia", "CELLULAR_COMPONENT", 168, 173], ["ciliated cells", "CELL", 194, 208], ["tubular gland cells", "CELL", 250, 269], ["cultivated oviduct epithelial cells", "CELL_LINE", 21, 56], ["lining epithelial cells", "CELL_TYPE", 115, 138], ["nonsecreting ciliated cells", "CELL_TYPE", 181, 208], ["secreting tubular gland cells", "CELL_TYPE", 240, 269], ["the cultivated oviduct epithelial cells", "PROBLEM", 17, 56], ["lining epithelial cells", "PROBLEM", 115, 138], ["the secreting tubular gland cells", "PROBLEM", 236, 269], ["cultivated oviduct", "OBSERVATION", 21, 39], ["epithelial cells", "OBSERVATION", 40, 56], ["lining epithelial cells", "OBSERVATION", 115, 138], ["rotatory movement", "OBSERVATION", 147, 164], ["cilia", "ANATOMY_MODIFIER", 168, 173], ["nonsecreting ciliated cells", "OBSERVATION", 181, 208], ["secreting tubular gland cells", "OBSERVATION", 240, 269]]]], "PMC7506567": [], "PMC7294189": [["Sir, on 26 April 2020, the US Centers for Disease Control and Prevention included 'New loss of taste (dysgeusia/ageusia) and smell (anosmia/hyposmia)' in its list of symptoms of COVID-19 disease.1", [["loss of taste", "DISEASE", 87, 100], ["anosmia", "DISEASE", 132, 139], ["COVID", "DISEASE", 178, 183], ["taste", "ORGANISM_SUBDIVISION", 95, 100], ["Disease Control", "TREATMENT", 42, 57], ["New loss of taste (dysgeusia/ageusia)", "PROBLEM", 83, 120], ["smell (anosmia/hyposmia)", "PROBLEM", 125, 149], ["symptoms", "PROBLEM", 166, 174], ["COVID-19 disease", "PROBLEM", 178, 194]]]], "PMC7173442": [["The Pathogens ::: Definition ::: DefinitionThe rhinoviruses cause at least half of all common cold illnesses.", [["rhinoviruses", "DISEASE", 47, 59], ["rhinoviruses", "ORGANISM", 47, 59], ["The rhinoviruses", "PROBLEM", 43, 59], ["all common cold illnesses", "PROBLEM", 83, 108], ["rhinoviruses", "OBSERVATION", 47, 59]]], ["The rhinoviruses, which are RNA viruses that infect the respiratory epithelium, have long been known as common cold viruses, but they also are important causes of exacerbations of chronic bronchitis and asthma.", [["respiratory epithelium", "ANATOMY", 56, 78], ["bronchitis", "DISEASE", 188, 198], ["asthma", "DISEASE", 203, 209], ["rhinoviruses", "ORGANISM", 4, 16], ["respiratory epithelium", "TISSUE", 56, 78], ["The rhinoviruses", "PROBLEM", 0, 16], ["RNA viruses", "PROBLEM", 28, 39], ["the respiratory epithelium", "PROBLEM", 52, 78], ["common cold viruses", "PROBLEM", 104, 123], ["chronic bronchitis", "PROBLEM", 180, 198], ["asthma", "PROBLEM", 203, 209], ["rhinoviruses", "OBSERVATION", 4, 16], ["RNA viruses", "OBSERVATION", 28, 39], ["respiratory epithelium", "OBSERVATION", 56, 78], ["common cold", "OBSERVATION_MODIFIER", 104, 115], ["viruses", "OBSERVATION", 116, 123], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["bronchitis", "OBSERVATION", 188, 198], ["asthma", "OBSERVATION", 203, 209]]], ["More recent data suggest that rhinoviruses may also be associated with bronchiolitis in young children.The Pathogens ::: Definition ::: DefinitionThe coronaviruses (Chapter 374), parainfluenza viruses (Chapter 371), respiratory syncytial virus (Chapter 370), metapneumoviruses, adenoviruses (Chapter 373), and influenza viruses (Chapter 372) may also cause common cold illnesses (Table 369-1).", [["bronchiolitis", "DISEASE", 71, 84], ["parainfluenza viruses", "DISEASE", 179, 200], ["respiratory syncytial virus", "DISEASE", 216, 243], ["influenza viruses", "DISEASE", 310, 327], ["rhinoviruses", "ORGANISM", 30, 42], ["children", "ORGANISM", 94, 102], ["coronaviruses", "ORGANISM", 150, 163], ["Chapter 374", "ORGANISM", 165, 176], ["parainfluenza viruses", "ORGANISM", 179, 200], ["Chapter 371", "ORGANISM", 202, 213], ["respiratory syncytial virus", "ORGANISM", 216, 243], ["Chapter 370", "ORGANISM", 245, 256], ["adenoviruses", "ORGANISM", 278, 290], ["Chapter 373", "ORGANISM", 292, 303], ["influenza viruses", "ORGANISM", 310, 327], ["children", "SPECIES", 94, 102], ["parainfluenza", "SPECIES", 179, 192], ["respiratory syncytial virus", "SPECIES", 216, 243], ["respiratory syncytial virus", "SPECIES", 216, 243], ["rhinoviruses", "PROBLEM", 30, 42], ["bronchiolitis", "PROBLEM", 71, 84], ["parainfluenza viruses", "PROBLEM", 179, 200], ["respiratory syncytial virus", "PROBLEM", 216, 243], ["metapneumoviruses", "PROBLEM", 259, 276], ["adenoviruses", "PROBLEM", 278, 290], ["influenza viruses", "PROBLEM", 310, 327], ["common cold illnesses", "PROBLEM", 357, 378], ["rhinoviruses", "OBSERVATION", 30, 42], ["may also be associated with", "UNCERTAINTY", 43, 70], ["bronchiolitis", "OBSERVATION", 71, 84], ["parainfluenza viruses", "OBSERVATION", 179, 200], ["syncytial virus", "OBSERVATION", 228, 243]]], ["Bocavirus has recently been associated with the common cold, but these viruses are also frequently isolated from healthy control subjects, so their role as pathogens is uncertain.", [["Bocavirus", "CHEMICAL", 0, 9], ["Bocavirus", "PROBLEM", 0, 9], ["the common cold", "PROBLEM", 44, 59], ["these viruses", "PROBLEM", 65, 78], ["common", "OBSERVATION_MODIFIER", 48, 54], ["cold", "OBSERVATION", 55, 59], ["viruses", "OBSERVATION", 71, 78]]], ["Bacterial pathogens such as Bordetella pertussis (Chapter 321) and group A streptococcus (Chapter 298) are occasionally associated with rhinorrhea, but these illnesses are generally readily distinguished from the common cold.Epidemiology ::: DefinitionThe incidence of common colds decreases with age, from at least six episodes per year in young children to approximately two episodes per year in adults.", [["Bordetella pertussis", "DISEASE", 28, 48], ["group A streptococcus", "DISEASE", 67, 88], ["rhinorrhea", "DISEASE", 136, 146], ["colds", "DISEASE", 276, 281], ["Bordetella pertussis", "ORGANISM", 28, 48], ["Chapter 321", "ORGANISM", 50, 61], ["group A streptococcus", "ORGANISM", 67, 88], ["Chapter 298", "ORGANISM", 90, 101], ["children", "ORGANISM", 347, 355], ["Bordetella pertussis", "SPECIES", 28, 48], ["group A streptococcus", "SPECIES", 67, 88], ["children", "SPECIES", 347, 355], ["Bordetella pertussis (Chapter 321", "SPECIES", 28, 61], ["Bacterial pathogens", "PROBLEM", 0, 19], ["Bordetella pertussis", "PROBLEM", 28, 48], ["group A streptococcus", "PROBLEM", 67, 88], ["rhinorrhea", "PROBLEM", 136, 146], ["these illnesses", "PROBLEM", 152, 167], ["common colds", "PROBLEM", 269, 281], ["pathogens", "OBSERVATION", 10, 19], ["rhinorrhea", "OBSERVATION", 136, 146], ["common", "OBSERVATION_MODIFIER", 269, 275], ["colds", "OBSERVATION", 276, 281], ["decreases", "OBSERVATION_MODIFIER", 282, 291]]], ["The incidence of illness is higher in adults who have occupational or household exposure to children and in children who are cared for in childcare centers.", [["illness", "DISEASE", 17, 24], ["children", "ORGANISM", 92, 100], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 92, 100], ["children", "SPECIES", 108, 116], ["illness", "PROBLEM", 17, 24], ["illness", "OBSERVATION", 17, 24], ["higher", "OBSERVATION_MODIFIER", 28, 34]]], ["Common cold illnesses occur year-round in temperate climates but have a substantially increased incidence between the early autumn and late spring.", [["Common cold illnesses", "PROBLEM", 0, 21], ["illnesses", "OBSERVATION", 12, 21], ["substantially", "OBSERVATION_MODIFIER", 72, 85], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["early", "OBSERVATION_MODIFIER", 118, 123], ["autumn", "OBSERVATION", 124, 130], ["late spring", "OBSERVATION_MODIFIER", 135, 146]]], ["This common cold \u201cseason\u201d consists of sequential outbreaks caused by the different respiratory viruses.", [["respiratory viruses", "DISEASE", 83, 102], ["sequential outbreaks", "PROBLEM", 38, 58], ["the different respiratory viruses", "PROBLEM", 69, 102], ["respiratory viruses", "OBSERVATION", 83, 102]]], ["In tropical climates, colds occur year-round without defined seasonality.Pathobiology ::: DefinitionRespiratory pathogens are spread from person to person by direct contact with either infected individuals or contaminated objects in the environment, by large-particle aerosols, or by small-particle aerosols.", [["colds", "DISEASE", 22, 27], ["person", "SPECIES", 138, 144], ["person", "SPECIES", 148, 154], ["colds", "PROBLEM", 22, 27], ["DefinitionRespiratory pathogens", "PROBLEM", 90, 121], ["tropical climates", "OBSERVATION", 3, 20], ["round", "OBSERVATION_MODIFIER", 39, 44], ["without defined", "OBSERVATION_MODIFIER", 45, 60], ["seasonality", "OBSERVATION", 61, 72]]], ["The rhinoviruses appear to be spread most efficiently by direct contact.", [["rhinoviruses", "ORGANISM", 4, 16], ["The rhinoviruses", "PROBLEM", 0, 16], ["rhinoviruses", "OBSERVATION", 4, 16]]], ["Respiratory syncytial virus (Chapter 370) may be spread by either direct contact or large-particle aerosols, and influenza (Chapter 372) may be spread by small-particle aerosols.Pathobiology ::: DefinitionRegardless of the route of spread, the common cold syndrome is initiated by infection of the nasal epithelium.", [["nasal epithelium", "ANATOMY", 298, 314], ["Respiratory syncytial virus", "DISEASE", 0, 27], ["Chapter 370", "CHEMICAL", 29, 40], ["influenza", "DISEASE", 113, 122], ["cold syndrome", "DISEASE", 251, 264], ["infection", "DISEASE", 281, 290], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["nasal epithelium", "TISSUE", 298, 314], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["large-particle aerosols", "PROBLEM", 84, 107], ["influenza", "PROBLEM", 113, 122], ["the common cold syndrome", "PROBLEM", 240, 264], ["infection of the nasal epithelium", "PROBLEM", 281, 314], ["syncytial virus", "OBSERVATION", 12, 27], ["small", "OBSERVATION_MODIFIER", 154, 159], ["particle aerosols", "OBSERVATION", 160, 177], ["spread", "OBSERVATION", 232, 238], ["common cold", "ANATOMY", 244, 255], ["syndrome", "OBSERVATION", 256, 264], ["infection", "OBSERVATION", 281, 290], ["nasal epithelium", "ANATOMY", 298, 314]]], ["Influenza and adenovirus produce obvious damage to the respiratory epithelium.", [["respiratory epithelium", "ANATOMY", 55, 77], ["Influenza", "DISEASE", 0, 9], ["adenovirus", "ORGANISM", 14, 24], ["respiratory epithelium", "TISSUE", 55, 77], ["Influenza", "SPECIES", 0, 9], ["adenovirus", "SPECIES", 14, 24], ["Influenza", "PROBLEM", 0, 9], ["adenovirus", "PROBLEM", 14, 24], ["damage to the respiratory epithelium", "PROBLEM", 41, 77], ["respiratory epithelium", "OBSERVATION", 55, 77]]], ["Rhinovirus and respiratory syncytial virus, in contrast, have little or no detectable impact on the epithelium.", [["epithelium", "ANATOMY", 100, 110], ["respiratory syncytial virus", "DISEASE", 15, 42], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["respiratory syncytial virus", "ORGANISM", 15, 42], ["epithelium", "TISSUE", 100, 110], ["respiratory syncytial virus", "SPECIES", 15, 42], ["respiratory syncytial virus", "SPECIES", 15, 42], ["Rhinovirus", "PROBLEM", 0, 10], ["respiratory syncytial virus", "PROBLEM", 15, 42], ["detectable impact on the epithelium", "PROBLEM", 75, 110], ["respiratory", "OBSERVATION", 15, 26], ["syncytial virus", "OBSERVATION", 27, 42], ["no", "UNCERTAINTY", 72, 74], ["detectable", "OBSERVATION_MODIFIER", 75, 85], ["impact", "OBSERVATION_MODIFIER", 86, 92], ["epithelium", "ANATOMY_MODIFIER", 100, 110]]], ["Regardless of the histopathology, all of these viruses stimulate a nonspecific host inflammatory response that appears to be responsible for many of the symptoms associated with the common cold (Fig. 369-1).Pathobiology ::: DefinitionThe nasal obstruction of the common cold appears to result primarily from increased nasal blood flow and pooling of blood in the capacitance vessels of the nose.", [["nasal", "ANATOMY", 238, 243], ["nasal", "ANATOMY", 318, 323], ["blood", "ANATOMY", 324, 329], ["blood", "ANATOMY", 350, 355], ["capacitance vessels", "ANATOMY", 363, 382], ["nose", "ANATOMY", 390, 394], ["nasal obstruction", "DISEASE", 238, 255], ["nasal", "ORGAN", 238, 243], ["blood", "ORGANISM_SUBSTANCE", 324, 329], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["capacitance vessels", "MULTI-TISSUE_STRUCTURE", 363, 382], ["nose", "ORGAN", 390, 394], ["the histopathology", "TEST", 14, 32], ["these viruses", "PROBLEM", 41, 54], ["a nonspecific host inflammatory response", "PROBLEM", 65, 105], ["the symptoms", "PROBLEM", 149, 161], ["The nasal obstruction of the common cold", "PROBLEM", 234, 274], ["increased nasal blood flow", "PROBLEM", 308, 334], ["pooling of blood in the capacitance vessels of the nose", "PROBLEM", 339, 394], ["nonspecific host", "OBSERVATION_MODIFIER", 67, 83], ["inflammatory", "OBSERVATION", 84, 96], ["nasal", "ANATOMY", 238, 243], ["obstruction", "OBSERVATION", 244, 255], ["common cold", "ANATOMY", 263, 274], ["increased", "OBSERVATION_MODIFIER", 308, 317], ["nasal blood flow", "OBSERVATION", 318, 334], ["blood", "OBSERVATION_MODIFIER", 350, 355], ["capacitance", "ANATOMY_MODIFIER", 363, 374], ["vessels", "ANATOMY", 375, 382], ["nose", "ANATOMY", 390, 394]]], ["The increase in nasal secretion associated with the common cold may also contribute to the nasal obstruction.", [["nasal", "ANATOMY", 16, 21], ["nasal", "ANATOMY", 91, 96], ["nasal obstruction", "DISEASE", 91, 108], ["nasal", "ORGAN", 16, 21], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 91, 108], ["The increase in nasal secretion", "PROBLEM", 0, 31], ["the nasal obstruction", "PROBLEM", 87, 108], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["nasal secretion", "OBSERVATION", 16, 31], ["may also contribute to", "UNCERTAINTY", 64, 86], ["nasal", "ANATOMY", 91, 96], ["obstruction", "OBSERVATION", 97, 108]]], ["Rhinorrhea is primarily a result of increased vascular permeability with leakage of serum into the nasal secretions.", [["vascular", "ANATOMY", 46, 54], ["serum", "ANATOMY", 84, 89], ["nasal secretions", "ANATOMY", 99, 115], ["Rhinorrhea", "DISEASE", 0, 10], ["vascular", "MULTI-TISSUE_STRUCTURE", 46, 54], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["nasal secretions", "ORGANISM_SUBSTANCE", 99, 115], ["Rhinorrhea", "PROBLEM", 0, 10], ["increased vascular permeability", "PROBLEM", 36, 67], ["leakage of serum into the nasal secretions", "PROBLEM", 73, 115], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["vascular", "ANATOMY", 46, 54], ["permeability", "OBSERVATION", 55, 67], ["leakage", "OBSERVATION", 73, 80], ["nasal", "ANATOMY", 99, 104], ["secretions", "OBSERVATION", 105, 115]]], ["Increased mucus production contributes to the secretions during the later stages of the illness.Pathobiology ::: DefinitionMultiple factors may play a role in the pathogenesis of cough.", [["mucus", "ANATOMY", 10, 15], ["cough", "DISEASE", 179, 184], ["mucus", "MULTI-TISSUE_STRUCTURE", 10, 15], ["DefinitionMultiple factors", "PROTEIN", 113, 139], ["Increased mucus production", "PROBLEM", 0, 26], ["the secretions", "PROBLEM", 42, 56], ["the illness", "PROBLEM", 84, 95], ["cough", "PROBLEM", 179, 184], ["mucus production", "OBSERVATION", 10, 26], ["secretions", "OBSERVATION", 46, 56], ["illness", "OBSERVATION", 88, 95], ["cough", "OBSERVATION", 179, 184]]], ["Cough may be related to infection of the lower airway, irritation of upper airway receptors with neurologically mediated airway reactivity, or postnasal drip with pharyngeal irritation.Pathobiology ::: DefinitionThe risk of infection after exposure to the respiratory viruses is primarily dependent on the presence of specific neutralizing antibodies.", [["lower airway", "ANATOMY", 41, 53], ["upper airway", "ANATOMY", 69, 81], ["airway", "ANATOMY", 121, 127], ["pharyngeal", "ANATOMY", 163, 173], ["Cough", "DISEASE", 0, 5], ["infection", "DISEASE", 24, 33], ["pharyngeal irritation", "DISEASE", 163, 184], ["infection", "DISEASE", 224, 233], ["respiratory viruses", "DISEASE", 256, 275], ["lower airway", "ORGANISM_SUBDIVISION", 41, 53], ["upper airway", "ORGANISM_SUBDIVISION", 69, 81], ["airway", "MULTI-TISSUE_STRUCTURE", 121, 127], ["pharyngeal", "ORGANISM_SUBDIVISION", 163, 173], ["upper airway receptors", "PROTEIN", 69, 91], ["neutralizing antibodies", "PROTEIN", 327, 350], ["Cough", "PROBLEM", 0, 5], ["infection of the lower airway", "PROBLEM", 24, 53], ["irritation of upper airway receptors", "PROBLEM", 55, 91], ["neurologically mediated airway reactivity", "PROBLEM", 97, 138], ["postnasal drip", "TREATMENT", 143, 157], ["pharyngeal irritation", "PROBLEM", 163, 184], ["infection", "PROBLEM", 224, 233], ["the respiratory viruses", "PROBLEM", 252, 275], ["specific neutralizing antibodies", "PROBLEM", 318, 350], ["may be related to", "UNCERTAINTY", 6, 23], ["infection", "OBSERVATION", 24, 33], ["lower", "ANATOMY_MODIFIER", 41, 46], ["airway", "ANATOMY", 47, 53], ["irritation", "OBSERVATION", 55, 65], ["upper", "ANATOMY_MODIFIER", 69, 74], ["airway", "ANATOMY", 75, 81], ["airway", "ANATOMY", 121, 127], ["pharyngeal", "ANATOMY", 163, 173], ["irritation", "OBSERVATION", 174, 184], ["infection", "OBSERVATION", 224, 233], ["respiratory viruses", "OBSERVATION", 256, 275], ["neutralizing antibodies", "OBSERVATION", 327, 350]]], ["Antibody responses to the rhinoviruses, adenoviruses, and influenza viruses are protective against subsequent infection.", [["influenza viruses", "DISEASE", 58, 75], ["infection", "DISEASE", 110, 119], ["rhinoviruses", "ORGANISM", 26, 38], ["adenoviruses", "ORGANISM", 40, 52], ["influenza viruses", "ORGANISM", 58, 75], ["Antibody responses", "TEST", 0, 18], ["the rhinoviruses", "PROBLEM", 22, 38], ["adenoviruses", "PROBLEM", 40, 52], ["influenza viruses", "PROBLEM", 58, 75], ["subsequent infection", "PROBLEM", 99, 119], ["infection", "OBSERVATION", 110, 119]]], ["The frequency of infection with these viruses is a result of the large number of distinct serotypes of rhinovirus and adenovirus and the ability of the influenza viruses to behave as though there are multiple virus serotypes by virtue of the rapid mutation of the antigens presented on the surface of the virus.", [["surface", "ANATOMY", 290, 297], ["infection", "DISEASE", 17, 26], ["rhinovirus", "DISEASE", 103, 113], ["influenza viruses", "DISEASE", 152, 169], ["rhinovirus", "ORGANISM", 103, 113], ["adenovirus", "ORGANISM", 118, 128], ["influenza viruses", "ORGANISM", 152, 169], ["surface", "CELLULAR_COMPONENT", 290, 297], ["antigens", "PROTEIN", 264, 272], ["adenovirus", "SPECIES", 118, 128], ["infection", "PROBLEM", 17, 26], ["these viruses", "PROBLEM", 32, 45], ["rhinovirus", "PROBLEM", 103, 113], ["adenovirus", "PROBLEM", 118, 128], ["the influenza viruses", "PROBLEM", 148, 169], ["multiple virus serotypes", "PROBLEM", 200, 224], ["the rapid mutation", "PROBLEM", 238, 256], ["the antigens", "PROBLEM", 260, 272], ["the virus", "PROBLEM", 301, 310], ["infection", "OBSERVATION", 17, 26], ["viruses", "OBSERVATION", 38, 45], ["large", "OBSERVATION_MODIFIER", 65, 70], ["number", "OBSERVATION_MODIFIER", 71, 77], ["distinct", "OBSERVATION_MODIFIER", 81, 89], ["serotypes", "OBSERVATION", 90, 99], ["rhinovirus", "OBSERVATION", 103, 113], ["multiple", "OBSERVATION_MODIFIER", 200, 208], ["virus", "OBSERVATION", 209, 214], ["virus", "OBSERVATION", 305, 310]]], ["The parainfluenza viruses, respiratory syncytial viruses, and metapneumoviruses do not produce protective immunity, so reinfection is common although preexisting antibody moderates the severity of illness.Pathobiology ::: DefinitionMannose-binding lectin deficiency has been associated with an increased incidence of common colds in young children.", [["parainfluenza viruses", "DISEASE", 4, 25], ["respiratory syncytial viruses", "DISEASE", 27, 56], ["illness", "DISEASE", 197, 204], ["Mannose", "CHEMICAL", 232, 239], ["colds", "DISEASE", 324, 329], ["parainfluenza viruses", "ORGANISM", 4, 25], ["respiratory syncytial viruses", "ORGANISM", 27, 56], ["Mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 232, 254], ["children", "ORGANISM", 339, 347], ["Mannose-binding lectin", "PROTEIN", 232, 254], ["parainfluenza", "SPECIES", 4, 17], ["children", "SPECIES", 339, 347], ["respiratory syncytial viruses", "SPECIES", 27, 56], ["The parainfluenza viruses", "PROBLEM", 0, 25], ["respiratory syncytial viruses", "PROBLEM", 27, 56], ["metapneumoviruses", "PROBLEM", 62, 79], ["reinfection", "PROBLEM", 119, 130], ["illness", "PROBLEM", 197, 204], ["Mannose-binding lectin deficiency", "PROBLEM", 232, 265], ["parainfluenza viruses", "OBSERVATION", 4, 25], ["respiratory syncytial viruses", "OBSERVATION", 27, 56], ["lectin deficiency", "OBSERVATION", 248, 265], ["increased", "OBSERVATION_MODIFIER", 294, 303], ["common", "OBSERVATION_MODIFIER", 317, 323], ["colds", "OBSERVATION", 324, 329]]], ["Protection by this innate response may become less important as children experience a variety of infections and develop specific immunity.", [["infections", "DISEASE", 97, 107], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["Protection", "TREATMENT", 0, 10], ["infections", "PROBLEM", 97, 107]]], ["Polymorphisms that enhance inflammatory cytokine responses may be associated with more severe respiratory illness.Clinical Manifestations ::: DefinitionThe incubation of common cold illness is generally short, ranging from 2 to 8 days, although the adenoviruses may have an incubation of as long as 13 days.", [["respiratory", "ANATOMY", 94, 105], ["respiratory illness", "DISEASE", 94, 113], ["cold illness", "DISEASE", 177, 189], ["adenoviruses", "ORGANISM", 249, 261], ["cytokine", "PROTEIN", 40, 48], ["Polymorphisms", "PROBLEM", 0, 13], ["inflammatory cytokine responses", "PROBLEM", 27, 58], ["more severe respiratory illness", "PROBLEM", 82, 113], ["common cold illness", "PROBLEM", 170, 189], ["the adenoviruses", "PROBLEM", 245, 261], ["inflammatory", "OBSERVATION_MODIFIER", 27, 39], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["respiratory illness", "OBSERVATION", 94, 113], ["common cold", "OBSERVATION_MODIFIER", 170, 181], ["illness", "OBSERVATION", 182, 189], ["short", "OBSERVATION_MODIFIER", 203, 208]]], ["A sore or scratchy throat is frequently reported as the first manifestation.", [["scratchy throat", "ANATOMY", 10, 25], ["sore", "DISEASE", 2, 6], ["scratchy throat", "DISEASE", 10, 25], ["A sore or scratchy throat", "PROBLEM", 0, 25], ["sore", "OBSERVATION", 2, 6], ["throat", "ANATOMY", 19, 25]]], ["Sneezing is also a common early symptom.", [["Sneezing", "DISEASE", 0, 8], ["Sneezing", "PROBLEM", 0, 8], ["a common early symptom", "PROBLEM", 17, 39]]], ["Nasal obstruction and rhinorrhea develop rapidly and, by day 2 or 3 after the onset of illness, are the most bothersome symptoms.", [["Nasal", "ANATOMY", 0, 5], ["Nasal obstruction", "DISEASE", 0, 17], ["rhinorrhea", "DISEASE", 22, 32], ["illness", "DISEASE", 87, 94], ["Nasal", "ORGAN", 0, 5], ["Nasal obstruction", "PROBLEM", 0, 17], ["rhinorrhea", "PROBLEM", 22, 32], ["illness", "PROBLEM", 87, 94], ["the most bothersome symptoms", "PROBLEM", 100, 128], ["obstruction", "OBSERVATION", 6, 17], ["rhinorrhea", "OBSERVATION", 22, 32], ["rapidly", "OBSERVATION_MODIFIER", 41, 48]]], ["Cough generally develops later in the illness and frequently is the most bothersome symptom as the cold resolves.", [["Cough", "DISEASE", 0, 5], ["Cough", "PROBLEM", 0, 5], ["the most bothersome symptom", "PROBLEM", 64, 91]]], ["Common cold illnesses generally persist for about 1 week, although about 25% may persist for as long as 2 weeks.Clinical Manifestations ::: DefinitionPhysical findings are restricted to the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 190, 213], ["upper respiratory", "ORGANISM_SUBDIVISION", 190, 207], ["tract", "ORGANISM_SUBDIVISION", 208, 213], ["Common cold illnesses", "PROBLEM", 0, 21], ["illnesses", "OBSERVATION", 12, 21], ["upper", "ANATOMY_MODIFIER", 190, 195], ["respiratory tract", "ANATOMY", 196, 213]]], ["Increased nasal secretion may be obvious to the examiner.", [["nasal", "ANATOMY", 10, 15], ["nasal", "ORGAN", 10, 15], ["Increased nasal secretion", "PROBLEM", 0, 25], ["nasal", "ANATOMY", 10, 15], ["secretion", "OBSERVATION", 16, 25]]], ["A change in the color or consistency of nasal secretions is common during the course of the illness and is not indicative of sinusitis or bacterial superinfection.Diagnosis ::: DefinitionThe differential diagnosis of the common cold includes noninfectious disorders as well as other upper respiratory tract infections.", [["nasal secretions", "ANATOMY", 40, 56], ["upper respiratory tract", "ANATOMY", 283, 306], ["sinusitis", "DISEASE", 125, 134], ["bacterial superinfection", "DISEASE", 138, 162], ["noninfectious disorders", "DISEASE", 242, 265], ["respiratory tract infections", "DISEASE", 289, 317], ["nasal secretions", "ORGANISM_SUBDIVISION", 40, 56], ["upper", "ORGANISM_SUBDIVISION", 283, 288], ["respiratory tract", "ORGANISM_SUBDIVISION", 289, 306], ["A change in the color", "PROBLEM", 0, 21], ["nasal secretions", "PROBLEM", 40, 56], ["the illness", "PROBLEM", 88, 99], ["sinusitis", "PROBLEM", 125, 134], ["bacterial superinfection", "PROBLEM", 138, 162], ["noninfectious disorders", "PROBLEM", 242, 265], ["other upper respiratory tract infections", "PROBLEM", 277, 317], ["change", "OBSERVATION_MODIFIER", 2, 8], ["color", "OBSERVATION_MODIFIER", 16, 21], ["consistency", "OBSERVATION_MODIFIER", 25, 36], ["nasal", "ANATOMY", 40, 45], ["secretions", "OBSERVATION", 46, 56], ["not indicative of", "UNCERTAINTY", 107, 124], ["sinusitis", "OBSERVATION", 125, 134], ["bacterial", "OBSERVATION_MODIFIER", 138, 147], ["superinfection", "OBSERVATION", 148, 162], ["noninfectious", "OBSERVATION", 242, 255], ["upper", "ANATOMY_MODIFIER", 283, 288], ["respiratory tract", "ANATOMY", 289, 306], ["infections", "OBSERVATION", 307, 317]]], ["Allergic rhinitis (Chapter 259) has a symptom complex similar to that of the common cold, although the presence of nasal or conjunctival itching suggests allergic disease.", [["nasal", "ANATOMY", 115, 120], ["conjunctival", "ANATOMY", 124, 136], ["Allergic rhinitis", "DISEASE", 0, 17], ["conjunctival itching", "DISEASE", 124, 144], ["allergic disease", "DISEASE", 154, 170], ["nasal", "ORGANISM_SUBDIVISION", 115, 120], ["Allergic rhinitis", "PROBLEM", 0, 17], ["a symptom complex", "PROBLEM", 36, 53], ["the common cold", "PROBLEM", 73, 88], ["nasal or conjunctival itching", "PROBLEM", 115, 144], ["allergic disease", "PROBLEM", 154, 170], ["rhinitis", "OBSERVATION", 9, 17], ["nasal", "ANATOMY", 115, 120], ["conjunctival", "ANATOMY", 124, 136], ["itching", "OBSERVATION", 137, 144], ["allergic disease", "OBSERVATION", 154, 170]]], ["Most patients can reliably differentiate these illnesses.Diagnosis ::: DefinitionSinus involvement is present in uncomplicated cold illnesses, and superimposed bacterial sinusitis (Chapter 434) is difficult to differentiate from an uncomplicated cold.", [["bacterial sinusitis", "DISEASE", 160, 179], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["these illnesses", "PROBLEM", 41, 56], ["uncomplicated cold illnesses", "PROBLEM", 113, 141], ["superimposed bacterial sinusitis", "PROBLEM", 147, 179], ["an uncomplicated cold", "PROBLEM", 229, 250], ["illnesses", "OBSERVATION", 47, 56], ["uncomplicated", "OBSERVATION_MODIFIER", 113, 126], ["superimposed", "OBSERVATION_MODIFIER", 147, 159], ["bacterial", "OBSERVATION_MODIFIER", 160, 169], ["sinusitis", "OBSERVATION", 170, 179], ["uncomplicated", "OBSERVATION_MODIFIER", 232, 245], ["cold", "OBSERVATION", 246, 250]]], ["Rhinorrhea that persists without improvement for more than 10 days may suggest the presence of bacterial sinusitis that will respond to antibiotics.Diagnosis ::: DefinitionRoutine laboratory studies are not helpful for the diagnosis or management of the common cold.", [["Rhinorrhea", "DISEASE", 0, 10], ["bacterial sinusitis", "DISEASE", 95, 114], ["Rhinorrhea", "PROBLEM", 0, 10], ["bacterial sinusitis", "PROBLEM", 95, 114], ["antibiotics", "TREATMENT", 136, 147], ["DefinitionRoutine laboratory studies", "TEST", 162, 198], ["management", "TREATMENT", 236, 246], ["the common cold", "PROBLEM", 250, 265], ["bacterial", "OBSERVATION_MODIFIER", 95, 104], ["sinusitis", "OBSERVATION", 105, 114]]], ["Although the viral pathogens associated with the common cold may be detected by culture, antigen detection, polymerase chain reaction, or serologic methods, these studies are of little value unless treatment with an antiviral agent is contemplated.Treatment Specific antiviral therapy is generally not useful for the treatment of common cold illnesses.", [["the viral pathogens", "PROBLEM", 9, 28], ["culture", "TEST", 80, 87], ["antigen detection", "TEST", 89, 106], ["polymerase chain reaction", "PROBLEM", 108, 133], ["serologic methods", "TEST", 138, 155], ["these studies", "TEST", 157, 170], ["an antiviral agent", "TREATMENT", 213, 231], ["Treatment", "TREATMENT", 248, 257], ["Specific antiviral therapy", "TREATMENT", 258, 284], ["common cold illnesses", "PROBLEM", 330, 351], ["viral pathogens", "OBSERVATION", 13, 28], ["antiviral therapy", "OBSERVATION", 267, 284]]], ["The neuraminidase inhibitors oseltamivir and zanamivir (Chapter 368) have a modest effect on influenza virus infections, but the difficulty of distinguishing influenza from other common cold pathogens and the need to start treatment early in the illness for maximum benefit are practical limitations to the use of these agents for mild upper respiratory infections.", [["respiratory", "ANATOMY", 342, 353], ["oseltamivir", "CHEMICAL", 29, 40], ["zanamivir", "CHEMICAL", 45, 54], ["Chapter 368", "CHEMICAL", 56, 67], ["influenza virus infections", "DISEASE", 93, 119], ["influenza", "DISEASE", 158, 167], ["upper respiratory infections", "DISEASE", 336, 364], ["oseltamivir", "CHEMICAL", 29, 40], ["zanamivir", "CHEMICAL", 45, 54], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 4, 17], ["oseltamivir", "SIMPLE_CHEMICAL", 29, 40], ["zanamivir", "SIMPLE_CHEMICAL", 45, 54], ["influenza virus", "ORGANISM", 93, 108], ["influenza virus", "SPECIES", 93, 108], ["influenza virus", "SPECIES", 93, 108], ["The neuraminidase inhibitors oseltamivir", "TREATMENT", 0, 40], ["zanamivir", "TREATMENT", 45, 54], ["influenza virus infections", "PROBLEM", 93, 119], ["influenza", "PROBLEM", 158, 167], ["other common cold pathogens", "PROBLEM", 173, 200], ["treatment", "TREATMENT", 223, 232], ["these agents", "TREATMENT", 314, 326], ["mild upper respiratory infections", "PROBLEM", 331, 364], ["mild", "OBSERVATION_MODIFIER", 331, 335], ["upper", "ANATOMY_MODIFIER", 336, 341], ["respiratory", "ANATOMY", 342, 353], ["infections", "OBSERVATION", 354, 364]]], ["Antibacterial therapy is of no benefit in the treatment of the common cold.Management of the common cold relies on symptomatic remedies.", [["Antibacterial therapy", "TREATMENT", 0, 21], ["the treatment", "TREATMENT", 42, 55], ["the common cold", "PROBLEM", 59, 74], ["symptomatic remedies", "TREATMENT", 115, 135], ["common", "OBSERVATION_MODIFIER", 63, 69], ["cold", "OBSERVATION", 70, 74]]], ["Treatments for nasal obstruction, rhinorrhea, and sore throat have demonstrated efficacy in adults but are not clearly beneficial in children and are not recommended for children younger than 4 years.Nasal CongestionBoth topical and oral adrenergic agents (Table 369-2) are effective nasal decongestants.", [["nasal", "ANATOMY", 15, 20], ["Nasal", "ANATOMY", 200, 205], ["oral", "ANATOMY", 233, 237], ["nasal", "ANATOMY", 284, 289], ["nasal obstruction", "DISEASE", 15, 32], ["rhinorrhea", "DISEASE", 34, 44], ["sore throat", "DISEASE", 50, 61], ["nasal", "ORGANISM_SUBDIVISION", 15, 20], ["children", "ORGANISM", 133, 141], ["children", "ORGANISM", 170, 178], ["oral adrenergic agents", "SIMPLE_CHEMICAL", 233, 255], ["nasal", "ORGANISM_SUBDIVISION", 284, 289], ["children", "SPECIES", 133, 141], ["children", "SPECIES", 170, 178], ["Treatments", "TREATMENT", 0, 10], ["nasal obstruction", "PROBLEM", 15, 32], ["rhinorrhea", "PROBLEM", 34, 44], ["sore throat", "PROBLEM", 50, 61], ["Nasal CongestionBoth topical", "TREATMENT", 200, 228], ["oral adrenergic agents", "TREATMENT", 233, 255], ["effective nasal decongestants", "PROBLEM", 274, 303], ["nasal", "ANATOMY", 15, 20], ["obstruction", "OBSERVATION", 21, 32], ["rhinorrhea", "OBSERVATION", 34, 44], ["nasal", "ANATOMY", 284, 289], ["decongestants", "OBSERVATION", 290, 303]]], ["Although direct comparison has not been performed in the common cold, it is generally accepted that topical agents, such as intranasal xylometazoline, are more effective than oral drugs for nasal congestion.1 Nevertheless, oral pseudoephedrine, 60 mg as a single dose or repeated for 3 to 5 days, is superior to placebo for relief of nasal congestion2, 3 and is safe.", [["oral", "ANATOMY", 175, 179], ["nasal", "ANATOMY", 190, 195], ["oral", "ANATOMY", 223, 227], ["nasal", "ANATOMY", 334, 339], ["xylometazoline", "CHEMICAL", 135, 149], ["nasal congestion", "DISEASE", 190, 206], ["pseudoephedrine", "CHEMICAL", 228, 243], ["nasal congestion2", "DISEASE", 334, 351], ["xylometazoline", "CHEMICAL", 135, 149], ["pseudoephedrine", "CHEMICAL", 228, 243], ["xylometazoline", "SIMPLE_CHEMICAL", 135, 149], ["oral", "ORGANISM_SUBDIVISION", 175, 179], ["nasal", "ORGANISM_SUBDIVISION", 190, 195], ["oral", "ORGANISM_SUBDIVISION", 223, 227], ["pseudoephedrine", "SIMPLE_CHEMICAL", 228, 243], ["topical agents", "TREATMENT", 100, 114], ["intranasal xylometazoline", "TREATMENT", 124, 149], ["oral drugs", "TREATMENT", 175, 185], ["nasal congestion", "PROBLEM", 190, 206], ["oral pseudoephedrine", "TREATMENT", 223, 243], ["nasal congestion2", "PROBLEM", 334, 351], ["nasal", "ANATOMY", 190, 195], ["congestion", "OBSERVATION", 196, 206], ["nasal", "ANATOMY", 334, 339], ["congestion2", "OBSERVATION", 340, 351]]], ["A 30-mg dose, however, may be no better than placebo.4 Prolonged use of the topical adrenergic agents should be avoided to prevent the development of an apparent rebound effect when the drug is discontinued.", [["the topical adrenergic agents", "TREATMENT", 72, 101], ["an apparent rebound effect", "PROBLEM", 150, 176], ["the drug", "TREATMENT", 182, 190], ["rebound", "OBSERVATION", 162, 169]]], ["Systemic absorption of oxymetazoline and xylometazoline has rarely been associated with bradycardia, hypotension, and coma.", [["oxymetazoline", "CHEMICAL", 23, 36], ["xylometazoline", "CHEMICAL", 41, 55], ["bradycardia", "DISEASE", 88, 99], ["hypotension", "DISEASE", 101, 112], ["coma", "DISEASE", 118, 122], ["oxymetazoline", "CHEMICAL", 23, 36], ["xylometazoline", "CHEMICAL", 41, 55], ["oxymetazoline", "SIMPLE_CHEMICAL", 23, 36], ["xylometazoline", "SIMPLE_CHEMICAL", 41, 55], ["oxymetazoline", "TREATMENT", 23, 36], ["xylometazoline", "TREATMENT", 41, 55], ["bradycardia", "PROBLEM", 88, 99], ["hypotension", "PROBLEM", 101, 112], ["coma", "PROBLEM", 118, 122], ["hypotension", "OBSERVATION", 101, 112]]], ["The antihistamines have no effect on nasal congestion.RhinorrheaThe treatment of rhinorrhea is primarily by blockade of cholinergic stimulation of glandular secretion.", [["nasal", "ANATOMY", 37, 42], ["glandular", "ANATOMY", 147, 156], ["nasal congestion", "DISEASE", 37, 53], ["Rhinorrhea", "CHEMICAL", 54, 64], ["rhinorrhea", "DISEASE", 81, 91], ["antihistamines", "SIMPLE_CHEMICAL", 4, 18], ["nasal", "ORGANISM_SUBDIVISION", 37, 42], ["glandular", "MULTI-TISSUE_STRUCTURE", 147, 156], ["Rhinorrhea", "SPECIES", 54, 64], ["The antihistamines", "TREATMENT", 0, 18], ["nasal congestion", "PROBLEM", 37, 53], ["Rhinorrhea", "PROBLEM", 54, 64], ["rhinorrhea", "PROBLEM", 81, 91], ["cholinergic stimulation", "TREATMENT", 120, 143], ["glandular secretion", "PROBLEM", 147, 166], ["no effect", "UNCERTAINTY", 24, 33], ["nasal", "ANATOMY", 37, 42], ["congestion", "OBSERVATION", 43, 53], ["rhinorrhea", "OBSERVATION", 81, 91], ["glandular secretion", "OBSERVATION", 147, 166]]], ["Intranasal ipratropium bromide reduces rhinorrhea in colds by 22 to 31% compared with placebo, and it can be used as a combined spray with xylometazoline to relieve both rhinorrhea and nasal congestion.1 The most common side effects of intranasal ipratropium are nasal irritation and bleeding.The first-generation (sedating) antihistamines reduce rhinorrhea by approximately 25% compared with placebo.", [["nasal", "ANATOMY", 185, 190], ["nasal", "ANATOMY", 263, 268], ["ipratropium bromide", "CHEMICAL", 11, 30], ["rhinorrhea", "DISEASE", 39, 49], ["colds", "DISEASE", 53, 58], ["xylometazoline", "CHEMICAL", 139, 153], ["rhinorrhea", "DISEASE", 170, 180], ["nasal congestion", "DISEASE", 185, 201], ["ipratropium", "CHEMICAL", 247, 258], ["nasal irritation", "DISEASE", 263, 279], ["bleeding", "DISEASE", 284, 292], ["rhinorrhea", "DISEASE", 347, 357], ["ipratropium bromide", "CHEMICAL", 11, 30], ["xylometazoline", "CHEMICAL", 139, 153], ["ipratropium", "CHEMICAL", 247, 258], ["ipratropium bromide", "SIMPLE_CHEMICAL", 11, 30], ["xylometazoline", "SIMPLE_CHEMICAL", 139, 153], ["nasal", "ORGANISM_SUBDIVISION", 185, 190], ["ipratropium", "SIMPLE_CHEMICAL", 247, 258], ["nasal", "ORGANISM_SUBDIVISION", 263, 268], ["antihistamines", "SIMPLE_CHEMICAL", 325, 339], ["Intranasal ipratropium bromide", "TREATMENT", 0, 30], ["rhinorrhea", "PROBLEM", 39, 49], ["placebo", "TREATMENT", 86, 93], ["a combined spray", "TREATMENT", 117, 133], ["xylometazoline", "TREATMENT", 139, 153], ["rhinorrhea", "PROBLEM", 170, 180], ["nasal congestion", "PROBLEM", 185, 201], ["intranasal ipratropium", "TREATMENT", 236, 258], ["nasal irritation", "PROBLEM", 263, 279], ["bleeding", "PROBLEM", 284, 292], ["The first-generation (sedating) antihistamines", "TREATMENT", 293, 339], ["rhinorrhea", "PROBLEM", 347, 357], ["placebo", "TREATMENT", 393, 400], ["rhinorrhea", "OBSERVATION", 170, 180], ["nasal", "ANATOMY", 185, 190], ["congestion", "OBSERVATION", 191, 201], ["most common", "OBSERVATION_MODIFIER", 208, 219], ["nasal", "ANATOMY", 263, 268], ["irritation", "OBSERVATION", 269, 279], ["bleeding", "OBSERVATION", 284, 292]]], ["The second-generation or \u201cnonsedating\u201d antihistamines have had no effect on common cold symptoms5 in a limited number of studies.", [["\u201cnonsedating\u201d antihistamines", "TREATMENT", 25, 53], ["common cold symptoms5", "PROBLEM", 76, 97]]], ["These observations, the absence of histamine in the secretions of most subjects with colds, and the similarity of the response to ipratropium and first-generation antihistamines suggest that any effect of antihistamines on rhinorrhea is related to their anticholinergic rather than their antihistaminic properties.", [["secretions", "ANATOMY", 52, 62], ["histamine", "CHEMICAL", 35, 44], ["colds", "DISEASE", 85, 90], ["ipratropium", "CHEMICAL", 130, 141], ["antihistamines", "CHEMICAL", 163, 177], ["antihistamines", "CHEMICAL", 205, 219], ["rhinorrhea", "DISEASE", 223, 233], ["histamine", "CHEMICAL", 35, 44], ["ipratropium", "CHEMICAL", 130, 141], ["histamine", "SIMPLE_CHEMICAL", 35, 44], ["ipratropium", "SIMPLE_CHEMICAL", 130, 141], ["antihistamines", "SIMPLE_CHEMICAL", 205, 219], ["histamine", "TREATMENT", 35, 44], ["colds", "PROBLEM", 85, 90], ["ipratropium", "TREATMENT", 130, 141], ["first-generation antihistamines", "TREATMENT", 146, 177], ["antihistamines", "TREATMENT", 205, 219], ["rhinorrhea", "PROBLEM", 223, 233], ["their anticholinergic", "TREATMENT", 248, 269], ["their antihistaminic properties", "TREATMENT", 282, 313]]], ["The major side effects associated with the use of the antihistamines are sedation and drying of the eyes, mouth, and nose.CoughCough during colds is produced by several different mechanisms, and treatment should be directed at the most likely underlying cause.", [["eyes", "ANATOMY", 100, 104], ["mouth", "ANATOMY", 106, 111], ["nose", "ANATOMY", 117, 121], ["CoughCough", "CHEMICAL", 122, 132], ["colds", "DISEASE", 140, 145], ["antihistamines", "SIMPLE_CHEMICAL", 54, 68], ["eyes", "ORGAN", 100, 104], ["mouth", "ORGANISM_SUBDIVISION", 106, 111], ["nose", "ORGANISM_SUBDIVISION", 117, 121], ["the antihistamines", "TREATMENT", 50, 68], ["sedation", "TREATMENT", 73, 81], ["drying of the eyes, mouth, and nose", "PROBLEM", 86, 121], ["colds", "PROBLEM", 140, 145], ["treatment", "TREATMENT", 195, 204], ["major", "OBSERVATION_MODIFIER", 4, 9], ["side effects", "OBSERVATION_MODIFIER", 10, 22], ["eyes", "ANATOMY", 100, 104], ["mouth", "ANATOMY", 106, 111], ["nose", "ANATOMY", 117, 121], ["colds", "OBSERVATION", 140, 145], ["most likely", "UNCERTAINTY", 231, 242]]], ["If cough is caused by nasal obstruction or postnasal drip, it may respond to treatment with an antihistamine or antihistamine-decongestant combination.", [["nasal", "ANATOMY", 22, 27], ["cough", "DISEASE", 3, 8], ["nasal obstruction", "DISEASE", 22, 39], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 22, 39], ["antihistamine", "SIMPLE_CHEMICAL", 95, 108], ["antihistamine", "SIMPLE_CHEMICAL", 112, 125], ["cough", "PROBLEM", 3, 8], ["nasal obstruction", "PROBLEM", 22, 39], ["postnasal drip", "TREATMENT", 43, 57], ["treatment", "TREATMENT", 77, 86], ["an antihistamine", "TREATMENT", 92, 108], ["antihistamine", "TREATMENT", 112, 125], ["decongestant combination", "TREATMENT", 126, 150], ["nasal", "ANATOMY", 22, 27], ["obstruction", "OBSERVATION", 28, 39]]], ["If a more persistent cough is the result of virus-induced reactive airway disease or viral infection of the lower airways, patients may benefit from bronchodilator therapy (Chapter 87).", [["airway", "ANATOMY", 67, 73], ["lower airways", "ANATOMY", 108, 121], ["cough", "DISEASE", 21, 26], ["airway disease", "DISEASE", 67, 81], ["viral infection", "DISEASE", 85, 100], ["airway", "MULTI-TISSUE_STRUCTURE", 67, 73], ["lower airways", "MULTI-TISSUE_STRUCTURE", 108, 121], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["a more persistent cough", "PROBLEM", 3, 26], ["virus", "PROBLEM", 44, 49], ["reactive airway disease", "PROBLEM", 58, 81], ["viral infection of the lower airways", "PROBLEM", 85, 121], ["bronchodilator therapy", "TREATMENT", 149, 171], ["persistent", "OBSERVATION_MODIFIER", 10, 20], ["cough", "OBSERVATION", 21, 26], ["reactive airway disease", "OBSERVATION", 58, 81], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["infection", "OBSERVATION", 91, 100], ["lower", "ANATOMY_MODIFIER", 108, 113], ["airways", "ANATOMY", 114, 121]]], ["Cough that persists after the resolution of other cold symptoms or that persists in association with unremitting rhinorrhea may be due to sinusitis and may respond to antibiotic therapy (Chapter 434).", [["Cough", "DISEASE", 0, 5], ["rhinorrhea", "DISEASE", 113, 123], ["sinusitis", "DISEASE", 138, 147], ["Cough", "PROBLEM", 0, 5], ["other cold symptoms", "PROBLEM", 44, 63], ["unremitting rhinorrhea", "PROBLEM", 101, 123], ["sinusitis", "PROBLEM", 138, 147], ["antibiotic therapy", "TREATMENT", 167, 185], ["unremitting", "OBSERVATION_MODIFIER", 101, 112], ["rhinorrhea", "OBSERVATION", 113, 123], ["may be due to", "UNCERTAINTY", 124, 137], ["sinusitis", "OBSERVATION", 138, 147]]], ["Nonspecific cough suppression with codeine or dextromethorphan hydrobromide has not been demonstrated to be efficacious, and expectorants such as guaifenesin are not effective antitussive agents.Other RemediesMany patients have a variety of other symptoms.", [["cough", "DISEASE", 12, 17], ["codeine", "CHEMICAL", 35, 42], ["dextromethorphan hydrobromide", "CHEMICAL", 46, 75], ["guaifenesin", "CHEMICAL", 146, 157], ["codeine", "CHEMICAL", 35, 42], ["dextromethorphan hydrobromide", "CHEMICAL", 46, 75], ["guaifenesin", "CHEMICAL", 146, 157], ["codeine", "SIMPLE_CHEMICAL", 35, 42], ["dextromethorphan hydrobromide", "SIMPLE_CHEMICAL", 46, 75], ["guaifenesin", "SIMPLE_CHEMICAL", 146, 157], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["Nonspecific cough suppression", "PROBLEM", 0, 29], ["codeine", "TREATMENT", 35, 42], ["dextromethorphan hydrobromide", "TREATMENT", 46, 75], ["guaifenesin", "TREATMENT", 146, 157], ["antitussive agents", "TREATMENT", 176, 194], ["other symptoms", "PROBLEM", 241, 255], ["cough", "OBSERVATION", 12, 17]]], ["Nonsteroidal anti-inflammatory agents are effective for headache, ear pain, and muscle and joint pain; however, they do not relieve nasal congestion, rhinorrhea, or cough.6Zinc, which is an inhibitor of rhinovirus 3C protease that is essential for virus replication, does not have a significant antiviral effect and has shown either no or relatively modest effects in reducing the severity of the common cold.7 This uncertain benefit must also be viewed in light of zinc's side effects; oral zinc lozenges may be associated with sore mouth and occasional nausea, whereas intranasal zinc may cause nasal irritation.Echinacea has not been shown to be beneficial in reducing symptoms of the common cold in several studies.8 Given the variation in echinacea products, however, it is possible that echinacea preparations with different phytochemical profiles might be helpful.", [["Nonsteroidal", "ANATOMY", 0, 12], ["ear", "ANATOMY", 66, 69], ["muscle", "ANATOMY", 80, 86], ["joint", "ANATOMY", 91, 96], ["nasal", "ANATOMY", 132, 137], ["oral", "ANATOMY", 487, 491], ["sore mouth", "ANATOMY", 529, 539], ["nasal", "ANATOMY", 597, 602], ["headache", "DISEASE", 56, 64], ["ear pain", "DISEASE", 66, 74], ["muscle and joint pain", "DISEASE", 80, 101], ["nasal congestion", "DISEASE", 132, 148], ["rhinorrhea", "DISEASE", 150, 160], ["cough", "DISEASE", 165, 170], ["6Zinc", "CHEMICAL", 171, 176], ["zinc", "CHEMICAL", 466, 470], ["zinc", "CHEMICAL", 492, 496], ["sore mouth", "DISEASE", 529, 539], ["nausea", "DISEASE", 555, 561], ["zinc", "CHEMICAL", 582, 586], ["nasal irritation", "DISEASE", 597, 613], ["Echinacea", "CHEMICAL", 614, 623], ["6Zinc", "CHEMICAL", 171, 176], ["zinc", "CHEMICAL", 466, 470], ["zinc", "CHEMICAL", 492, 496], ["zinc", "CHEMICAL", 582, 586], ["ear", "ORGAN", 66, 69], ["muscle", "ORGAN", 80, 86], ["joint", "MULTI-TISSUE_STRUCTURE", 91, 96], ["nasal", "ORGANISM_SUBDIVISION", 132, 137], ["6Zinc", "SIMPLE_CHEMICAL", 171, 176], ["rhinovirus 3C", "ORGANISM", 203, 216], ["zinc", "SIMPLE_CHEMICAL", 466, 470], ["oral", "ORGANISM_SUBDIVISION", 487, 491], ["mouth", "ORGANISM_SUBDIVISION", 534, 539], ["zinc", "SIMPLE_CHEMICAL", 582, 586], ["nasal", "ORGANISM_SUBDIVISION", 597, 602], ["Echinacea", "ORGANISM", 614, 623], ["echinacea", "ORGANISM", 793, 802], ["rhinovirus 3C protease", "PROTEIN", 203, 225], ["Echinacea", "SPECIES", 614, 623], ["Nonsteroidal anti-inflammatory agents", "TREATMENT", 0, 37], ["headache", "PROBLEM", 56, 64], ["ear pain", "PROBLEM", 66, 74], ["muscle and joint pain", "PROBLEM", 80, 101], ["nasal congestion", "PROBLEM", 132, 148], ["rhinorrhea", "PROBLEM", 150, 160], ["cough", "PROBLEM", 165, 170], ["6Zinc", "TREATMENT", 171, 176], ["an inhibitor", "TREATMENT", 187, 199], ["rhinovirus 3C protease", "TREATMENT", 203, 225], ["virus replication", "TREATMENT", 248, 265], ["zinc's side effects", "TREATMENT", 466, 485], ["oral zinc lozenges", "TREATMENT", 487, 505], ["sore mouth", "PROBLEM", 529, 539], ["occasional nausea", "PROBLEM", 544, 561], ["intranasal zinc", "TREATMENT", 571, 586], ["nasal irritation", "PROBLEM", 597, 613], ["Echinacea", "PROBLEM", 614, 623], ["reducing symptoms", "PROBLEM", 663, 680], ["several studies", "TEST", 703, 718], ["echinacea products", "TREATMENT", 744, 762], ["echinacea preparations", "TREATMENT", 793, 815], ["ear", "ANATOMY", 66, 69], ["pain", "OBSERVATION", 70, 74], ["muscle", "ANATOMY", 80, 86], ["joint", "ANATOMY", 91, 96], ["nasal", "ANATOMY", 132, 137], ["congestion", "OBSERVATION", 138, 148], ["rhinorrhea", "OBSERVATION", 150, 160], ["cough", "OBSERVATION", 165, 170], ["significant", "OBSERVATION_MODIFIER", 283, 294], ["antiviral effect", "OBSERVATION", 295, 311], ["modest", "OBSERVATION_MODIFIER", 350, 356], ["common cold", "ANATOMY", 397, 408], ["nasal", "ANATOMY", 597, 602], ["irritation", "OBSERVATION", 603, 613], ["variation", "OBSERVATION_MODIFIER", 731, 740], ["echinacea products", "OBSERVATION", 744, 762]]], ["The accumulating evidence, however, suggests that it is prudent to assume that echinacea has no beneficial effect until positive evidence of a treatment effect is produced.", [["echinacea", "CHEMICAL", 79, 88], ["echinacea", "SIMPLE_CHEMICAL", 79, 88], ["echinacea", "PROBLEM", 79, 88], ["treatment", "OBSERVATION", 143, 152]]]], "PMC4068970": [["FindingsEmerging infectious diseases are a constant threat to human health.", [["infectious diseases", "DISEASE", 17, 36], ["human", "ORGANISM", 62, 67], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["FindingsEmerging infectious diseases", "PROBLEM", 0, 36], ["infectious", "OBSERVATION", 17, 27]]], ["Of specific concern is the uncertainty associated with their early stages and potentially high impact outcome.", [["high", "OBSERVATION_MODIFIER", 90, 94]]], ["In April 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV) emerged [1] and spread from the Arabian Peninsula to various countries in Europe, North Africa, Southeast Asia, the United States and Middle East.", [["respiratory syndrome coronavirus", "DISEASE", 31, 63], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 19, 63], ["MERS-CoV", "ORGANISM", 65, 73], ["Middle East respiratory syndrome coronavirus", "SPECIES", 19, 63], ["MERS-CoV", "SPECIES", 65, 73], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 15, 63], ["Middle", "ANATOMY_MODIFIER", 19, 25], ["respiratory syndrome", "OBSERVATION", 31, 51], ["Middle", "ANATOMY_MODIFIER", 209, 215]]], ["MERS-CoV is characterized by a severe respiratory illness and high case-fatality rate [2].", [["respiratory", "ANATOMY", 38, 49], ["respiratory illness", "DISEASE", 38, 57], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8], ["a severe respiratory illness", "PROBLEM", 29, 57], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["respiratory illness", "OBSERVATION", 38, 57]]], ["A decade prior, a pandemic of SARS, a related coronavirus, caused 8,273 cases and 775 deaths in only 8 months [3].", [["SARS", "DISEASE", 30, 34], ["coronavirus", "DISEASE", 46, 57], ["deaths", "DISEASE", 86, 92], ["SARS", "PROBLEM", 30, 34], ["a related coronavirus", "PROBLEM", 36, 57]]], ["In contrast, MERS-CoV is still ongoing after two years, and as of June 2014 has apparently infected only 688 people and killed 282, with no clear source of infection to humans and an epidemiologic pattern that is more sporadic than the classic epidemic pattern of SARS [2].", [["infection", "DISEASE", 156, 165], ["SARS", "DISEASE", 264, 268], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["people", "ORGANISM", 109, 115], ["humans", "ORGANISM", 169, 175], ["people", "SPECIES", 109, 115], ["humans", "SPECIES", 169, 175], ["MERS-CoV", "SPECIES", 13, 21], ["humans", "SPECIES", 169, 175], ["infection to humans", "PROBLEM", 156, 175], ["infected", "OBSERVATION_MODIFIER", 91, 99], ["infection", "OBSERVATION", 156, 165]]], ["Of further concern is the significant increase in reported cases since March 2014; in April 2014 alone, the number of reported cases exceeded the total number of cases that had been reported in the two years prior [2].FindingsThe first outbreak of MERS-CoV occurred in a hospital in Jordan in April 2012, with subsequent cases and clusters occurring throughout the Arabian Peninsula.", [["MERS-CoV", "DISEASE", 248, 256], ["MERS-CoV", "ORGANISM", 248, 256], ["MERS-CoV", "SPECIES", 248, 256], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["Arabian Peninsula", "ANATOMY", 365, 382]]], ["Phylogenetic analysis of the virus has revealed that MERS-CoV has been in circulation since at least 2003 [4], much longer than previously estimated based on the most common ancestor for the MERS-CoV strains found in humans [5], and well before the first confirmed case in Jordon.", [["MERS-CoV", "ORGANISM", 53, 61], ["MERS-CoV strains", "ORGANISM", 191, 207], ["humans", "ORGANISM", 217, 223], ["MERS-CoV", "DNA", 53, 61], ["humans", "SPECIES", 217, 223], ["MERS-CoV", "SPECIES", 53, 61], ["MERS-CoV", "SPECIES", 191, 199], ["humans", "SPECIES", 217, 223], ["Phylogenetic analysis", "TEST", 0, 21], ["the virus", "PROBLEM", 25, 34], ["MERS", "PROBLEM", 53, 57], ["CoV", "PROBLEM", 58, 61], ["CoV strains", "PROBLEM", 196, 207]]], ["Travel from the infected regions has resulted in additional cases in over a dozen countries, with limited local transmission occurring in the UK, France, Tunisia, and Iran.", [["infected", "OBSERVATION", 16, 24]]], ["Furthermore, five of the highest travelled airports in the world are located in countries where MERS-CoV has been transmitted [6], creating the possibility of a pandemic [7].FindingsHospital clusters represent the majority of MERS-CoV confirmed cases, and are the primary location where human-to-human transmission of MERS-CoV has been confirmed [8-10]; although limited spread among family members has also been confirmed [11].", [["MERS-CoV", "ORGANISM", 96, 104], ["MERS-CoV", "ORGANISM", 226, 234], ["human", "ORGANISM", 287, 292], ["human", "ORGANISM", 296, 301], ["MERS-CoV", "ORGANISM", 318, 326], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 296, 301], ["MERS-CoV", "SPECIES", 96, 104], ["MERS-CoV", "SPECIES", 226, 234], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 296, 301], ["MERS-CoV", "SPECIES", 318, 326]]], ["SARS was also predominantly a nosocomial infection [12], but the epidemiology of MERS-CoV is less clear.", [["SARS", "DISEASE", 0, 4], ["nosocomial infection", "DISEASE", 30, 50], ["MERS-CoV", "ORGANISM", 81, 89], ["MERS-CoV", "SPECIES", 81, 89], ["SARS", "PROBLEM", 0, 4], ["a nosocomial infection", "PROBLEM", 28, 50], ["predominantly", "OBSERVATION_MODIFIER", 14, 27], ["nosocomial", "OBSERVATION_MODIFIER", 30, 40], ["infection", "OBSERVATION", 41, 50], ["less", "OBSERVATION_MODIFIER", 93, 97], ["clear", "OBSERVATION", 98, 103]]], ["The risk factors associated with MERS-CoV include male gender, underlying disease, immunosuppression and hospitalization.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["MERS-CoV", "SPECIES", 33, 41], ["The risk factors", "PROBLEM", 0, 16], ["MERS", "PROBLEM", 33, 37], ["underlying disease", "PROBLEM", 63, 81], ["immunosuppression", "TREATMENT", 83, 100], ["disease", "OBSERVATION", 74, 81]]], ["These patterns contrast the epidemiology of SARS, where there was a small female excess, less evidence of co-morbidities, and a younger median age.", [["SARS", "DISEASE", 44, 48], ["a small female excess", "PROBLEM", 66, 87], ["co-morbidities", "PROBLEM", 106, 120], ["small", "OBSERVATION_MODIFIER", 68, 73]]], ["The male predominance of MERS-CoV may reflect higher likelihood of exposure to infectious agents for males than females in Middle Eastern cultures.", [["MERS-CoV", "ORGANISM", 25, 33], ["Middle Eastern cultures", "CELL", 123, 146], ["MERS-CoV", "SPECIES", 25, 33], ["MERS", "PROBLEM", 25, 29], ["CoV", "PROBLEM", 30, 33], ["infectious agents", "TREATMENT", 79, 96], ["males than females", "PROBLEM", 101, 119], ["Middle Eastern cultures", "TEST", 123, 146], ["infectious", "OBSERVATION", 79, 89]]], ["In addition, most males who tested positive for the virus and died also had underlying medical conditions, which could explain the severity of cases in older males.", [["males", "ORGANISM", 18, 23], ["the virus", "PROBLEM", 48, 57], ["underlying medical conditions", "PROBLEM", 76, 105]]], ["Asymptomatic, child and female cases have been increasingly recently reported [9], however a large number of undetected asymptomatic or mild cases have not been found during contact tracing among healthcare workers or close contacts of MERS-CoV patients at the German [13], UK [14] and KSA hospitals [1], nor in a serologic survey conducted on blood donors and abattoir workers in the infected region in 2012 [15].FindingsIn contrast to SARS which was rapidly identified as zoonotic in origin [3], there has been no clear animal source of infection, nor consistent history of animal contact in a majority of the reported cases.", [["blood", "ANATOMY", 344, 349], ["SARS", "DISEASE", 437, 441], ["infection", "DISEASE", 539, 548], ["MERS-CoV", "ORGANISM", 236, 244], ["patients", "ORGANISM", 245, 253], ["blood", "ORGANISM_SUBSTANCE", 344, 349], ["patients", "SPECIES", 245, 253], ["MERS-CoV", "SPECIES", 236, 244], ["mild cases", "PROBLEM", 136, 146], ["a serologic survey", "TEST", 312, 330], ["SARS", "PROBLEM", 437, 441], ["infection", "PROBLEM", 539, 548], ["zoonotic", "OBSERVATION_MODIFIER", 474, 482], ["no", "UNCERTAINTY", 513, 515], ["clear", "OBSERVATION_MODIFIER", 516, 521], ["infection", "OBSERVATION", 539, 548]]], ["Phylogenetic analysis has identified a close relationship between MERS-CoV in humans and various bat species [16-19], however the exact virus has not been confirmed in any bat.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["humans", "ORGANISM", 78, 84], ["bat species", "ORGANISM", 97, 108], ["MERS-CoV", "DNA", 66, 74], ["humans", "SPECIES", 78, 84], ["MERS-CoV", "SPECIES", 66, 74], ["humans", "SPECIES", 78, 84], ["Phylogenetic analysis", "TEST", 0, 21], ["CoV in humans and various bat species", "PROBLEM", 71, 108], ["the exact virus", "PROBLEM", 126, 141]]], ["In contrast, MERS-CoV and MERS-CoV-like antibodies have been identified in dromedary camels [4,20-31], suggesting MERS-CoV is widespread, and previously infected various camel populations (including countries where human cases have yet to be reported).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["MERS-CoV", "ORGANISM", 26, 34], ["MERS-CoV", "ORGANISM", 114, 122], ["camel", "ORGANISM", 170, 175], ["human", "ORGANISM", 215, 220], ["MERS-CoV and MERS-CoV-like antibodies", "PROTEIN", 13, 50], ["human", "SPECIES", 215, 220], ["MERS-CoV", "SPECIES", 13, 21], ["MERS-CoV", "SPECIES", 26, 34], ["MERS-CoV", "SPECIES", 114, 122], ["camel", "SPECIES", 170, 175], ["human", "SPECIES", 215, 220], ["MERS", "TEST", 13, 17], ["MERS", "TEST", 26, 30], ["CoV-like antibodies", "PROBLEM", 31, 50], ["widespread", "OBSERVATION_MODIFIER", 126, 136]]], ["A recent study by Memish et al. [32] analyzed the virus in an infected camel and infected care taker of the camel, and the findings suggested cross-species transmission, though it is unknown if the camel infected the human, or the other way around.", [["camel", "ORGANISM", 71, 76], ["camel", "ORGANISM", 108, 113], ["camel", "ORGANISM", 198, 203], ["human", "ORGANISM", 217, 222], ["camel", "SPECIES", 71, 76], ["camel", "SPECIES", 198, 203], ["human", "SPECIES", 217, 222], ["camel", "SPECIES", 71, 76], ["camel", "SPECIES", 198, 203], ["human", "SPECIES", 217, 222], ["A recent study", "TEST", 0, 14], ["the virus", "PROBLEM", 46, 55], ["infected", "OBSERVATION", 62, 70], ["infected", "OBSERVATION", 81, 89]]], ["Infected camels may therefore represent a direct source to humans, or the virus may have crossed from camels to alternative zoonotic hosts or environmental sources responsible for the recent transmission to humans.", [["camels", "ORGANISM", 9, 15], ["humans", "ORGANISM", 59, 65], ["humans", "ORGANISM", 207, 213], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 207, 213], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 207, 213], ["Infected camels", "PROBLEM", 0, 15], ["the virus", "PROBLEM", 70, 79]]], ["Additional evidence supporting camels as a host animal was provided by a study which sequenced complete MERS-CoV isolates from five camels in Saudi Arabia, which were shown to be identical to published sequences of human isolates [31].", [["camels", "ORGANISM", 31, 37], ["MERS-CoV", "ORGANISM", 104, 112], ["human", "ORGANISM", 215, 220], ["human", "SPECIES", 215, 220], ["MERS-CoV", "SPECIES", 104, 112], ["human", "SPECIES", 215, 220], ["a study", "TEST", 71, 78]]], ["The same study found that viral particles from individual camels contained more genetic variation than MERS-CoV isolates from humans; therefore only certain genotypes may be able to infect humans, offering a possible explanation to why human cases are less common [31].FindingsWith MERS CoV there was no epidemic peak in the first 12 months as there was with SARS [12].", [["SARS", "DISEASE", 359, 363], ["camels", "ORGANISM", 58, 64], ["MERS-CoV isolates", "ORGANISM", 103, 120], ["humans", "ORGANISM", 126, 132], ["humans", "ORGANISM", 189, 195], ["human", "ORGANISM", 236, 241], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 189, 195], ["human", "SPECIES", 236, 241], ["MERS-CoV", "SPECIES", 103, 111], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 189, 195], ["human", "SPECIES", 236, 241], ["FindingsWith MERS CoV", "SPECIES", 269, 290], ["The same study", "TEST", 0, 14], ["viral particles", "PROBLEM", 26, 41], ["individual camels", "PROBLEM", 47, 64], ["CoV isolates", "TEST", 108, 120], ["epidemic peak", "PROBLEM", 304, 317], ["SARS", "PROBLEM", 359, 363], ["viral particles", "OBSERVATION", 26, 41], ["no", "UNCERTAINTY", 301, 303], ["epidemic", "OBSERVATION_MODIFIER", 304, 312], ["peak", "OBSERVATION_MODIFIER", 313, 317]]], ["Instead, there were infrequent cases over a longer period than would be expected for a disease that is not highly infectious (see Figure 1).", [["a disease", "PROBLEM", 85, 94], ["disease", "OBSERVATION", 87, 94], ["not highly", "UNCERTAINTY", 103, 113], ["infectious", "OBSERVATION", 114, 124]]], ["This pattern is suggestive of a sporadic rather than epidemic source of ongoing infection in humans.", [["infection", "DISEASE", 80, 89], ["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["a sporadic", "PROBLEM", 30, 40], ["ongoing infection in humans", "PROBLEM", 72, 99], ["suggestive of", "UNCERTAINTY", 16, 29], ["sporadic", "OBSERVATION", 32, 40], ["ongoing", "OBSERVATION_MODIFIER", 72, 79], ["infection", "OBSERVATION", 80, 89]]], ["Estimates of the reproductive number, R0, are low, and range from 0.42 < R0 < 0.92 [33], and 0.8 < R0 < 1.5 [34], suggesting the infection does not have epidemic potential and cannot be easily sustained in the human population by human-to-human transmission alone [9,35,36].", [["infection", "DISEASE", 129, 138], ["human", "ORGANISM", 210, 215], ["human", "ORGANISM", 230, 235], ["human", "ORGANISM", 239, 244], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 239, 244], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 239, 244], ["the reproductive number", "TEST", 13, 36], ["R0", "TEST", 73, 75], ["R0", "TEST", 99, 101], ["the infection", "PROBLEM", 125, 138], ["reproductive", "OBSERVATION_MODIFIER", 17, 29], ["number", "OBSERVATION_MODIFIER", 30, 36], ["low", "OBSERVATION_MODIFIER", 46, 49], ["infection", "OBSERVATION", 129, 138]]], ["A low reproductive number is supported by the epidemiologic pattern, however, the surge of cases in April 2014, inclusion of asymptomatic and mild infections and the increasing size and transmission generations of recent clusters would under-estimate this calculation.FindingsAt odds with these estimates of R0, in April and May 2013, a peak of infections occurred in Al Ahsa (see Figure 1).", [["infections", "DISEASE", 147, 157], ["infections", "DISEASE", 345, 355], ["A low reproductive number", "PROBLEM", 0, 25], ["asymptomatic", "PROBLEM", 125, 137], ["mild infections", "PROBLEM", 142, 157], ["the increasing size", "PROBLEM", 162, 181], ["recent clusters", "PROBLEM", 214, 229], ["this calculation", "TEST", 251, 267], ["a peak of infections", "PROBLEM", 335, 355], ["low reproductive", "OBSERVATION_MODIFIER", 2, 18], ["mild", "OBSERVATION_MODIFIER", 142, 146], ["infections", "OBSERVATION", 147, 157], ["increasing", "OBSERVATION_MODIFIER", 166, 176], ["size", "OBSERVATION_MODIFIER", 177, 181], ["infections", "OBSERVATION", 345, 355]]], ["This outbreak resulted in 26 cases, and shows a classic epidemic curve characteristic of an infection with a R0 > 1, which on the surface can be interpreted as a single strain human-to-human, rapid-onset, short time- frame nosocomial outbreak [37].", [["surface", "ANATOMY", 130, 137], ["infection", "DISEASE", 92, 101], ["surface", "CELLULAR_COMPONENT", 130, 137], ["human", "ORGANISM", 176, 181], ["human", "ORGANISM", 185, 190], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 185, 190], ["a classic epidemic curve", "PROBLEM", 46, 70], ["an infection", "PROBLEM", 89, 101], ["infection", "OBSERVATION", 92, 101]]], ["Yet phylogenetic analysis of the patient samples showed multiple different strains, and at least three transmission events which could not be explained by human-to-human transmission within the hospital [38].", [["samples", "ANATOMY", 41, 48], ["patient", "ORGANISM", 33, 40], ["human", "ORGANISM", 155, 160], ["human", "ORGANISM", 164, 169], ["patient", "SPECIES", 33, 40], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 164, 169], ["phylogenetic analysis", "TEST", 4, 25], ["the patient samples", "TEST", 29, 48], ["multiple different strains", "PROBLEM", 56, 82], ["multiple", "OBSERVATION_MODIFIER", 56, 64], ["different strains", "OBSERVATION", 65, 82]]], ["These data suggests the outbreak was a result of multiple independent transmission events, combined with some human-to-human transmission within the hospital [38].", [["human", "ORGANISM", 110, 115], ["human", "ORGANISM", 119, 124], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 119, 124], ["multiple independent transmission events", "PROBLEM", 49, 89]]], ["Multiple sources of transmission were again identified in a study of the Hafr Al-Batin outbreak conducted by Memish et al. [39], with camels suggested as the most likely source.FindingsIn yet another paradox, given apparent human-to-human transmission in Al Ahsa and Hafr Al-Batin, among others, it is puzzling that MERS-CoV was present in Saudi Arabia around the period of significant mass gatherings such as the Umrah and Hajj pilgrimages in 2012 and 2013, yet no cases were reported in returning pilgrims either year [2].", [["Al", "CHEMICAL", 78, 80], ["camels", "ORGANISM", 134, 140], ["human", "ORGANISM", 224, 229], ["human", "ORGANISM", 233, 238], ["Al Ahsa", "CELL", 255, 262], ["Hafr Al-Batin", "CELL", 267, 280], ["MERS-CoV", "ORGANISM", 316, 324], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 233, 238], ["MERS-CoV", "SPECIES", 316, 324], ["a study", "TEST", 58, 65], ["significant mass", "PROBLEM", 374, 390], ["most likely", "UNCERTAINTY", 158, 169], ["significant", "OBSERVATION_MODIFIER", 374, 385], ["mass", "OBSERVATION", 386, 390]]], ["The Hajj is a significant mass gathering, with over four million pilgrims congregating in Mecca, and is associated with significant epidemics of infectious diseases [40].", [["infectious diseases", "DISEASE", 145, 164], ["a significant mass", "PROBLEM", 12, 30], ["infectious diseases", "PROBLEM", 145, 164], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["mass", "OBSERVATION", 26, 30], ["associated with", "UNCERTAINTY", 104, 119], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["epidemics", "OBSERVATION", 132, 141], ["infectious", "OBSERVATION", 145, 155]]], ["Active surveillance of symptomatic pilgrims in 2012 and 2013 failed to detect MERS-CoV infections [41-44], a serologic survey conducted on blood donors and abattoir workers in the infected region in 2012 did not detect any antibodies [15].", [["blood", "ANATOMY", 139, 144], ["MERS-CoV infections", "DISEASE", 78, 97], ["MERS-CoV", "ORGANISM", 78, 86], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["donors", "ORGANISM", 145, 151], ["antibodies", "PROTEIN", 223, 233], ["MERS-CoV", "SPECIES", 78, 86], ["symptomatic pilgrims", "PROBLEM", 23, 43], ["CoV infections", "PROBLEM", 83, 97], ["a serologic survey", "TEST", 107, 125], ["blood donors", "TREATMENT", 139, 151], ["any antibodies", "PROBLEM", 219, 233]]], ["Additionally, no cases were reported by pilgrims who travelled to Saudi Arabia to perform Umrah during July and August, 2013.The lack of an epidemic sparked by the close contact conditions of four mass gatherings in Saudi Arabia during 2012 and 2013 supports the low estimates of R0.FindingsThe persistence of MERS-CoV for more than 3 times the duration than SARS, which had a higher R0, highlights the question of why the infection is still ongoing in humans, and what is the source of ongoing transmission to humans?", [["SARS", "DISEASE", 359, 363], ["infection", "DISEASE", 423, 432], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 310, 318], ["humans", "ORGANISM", 453, 459], ["humans", "ORGANISM", 511, 517], ["humans", "SPECIES", 453, 459], ["humans", "SPECIES", 511, 517], ["MERS-CoV", "SPECIES", 310, 318], ["humans", "SPECIES", 453, 459], ["humans", "SPECIES", 511, 517], ["SARS", "PROBLEM", 359, 363], ["the infection", "PROBLEM", 419, 432], ["epidemic", "OBSERVATION", 140, 148], ["mass", "OBSERVATION", 197, 201], ["persistence", "OBSERVATION_MODIFIER", 295, 306], ["MERS", "OBSERVATION", 310, 314], ["infection", "OBSERVATION", 423, 432]]], ["The possible sources of ongoing infection include a non-human source which is infecting humans (such as an animal reservoir or an environmental source), or human-to-human transmission.", [["infection", "DISEASE", 32, 41], ["humans", "ORGANISM", 88, 94], ["human", "ORGANISM", 156, 161], ["human", "ORGANISM", 165, 170], ["humans", "SPECIES", 88, 94], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 165, 170], ["humans", "SPECIES", 88, 94], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 165, 170], ["ongoing infection", "PROBLEM", 24, 41], ["a non-human source", "PROBLEM", 50, 68], ["an animal reservoir", "TREATMENT", 104, 123], ["possible sources of", "UNCERTAINTY", 4, 23], ["ongoing", "OBSERVATION_MODIFIER", 24, 31], ["infection", "OBSERVATION", 32, 41]]], ["Human to human transmission is apparent in some clusters of individuals in close contact and in the hospital setting, but does not appear frequent, supporting a low infectivity of the virus.", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 9, 14], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["a low infectivity of the virus", "PROBLEM", 159, 189], ["low infectivity", "OBSERVATION_MODIFIER", 161, 176]]], ["While it is possible MERS-CoV has been circulating solely from sustained human to human transmission since it was initially reported in mid 2012, it is unlikely given the low number of reported cases.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["human", "ORGANISM", 73, 78], ["human", "ORGANISM", 82, 87], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 82, 87], ["MERS-CoV", "SPECIES", 21, 29], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 82, 87], ["MERS-CoV", "PROBLEM", 21, 29]]], ["It is possible that cases have been either asymptomatic or escaped detection, as cases with mild or no symptoms do appear to occur.", [["asymptomatic", "PROBLEM", 43, 55], ["symptoms", "PROBLEM", 103, 111]]], ["Undetected mild cases have been suggested as a factor in the apparent decrease in the case fatality rate over time in a model estimating a total of 940 (95% CI 290\u20132200) symptomatic cases, with 62% of these undetected [45].", [["Undetected mild cases", "PROBLEM", 0, 21], ["symptomatic cases", "TEST", 170, 187], ["mild", "OBSERVATION_MODIFIER", 11, 15], ["decrease", "OBSERVATION_MODIFIER", 70, 78]]], ["However, efforts to identify a large pool of undetected cases have failed to identify asymptomtic or mild cases [1,13,14], and similarly, a serological study showed no evidence that MERS-CoV circulated widely in the study region in fall 2012 [15].", [["MERS-CoV", "ORGANISM", 182, 190], ["MERS-CoV", "SPECIES", 182, 190], ["mild cases", "PROBLEM", 101, 111], ["a serological study", "TEST", 138, 157], ["CoV", "PROBLEM", 187, 190], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["no evidence", "UNCERTAINTY", 165, 176]]], ["In other words, the model [45] can only explain the observed epidemiology if a large proportion of undetected cases have occurred, yet there is no evidence to support this.", [["no evidence to", "UNCERTAINTY", 144, 158]]], ["Based on the available evidence, multiple introductions from zoonotic sources to humans, resulting in limited clusters of cases is the most likely explanation of how MERS CoV has persisted in human populations for a prolonged period despite a low R0, although it is unknown how many jumps to humans have occurred, or what the mode of transmission is between the animals and humans [34].FindingsClearly, there are still unanswered questions and unusual features of the epidemiology of MERS-CoV which warrant ongoing investigation.", [["humans", "ORGANISM", 81, 87], ["MERS CoV", "ORGANISM", 166, 174], ["human", "ORGANISM", 192, 197], ["humans", "ORGANISM", 292, 298], ["humans", "ORGANISM", 374, 380], ["MERS-CoV", "ORGANISM", 484, 492], ["humans", "SPECIES", 81, 87], ["human", "SPECIES", 192, 197], ["humans", "SPECIES", 292, 298], ["humans", "SPECIES", 374, 380], ["humans", "SPECIES", 81, 87], ["MERS CoV", "SPECIES", 166, 174], ["human", "SPECIES", 192, 197], ["humans", "SPECIES", 292, 298], ["humans", "SPECIES", 374, 380], ["MERS-CoV", "SPECIES", 484, 492], ["a low R0", "PROBLEM", 241, 249], ["ongoing investigation", "TEST", 507, 528], ["multiple", "OBSERVATION_MODIFIER", 33, 41], ["low R0", "OBSERVATION_MODIFIER", 243, 249]]], ["Given the remaining uncertainties surrounding MERS CoV, and the lack of an available vaccine, a strategic approach is required to control future spread.", [["MERS CoV", "ORGANISM", 46, 54], ["MERS CoV", "SPECIES", 46, 54], ["an available vaccine", "TREATMENT", 72, 92], ["a strategic approach", "TREATMENT", 94, 114], ["MERS CoV", "OBSERVATION", 46, 54]]], ["Firstly, zoonotic sources of infection should continue to be investigated, with a focused interest in identifying the possible zoonotic hosts or environmental sources which may act as modes of transmission between camels and humans.", [["infection", "DISEASE", 29, 38], ["camels", "ORGANISM", 214, 220], ["humans", "ORGANISM", 225, 231], ["humans", "SPECIES", 225, 231], ["humans", "SPECIES", 225, 231], ["infection", "PROBLEM", 29, 38], ["zoonotic hosts", "PROBLEM", 127, 141], ["zoonotic", "OBSERVATION_MODIFIER", 9, 17], ["infection", "OBSERVATION", 29, 38]]], ["A protocol has been adopted by WHO with the primary purpose of determining the non-human source of infection and corresponding route and mode of transmission to humans.", [["infection", "DISEASE", 99, 108], ["humans", "ORGANISM", 161, 167], ["humans", "SPECIES", 161, 167], ["humans", "SPECIES", 161, 167], ["A protocol", "TREATMENT", 0, 10], ["infection", "PROBLEM", 99, 108], ["infection", "OBSERVATION", 99, 108]]], ["Second, genetic testing over time should be conducted to determine if the virus is evolving, in which case the epidemiology of MERS-CoV could significantly alter.", [["MERS-CoV", "ORGANISM", 127, 135], ["MERS-CoV", "SPECIES", 127, 135], ["genetic testing", "TEST", 8, 23], ["the virus", "PROBLEM", 70, 79], ["CoV", "PROBLEM", 132, 135]]], ["The required serological tools for the detection of specific MERS-CoV antibodies (e.g. ELISA) have been developed and validated, and are currently being administered [32].", [["MERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 61, 80], ["MERS-CoV antibodies", "PROTEIN", 61, 80], ["MERS-CoV", "SPECIES", 61, 69], ["serological tools", "TEST", 13, 30], ["the detection", "TEST", 35, 48], ["specific MERS", "PROBLEM", 52, 65], ["CoV antibodies", "TEST", 66, 80], ["ELISA", "TEST", 87, 92]]], ["Further serological surveys, contact tracing and other surveillance in affected areas are needed to quantify asymptomatic or mild infection and to identify exposures to non-human sources of infection.", [["infection", "DISEASE", 130, 139], ["infection", "DISEASE", 190, 199], ["non-human", "ORGANISM", 169, 178], ["Further serological surveys", "TEST", 0, 27], ["contact tracing", "TEST", 29, 44], ["other surveillance in affected areas", "TEST", 49, 85], ["asymptomatic or mild infection", "PROBLEM", 109, 139], ["infection", "PROBLEM", 190, 199], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["infection", "OBSERVATION", 130, 139], ["infection", "OBSERVATION", 190, 199]]], ["Third, the possibility of a large number of cases having escaped detection, resulting in a falsely skewed epidemiology must be considered.", [["a falsely skewed epidemiology", "PROBLEM", 89, 118], ["large", "OBSERVATION_MODIFIER", 28, 33], ["number", "OBSERVATION_MODIFIER", 34, 40]]], ["Based on the viral load of MERS-CoV, the shedding patterns of MERS-CoV are different than those of SARS, possibly requiring alternative diagnostic approached [10].", [["SARS", "DISEASE", 99, 103], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["MERS-CoV", "SPECIES", 27, 35], ["MERS-CoV", "SPECIES", 62, 70], ["the viral load", "TEST", 9, 23], ["CoV", "PROBLEM", 32, 35], ["MERS", "PROBLEM", 62, 66], ["CoV", "PROBLEM", 67, 70], ["SARS", "PROBLEM", 99, 103]]], ["Further inquiry should also address the difference in symptoms between cases resulting from person-to-person transmission compared with transmission from unknown sources, presumably non-human, which may be more virulent; however a larger sample of case data is required to confirm this phenomenon.", [["non-human", "ORGANISM", 182, 191], ["person", "SPECIES", 92, 98], ["the difference in symptoms", "PROBLEM", 36, 62], ["case data", "TEST", 248, 257], ["this phenomenon", "PROBLEM", 281, 296]]], ["Lastly, open international collaboration and public access to laboratory findings from surveys such as that by ECDC-WHO can reveal the true geographical extent and source of these infections.Competing interestsThe authors declare there is no conflict of interest.Authors\u2019 contributionsBoth authors contributed equally to the writing of this manuscript.", [["infections", "DISEASE", 180, 190], ["these infections", "PROBLEM", 174, 190], ["infections", "OBSERVATION", 180, 190], ["no", "UNCERTAINTY", 239, 241]]]], "PMC7394629": [["Suicide is an important cause for death across the globe and the World Health Organization denotes it as the second largest contributor in mortality in between 15 and 29 years of age as well as a global phenomenon of which more than three quarters (76%) is contributed by the developing and low-income countries, but the risk factors which predispose to the same, especially in the context of mood disorders have not been studied in great detail.12", [["Suicide", "DISEASE", 0, 7], ["death", "DISEASE", 34, 39], ["mood disorders", "DISEASE", 393, 407], ["death across the globe", "PROBLEM", 34, 56], ["a global phenomenon", "PROBLEM", 194, 213], ["the risk factors", "PROBLEM", 317, 333], ["mood disorders", "PROBLEM", 393, 407], ["globe", "ANATOMY", 51, 56], ["global", "OBSERVATION_MODIFIER", 196, 202], ["phenomenon", "OBSERVATION", 203, 213]]]], "PMC7368658": [["IntroductionThe ongoing global pandemic of coronavirus disease 2019 (named as COVID-19) is today's most significant health concern.", [["coronavirus disease", "DISEASE", 43, 62], ["coronavirus", "ORGANISM", 43, 54], ["coronavirus disease", "PROBLEM", 43, 62], ["COVID", "TEST", 78, 83], ["global", "OBSERVATION_MODIFIER", 24, 30], ["pandemic", "OBSERVATION_MODIFIER", 31, 39], ["coronavirus disease", "OBSERVATION", 43, 62]]], ["This disease was first reported in Wuhan, China in December 2019.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12]]], ["As of June 30, 2020, this pandemic has infected >10 millions of people and caused >0.5 million deaths.", [["deaths", "DISEASE", 95, 101], ["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70], ["infected", "OBSERVATION_MODIFIER", 39, 47]]], ["There is a global urgency to develop vaccines to prevent infection and create treatments for this disease.", [["infection", "DISEASE", 57, 66], ["a global urgency", "PROBLEM", 9, 25], ["vaccines", "TREATMENT", 37, 45], ["infection", "PROBLEM", 57, 66], ["create treatments", "TREATMENT", 71, 88], ["this disease", "PROBLEM", 93, 105], ["global", "OBSERVATION_MODIFIER", 11, 17], ["urgency", "OBSERVATION", 18, 25], ["infection", "OBSERVATION", 57, 66]]], ["As a response to this pandemic there has been rapid adaptation of infection control and antimicrobial stewardship programs.IntroductionUse of antibiotics in the treatment and prevention of COVID-19 is rising (Rawson et al., 2020a) despite it being a viral disease (caused by a novel coronavirus\u2014SARS-CoV-2).", [["infection", "DISEASE", 66, 75], ["COVID-19", "CHEMICAL", 189, 197], ["viral disease", "DISEASE", 250, 263], ["SARS", "DISEASE", 295, 299], ["COVID-19", "CHEMICAL", 189, 197], ["coronavirus", "ORGANISM", 283, 294], ["coronavirus", "SPECIES", 283, 294], ["infection control", "TREATMENT", 66, 83], ["antimicrobial stewardship programs", "TREATMENT", 88, 122], ["antibiotics", "TREATMENT", 142, 153], ["the treatment", "TREATMENT", 157, 170], ["COVID", "TEST", 189, 194], ["a viral disease", "PROBLEM", 248, 263], ["a novel coronavirus", "PROBLEM", 275, 294], ["rapid", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 66, 75], ["viral disease", "OBSERVATION", 250, 263]]], ["Therefore, researchers have become increasingly concerned about the in-clinic impacts of COVID-19 on overall levels of antimicrobial resistance (AMR) (Hsu, 2020).IntroductionIt is well recognized that excessive use of antimicrobials in medicine and agriculture drives AMR which is a global threat to human, animal and environmental health (Maillard et al., 2020).", [["COVID-19", "CHEMICAL", 89, 97], ["AMR", "DISEASE", 145, 148], ["AMR", "DISEASE", 268, 271], ["COVID-19", "CHEMICAL", 89, 97], ["human", "ORGANISM", 300, 305], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 300, 305], ["COVID", "TEST", 89, 94], ["antimicrobial resistance", "TREATMENT", 119, 143], ["antimicrobials", "TREATMENT", 218, 232], ["antimicrobial resistance", "OBSERVATION", 119, 143]]], ["According to the US Center for Disease Prevention and Control (2019), up to 50% of antibiotic use is not medically justified.", [["Disease Prevention", "TREATMENT", 31, 49], ["antibiotic use", "TREATMENT", 83, 97], ["Disease", "OBSERVATION", 31, 38]]], ["This situation is particularly worse in developing communities which have unregulated over-the-counter sales and a weak water and sewage infrastructure.", [["a weak water and sewage infrastructure", "PROBLEM", 113, 151], ["worse", "OBSERVATION_MODIFIER", 31, 36], ["sewage infrastructure", "OBSERVATION", 130, 151]]], ["For example, a recent typhoid fever outbreak in Pakistan has been associated to the antibiotic resistance caused by inappropriate use of drugs as well as poor sanitation and contaminated water supplies (Cohen, 2018).", [["typhoid fever", "DISEASE", 22, 35], ["a recent typhoid fever", "PROBLEM", 13, 35], ["the antibiotic resistance", "TREATMENT", 80, 105], ["drugs", "TREATMENT", 137, 142], ["typhoid", "OBSERVATION_MODIFIER", 22, 29], ["fever", "OBSERVATION", 30, 35]]], ["Recent estimates by UN Interagency Coordination Group on Antimicrobial Resistance (2019) suggest that AMR diseases are responsible for about 700,000 annual deaths worldwide.", [["AMR diseases", "DISEASE", 102, 114], ["deaths", "DISEASE", 156, 162], ["Antimicrobial Resistance", "TEST", 57, 81], ["AMR diseases", "PROBLEM", 102, 114], ["AMR diseases", "OBSERVATION", 102, 114]]], ["Without concrete action, the death toll could reach up to 10 million a year by 2050.IntroductionThe intent of this communication is to highlight the consequences of COVID-19 management on the environment.", [["death", "DISEASE", 29, 34], ["COVID-19 management", "TREATMENT", 165, 184]]], ["The focus will be on the unnecessary use of antibacterial drugs and personal hygiene products in the treatment and prevention of COVID-19.", [["antibacterial drugs", "TREATMENT", 44, 63], ["personal hygiene products", "TREATMENT", 68, 93], ["the treatment", "TREATMENT", 97, 110], ["COVID", "TEST", 129, 134]]], ["A brief description of these issues is provided below.Excessive use of therapeutic antimicrobialsAntibiotics have reasonable roles in the management of COVID-19 particularly to treat suspected or confirmed bacterial co-infections (Rawson et al., 2020a).", [["COVID-19", "CHEMICAL", 152, 160], ["bacterial co-infections", "DISEASE", 206, 229], ["COVID-19", "CHEMICAL", 152, 160], ["therapeutic antimicrobials", "TREATMENT", 71, 97], ["Antibiotics", "TREATMENT", 97, 108], ["COVID", "TEST", 152, 157], ["bacterial co-infections", "PROBLEM", 206, 229], ["bacterial", "OBSERVATION_MODIFIER", 206, 215], ["co-infections", "OBSERVATION", 216, 229]]], ["The World Health Organization has advised that antibiotics should not be used for the purposes of treating COVID-19 except in the presence of bacterial co-infections (WHO, 2020).", [["COVID-19", "CHEMICAL", 107, 115], ["bacterial co-infections", "DISEASE", 142, 165], ["antibiotics", "TREATMENT", 47, 58], ["COVID", "TREATMENT", 107, 112], ["bacterial co-infections", "PROBLEM", 142, 165], ["bacterial", "OBSERVATION_MODIFIER", 142, 151], ["co-infections", "OBSERVATION", 152, 165]]], ["However, growing evidence suggests that very high proportion of COVID-19 patients are being unnecessarily treated with antibiotics.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["COVID", "TEST", 64, 69], ["antibiotics", "TREATMENT", 119, 130], ["very", "OBSERVATION_MODIFIER", 40, 44], ["high", "OBSERVATION_MODIFIER", 45, 49]]], ["Empirical antibiotics were prescribed for 90% of patients despite low confirmation of secondary bacterial infections (<10%) (Lai et al., 2020).", [["bacterial infections", "DISEASE", 96, 116], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Empirical antibiotics", "TREATMENT", 0, 21], ["secondary bacterial infections", "PROBLEM", 86, 116], ["secondary", "OBSERVATION_MODIFIER", 86, 95], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["infections", "OBSERVATION", 106, 116]]], ["Wei et al. (2020) also noted that antibiotics were started on admission in 59% of COVID-19 patients despite the absence of definitive evidence of bacterial coinfection in these patients.", [["bacterial coinfection", "DISEASE", 146, 167], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 177, 185], ["antibiotics", "TREATMENT", 34, 45], ["COVID", "TEST", 82, 87], ["bacterial coinfection", "PROBLEM", 146, 167], ["evidence of", "UNCERTAINTY", 134, 145], ["bacterial", "OBSERVATION_MODIFIER", 146, 155], ["coinfection", "OBSERVATION", 156, 167]]], ["Moreover, 98% of these prescriptions were empiric.", [["these prescriptions", "TREATMENT", 17, 36], ["empiric", "TREATMENT", 42, 49]]], ["Similarly, another very recent review of data from covid-19 cases, mostly from Asia, reported that >70% of patients received antimicrobial treatment despite only <10% having bacterial or fungal coinfections (Rawson et al., 2020a).", [["bacterial or fungal coinfections", "DISEASE", 174, 206], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["covid", "TEST", 51, 56], ["antimicrobial treatment", "TREATMENT", 125, 148], ["bacterial or fungal coinfections", "PROBLEM", 174, 206], ["fungal coinfections", "OBSERVATION", 187, 206]]], ["Moreover, the same study found that broad spectrum antibiotics, intended to kill a wide range of bacteria, are being administered.", [["the same study", "TEST", 10, 24], ["broad spectrum antibiotics", "TREATMENT", 36, 62], ["bacteria", "PROBLEM", 97, 105]]], ["Overuse of these antibiotics can stimulate AMR in the acute care settings (Hsu, 2020; Rawson et al., 2020b).", [["AMR", "DISEASE", 43, 46], ["these antibiotics", "TREATMENT", 11, 28], ["acute", "OBSERVATION_MODIFIER", 54, 59]]], ["Premature hype surrounding possible treatments for COVID-19 could also spike the prescription of antibiotics.", [["COVID-19", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 51, 59], ["Premature hype", "PROBLEM", 0, 14], ["treatments", "TREATMENT", 36, 46], ["COVID", "TREATMENT", 51, 56], ["antibiotics", "TREATMENT", 97, 108]]], ["This has been seen for the antibiotic azithromycin in combination with the drug hydroxychloroquine causing shortages in the US (Reardon, 2020).", [["azithromycin", "CHEMICAL", 38, 50], ["hydroxychloroquine", "CHEMICAL", 80, 98], ["azithromycin", "CHEMICAL", 38, 50], ["hydroxychloroquine", "CHEMICAL", 80, 98], ["azithromycin", "SIMPLE_CHEMICAL", 38, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 80, 98], ["the antibiotic azithromycin", "TREATMENT", 23, 50], ["the drug hydroxychloroquine", "TREATMENT", 71, 98]]], ["Though unmeasured, there is a possibility of a large number of people taking antibiotics in misguided attempts to self-medicate to protect themselves from the virus.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["antibiotics", "TREATMENT", 77, 88], ["the virus", "PROBLEM", 155, 164], ["large", "OBSERVATION_MODIFIER", 47, 52], ["number", "OBSERVATION_MODIFIER", 53, 59], ["virus", "OBSERVATION", 159, 164]]], ["This has the potential to be very prevalent in developing communities where antibiotics can be easily obtained without a prescription.", [["antibiotics", "TREATMENT", 76, 87]]], ["A high proportion of these drugs in bioactive forms is excreted into the wastewater from where they may enter in natural systems (Slater et al., 2011).Excessive use of therapeutic antimicrobialsRelease of antibiotic resistant bacteria along with large quantities of antibiotics to the wastewater would spur the AMR and other unintended consequences on the environment.", [["AMR", "DISEASE", 311, 314], ["these drugs", "TREATMENT", 21, 32], ["therapeutic antimicrobials", "TREATMENT", 168, 194], ["antibiotic resistant bacteria", "PROBLEM", 205, 234], ["antibiotics", "TREATMENT", 266, 277], ["high", "OBSERVATION_MODIFIER", 2, 6], ["antibiotic resistant bacteria", "OBSERVATION", 205, 234], ["large", "OBSERVATION_MODIFIER", 246, 251], ["quantities", "OBSERVATION_MODIFIER", 252, 262]]], ["A recent review detailing pharmaceutical pollutants in global aquatic systems found antibiotics as the most-frequently detected compounds (Patel et al., 2019).", [["antibiotics", "TREATMENT", 84, 95]]], ["It should be noted that wastewater is the major hotspot for AMR as it is characterized by extremely high bacterial loads coupled with subtherapeutic antibiotics (Berendonk et al., 2015).Excessive use of non-therapeutic antimicrobialsProper hand hygiene has been recognized as the first line of defense against this pandemic.", [["hand", "ANATOMY", 240, 244], ["AMR", "DISEASE", 60, 63], ["hand", "ORGANISM_SUBDIVISION", 240, 244], ["AMR", "PROBLEM", 60, 63], ["extremely high bacterial loads", "PROBLEM", 90, 120], ["subtherapeutic antibiotics", "TREATMENT", 134, 160], ["non-therapeutic antimicrobials", "TREATMENT", 203, 233], ["this pandemic", "PROBLEM", 310, 323], ["high", "OBSERVATION_MODIFIER", 100, 104], ["bacterial loads", "OBSERVATION", 105, 120], ["hand", "ANATOMY", 240, 244], ["hygiene", "OBSERVATION", 245, 252]]], ["Therefore, frequent hand-washing with plain soap and water for at least 20 s has been advised as an impactful way to prevent the spread of COVID-19 (WHO, 2020).", [["hand", "ANATOMY", 20, 24], ["frequent hand-washing", "TREATMENT", 11, 32], ["plain soap and water", "TREATMENT", 38, 58]]], ["Soaps contain surfactants that dissolve the lipid-bilayer, an integral part of SARS-CoV-2 envelop, leading to the deactivation of virus.", [["lipid-bilayer", "ANATOMY", 44, 57], ["surfactants", "SIMPLE_CHEMICAL", 14, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["Soaps", "TREATMENT", 0, 5], ["surfactants", "TREATMENT", 14, 25], ["SARS", "PROBLEM", 79, 83], ["the deactivation of virus", "PROBLEM", 110, 135], ["virus", "OBSERVATION", 130, 135]]], ["These deactivated viral molecules are then encapsulated within micelles which are then washed away (Chaudhary et al., 2020).", [["deactivated viral molecules", "PROTEIN", 6, 33], ["These deactivated viral molecules", "PROBLEM", 0, 33], ["viral molecules", "OBSERVATION", 18, 33]]], ["A 20-second wash provides sufficient time for the soap molecules to dissolve the lipid-bilayer of the SARS-CoV-2 virus.Excessive use of non-therapeutic antimicrobialsAll regular soaps available in the marketplace have the basic ingredients and chemistry required to disrupt the virus (Chaudhary et al., 2020).", [["SARS", "DISEASE", 102, 106], ["SARS-CoV-2 virus", "ORGANISM", 102, 118], ["SARS-CoV-2 virus", "SPECIES", 102, 118], ["A 20-second wash", "TREATMENT", 0, 16], ["the soap molecules", "TREATMENT", 46, 64], ["the lipid", "TEST", 77, 86], ["the SARS", "PROBLEM", 98, 106], ["non-therapeutic antimicrobials", "TREATMENT", 136, 166], ["the basic ingredients", "TREATMENT", 218, 239]]], ["Common soaps are effective at inactivating the enveloped viruses such as the SARS-CoV-2 therefore, antibacterial soaps are not required (UNESCO, 2020).", [["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "SPECIES", 77, 85], ["Common soaps", "TREATMENT", 0, 12], ["the enveloped viruses", "PROBLEM", 43, 64], ["the SARS", "TEST", 73, 81], ["antibacterial soaps", "TREATMENT", 99, 118], ["enveloped", "OBSERVATION_MODIFIER", 47, 56], ["viruses", "OBSERVATION", 57, 64]]], ["The US-Food and Drug Administration (FDA) has also advocated the same and moved to ban 19 antimicrobial chemicals from soaps acknowledging their dangerous impacts (McNamara and Levy, 2016).", [["The US", "TEST", 0, 6], ["Drug Administration", "TREATMENT", 16, 35]]], ["Despite this, use of antibacterial soaps and disinfectants has increased during this pandemic as evident from sharp increase in their sale worldwide (Cleaning Matters, 2020).", [["antibacterial soaps", "TREATMENT", 21, 40], ["disinfectants", "TREATMENT", 45, 58], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["sharp", "OBSERVATION_MODIFIER", 110, 115], ["increase", "OBSERVATION_MODIFIER", 116, 124]]], ["Similar increase in demand for antibacterial products/soaps was noted in the era of 2009 Swine flu (Hickman, 2009; Slater et al., 2011).Excessive use of non-therapeutic antimicrobialsAntibacterial products contain high amounts of biocides which result in a sharp increase in their presence in wastewater.", [["antibacterial products", "TREATMENT", 31, 53], ["soaps", "TREATMENT", 54, 59], ["non-therapeutic antimicrobials", "TREATMENT", 153, 183], ["Antibacterial products", "TREATMENT", 183, 205], ["high amounts of biocides", "TREATMENT", 214, 238], ["a sharp increase", "PROBLEM", 255, 271], ["increase", "OBSERVATION_MODIFIER", 8, 16], ["demand", "OBSERVATION_MODIFIER", 20, 26], ["antibacterial products", "OBSERVATION", 31, 53], ["high amounts", "OBSERVATION_MODIFIER", 214, 226], ["sharp", "OBSERVATION_MODIFIER", 257, 262], ["increase", "OBSERVATION_MODIFIER", 263, 271]]], ["As a matter of fact, antimicrobial chemicals from soaps could occur in wastewater biosolids (that are land applied as soil conditioners) at multiple orders of magnitude higher than the concentrations of antibiotics (McClellan and Halden, 2010).", [["antimicrobial chemicals", "TREATMENT", 21, 44], ["soaps", "TREATMENT", 50, 55], ["wastewater biosolids", "TREATMENT", 71, 91], ["soil conditioners", "TREATMENT", 118, 135], ["antibiotics", "TREATMENT", 203, 214], ["McClellan", "TREATMENT", 216, 225]]], ["This may pose severe risks to ecosystem and to the spread of AMR in the environment.", [["AMR", "DISEASE", 61, 64], ["severe", "OBSERVATION_MODIFIER", 14, 20]]], ["In addition to the AMR, persistence of these biocides in the environment is a major environmental threat that calls for suitable remediation (McNamara and Levy, 2016).", [["AMR", "DISEASE", 19, 22]]], ["Moreover, presence of these biocides can sabotage the wastewater treatment processes that rely on microbial activity (McNamara et al., 2014).", [["these biocides", "TREATMENT", 22, 36], ["the wastewater treatment processes", "TREATMENT", 50, 84], ["wastewater treatment", "OBSERVATION", 54, 74]]], ["These compounds may enter into soil system disrupting the functioning of native biota playing crucial roles in biogeochemical cycling of elements and environmental remediation (Patel et al., 2019).Concluding remarks and recommendationsAntibiotic stewardship principles should continue to be applied and promoted in the times of COVID-19 (Huttner et al., 2020).", [["environmental remediation", "TREATMENT", 150, 175], ["Antibiotic stewardship principles", "TREATMENT", 235, 268], ["biogeochemical cycling", "OBSERVATION", 111, 133]]], ["However, development of an antimicrobial policy specific for COVID-19 is urgently needed.", [["COVID-19", "CHEMICAL", 61, 69], ["COVID-19", "CHEMICAL", 61, 69], ["COVID", "TEST", 61, 66], ["antimicrobial", "OBSERVATION_MODIFIER", 27, 40]]], ["For this, coordinated strategies at the individual, health-care and policy levels are essential (Rawson et al., 2020b).Concluding remarks and recommendationsSince current wastewater treatment techniques are unable to offer complete elimination of these compounds (K\u00fcmmerer et al., 2018; Rodriguez-Mozaz et al., 2020), our daily exposure to various antibiotics, biocides and their active metabolites in environment becomes inevitable.", [["current wastewater treatment techniques", "TREATMENT", 163, 202], ["various antibiotics", "TREATMENT", 340, 359], ["biocides", "TREATMENT", 361, 369]]], ["Pollutant input prevention at the production source complemented with wastewater treatment is crucial to ensure water safety (K\u00fcmmerer et al., 2018).", [["Pollutant", "CHEMICAL", 0, 9], ["Pollutant input prevention", "TREATMENT", 0, 26], ["wastewater treatment", "TREATMENT", 70, 90]]], ["However, effective input prevention in case of antimicrobials and other pharmaceuticals calls for responsible use of drugs and personal care products by individuals.", [["antimicrobials", "TREATMENT", 47, 61], ["drugs", "TREATMENT", 117, 122], ["personal care products", "TREATMENT", 127, 149]]], ["Intensive information campaigns should be launched to educate the masses about the ecological consequences of misusing antibacterial products.", [["the masses", "PROBLEM", 62, 72], ["misusing antibacterial products", "TREATMENT", 110, 141], ["masses", "OBSERVATION", 66, 72], ["antibacterial products", "OBSERVATION", 119, 141]]], ["A large portion of the population is creating the habit of regular hand washing as a result of the pandemic.", [["hand", "ANATOMY", 67, 71], ["hand", "ORGANISM_SUBDIVISION", 67, 71], ["regular hand washing", "TREATMENT", 59, 79], ["the pandemic", "PROBLEM", 95, 107], ["large", "OBSERVATION_MODIFIER", 2, 7], ["portion", "OBSERVATION_MODIFIER", 8, 15], ["population", "OBSERVATION", 23, 33], ["habit", "OBSERVATION_MODIFIER", 50, 55], ["pandemic", "OBSERVATION", 99, 107]]], ["These practices will remain embedded even after the pandemic subsides.", [["the pandemic subsides", "PROBLEM", 48, 69]]], ["Therefore, educating the public about the unwanted effects of antimicrobial/antibacterial products during the pandemic will have the greatest opportunity to instilling change.", [["antimicrobial/antibacterial products", "TREATMENT", 62, 98]]], ["Governments should ensure that advertising material and message of hygienic products are aligned with COVID-19 guidelines.", [["hygienic products", "TREATMENT", 67, 84]]], ["We also urge researchers to evaluate the environmental consequences of the response measures to COVID-19 by focusing on therapeutic as well as non-therapeutic antimicrobials.CRediT authorship contribution statement", [["COVID-19", "CHEMICAL", 96, 104], ["COVID", "TEST", 96, 101], ["non-therapeutic antimicrobials", "TREATMENT", 143, 173]]]], "e1ea00b49f09c1e86ae12a1f12346050acd5d618": [["Although most patients died from acute respiratory failure, several studies discovered that acute cardiac injury, which would process to heart failure, is common in COVID-19 patients 1 .", [["respiratory", "ANATOMY", 39, 50], ["cardiac", "ANATOMY", 98, 105], ["heart", "ANATOMY", 137, 142], ["acute respiratory failure", "DISEASE", 33, 58], ["cardiac injury", "DISEASE", 98, 112], ["heart failure", "DISEASE", 137, 150], ["patients", "ORGANISM", 14, 22], ["cardiac", "ORGAN", 98, 105], ["heart", "ORGAN", 137, 142], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 174, 182], ["acute respiratory failure", "PROBLEM", 33, 58], ["several studies", "TEST", 60, 75], ["acute cardiac injury", "PROBLEM", 92, 112], ["heart failure", "PROBLEM", 137, 150], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory failure", "OBSERVATION", 39, 58], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["cardiac", "ANATOMY", 98, 105], ["injury", "OBSERVATION", 106, 112], ["heart", "ANATOMY", 137, 142], ["failure", "OBSERVATION", 143, 150]]]], "PMC3192843": [["IntroductionCoronaviruses are etiological agents of respiratory and enteric diseases in livestock, companion animals and humans, exemplified by severe acute respiratory syndrome coronavirus (SARS-CoV) which was responsible for a worldwide SARS outbreak in 2003 and caused over 8000 cases of infection with about 10% fatality rate.", [["respiratory", "ANATOMY", 52, 63], ["respiratory and enteric diseases", "DISEASE", 52, 84], ["acute respiratory syndrome coronavirus", "DISEASE", 151, 189], ["SARS-CoV)", "DISEASE", 191, 200], ["SARS", "DISEASE", 239, 243], ["infection", "DISEASE", 291, 300], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 121, 127], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 144, 189], ["SARS-CoV", "ORGANISM", 191, 199], ["humans", "SPECIES", 121, 127], ["humans", "SPECIES", 121, 127], ["severe acute respiratory syndrome coronavirus", "SPECIES", 144, 189], ["SARS-CoV", "SPECIES", 191, 199], ["respiratory and enteric diseases", "PROBLEM", 52, 84], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 144, 189], ["infection", "PROBLEM", 291, 300], ["enteric", "OBSERVATION_MODIFIER", 68, 75], ["diseases", "OBSERVATION", 76, 84], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["respiratory syndrome", "OBSERVATION", 157, 177], ["infection", "OBSERVATION", 291, 300]]], ["They are characterized by possessing the largest and most complex positive-stranded RNA genome (ranging from 27 to 31 kb) among RNA viruses.", [["positive-stranded RNA genome", "DNA", 66, 94], ["most complex positive-stranded RNA genome", "PROBLEM", 53, 94], ["RNA viruses", "PROBLEM", 128, 139], ["largest", "OBSERVATION_MODIFIER", 41, 48], ["most complex", "OBSERVATION_MODIFIER", 53, 65], ["positive", "OBSERVATION", 66, 74], ["stranded RNA genome", "OBSERVATION", 75, 94], ["RNA viruses", "OBSERVATION", 128, 139]]], ["Fourteen open reading frames (ORFs) have been identified in the genome of SARS-CoV, of which 12 are located in the 3\u2032-one third of the genome, encoding the structural and accessory proteins translated through a nested set of subgenomic RNAs [1], [2].", [["SARS", "DISEASE", 74, 78], ["SARS-CoV", "ORGANISM", 74, 82], ["open reading frames", "DNA", 9, 28], ["ORFs", "DNA", 30, 34], ["3\u2032-one third of the genome", "DNA", 115, 141], ["structural and accessory proteins", "PROTEIN", 156, 189], ["subgenomic RNAs", "RNA", 225, 240], ["SARS-CoV", "SPECIES", 74, 82], ["subgenomic RNAs", "PROBLEM", 225, 240], ["genome", "OBSERVATION", 135, 141]]], ["The 5\u2032-proximal two thirds of the genome comprise 2 large overlapping ORFs (1a and 1b), which encode two large replicase polyproteins that are translated directly from the genome RNA, with 1b as the frameshifted extension of 1a.", [["1b", "GENE_OR_GENE_PRODUCT", 83, 85], ["5\u2032", "DNA", 4, 6], ["ORFs", "DNA", 70, 74], ["replicase polyproteins", "PROTEIN", 111, 133], ["genome RNA", "RNA", 172, 182], ["2 large overlapping ORFs", "PROBLEM", 50, 74], ["two large replicase polyproteins", "PROBLEM", 101, 133], ["proximal", "ANATOMY_MODIFIER", 7, 15], ["large", "OBSERVATION_MODIFIER", 52, 57], ["overlapping ORFs", "OBSERVATION", 58, 74], ["two", "OBSERVATION_MODIFIER", 101, 104], ["large", "OBSERVATION_MODIFIER", 105, 110], ["replicase polyproteins", "OBSERVATION", 111, 133], ["genome RNA", "OBSERVATION", 172, 182]]], ["These two precursor polyproteins are cleaved into 16 mature replicase proteins, named as non-structural protein (nsp) 1\u201316, which form the replication-transcription complex (RTC) localized in endoplasmic reticulum-derived membranes [3], [4].", [["endoplasmic reticulum", "ANATOMY", 192, 213], ["membranes", "ANATOMY", 222, 231], ["non-structural protein (nsp) 1\u201316", "GENE_OR_GENE_PRODUCT", 89, 122], ["RTC", "GENE_OR_GENE_PRODUCT", 174, 177], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 192, 213], ["membranes", "CELLULAR_COMPONENT", 222, 231], ["precursor polyproteins", "PROTEIN", 10, 32], ["16 mature replicase proteins", "PROTEIN", 50, 78], ["non-structural protein (nsp) 1\u201316", "PROTEIN", 89, 122], ["replication-transcription complex", "PROTEIN", 139, 172], ["RTC", "PROTEIN", 174, 177], ["These two precursor polyproteins", "PROBLEM", 0, 32], ["non-structural protein (nsp)", "TEST", 89, 117], ["polyproteins", "OBSERVATION", 20, 32], ["endoplasmic reticulum", "OBSERVATION", 192, 213]]], ["Strikingly, the coronavirus genome is predicted to encode several RNA processing enzymes that are not common to small RNA viruses [1], including nsp14 as an exoribonuclease and guanine N7-methyltransferase (N7-MTase) [5], [6], [7], [8] and nsp15 as a nidovirus-specific endonuclease [9], [10].IntroductionEukaryotic and most viral mRNAs possess a 5\u2032-terminal cap structure, in which an N7-methyl-guanine moiety is linked to the first transcribed nucleotide by a 5\u2032-5\u2032 triphosphate bridge [11], [12].", [["guanine", "CHEMICAL", 177, 184], ["N7-methyl-guanine", "CHEMICAL", 386, 403], ["nucleotide", "CHEMICAL", 446, 456], ["5\u2032-5\u2032 triphosphate", "CHEMICAL", 462, 480], ["guanine", "CHEMICAL", 177, 184], ["N7-methyl-guanine", "CHEMICAL", 386, 403], ["nucleotide", "CHEMICAL", 446, 456], ["5\u2032-5\u2032 triphosphate", "CHEMICAL", 462, 480], ["coronavirus", "ORGANISM", 16, 27], ["nsp14", "GENE_OR_GENE_PRODUCT", 145, 150], ["guanine N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 177, 205], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 207, 215], ["[7]", "SIMPLE_CHEMICAL", 227, 230], ["[8]", "SIMPLE_CHEMICAL", 232, 235], ["nsp15", "GENE_OR_GENE_PRODUCT", 240, 245], ["nidovirus", "SIMPLE_CHEMICAL", 251, 260], ["N7-methyl-guanine moiety", "SIMPLE_CHEMICAL", 386, 410], ["5\u2032-5\u2032 triphosphate", "SIMPLE_CHEMICAL", 462, 480], ["[12]", "SIMPLE_CHEMICAL", 494, 498], ["coronavirus genome", "DNA", 16, 34], ["RNA processing enzymes", "PROTEIN", 66, 88], ["nsp14", "PROTEIN", 145, 150], ["guanine N7-methyltransferase", "PROTEIN", 177, 205], ["N7", "PROTEIN", 207, 209], ["MTase", "PROTEIN", 210, 215], ["nsp15", "PROTEIN", 240, 245], ["nidovirus", "PROTEIN", 251, 260], ["viral mRNAs", "RNA", 325, 336], ["5\u2032-terminal cap structure", "PROTEIN", 347, 372], ["coronavirus", "SPECIES", 16, 27], ["the coronavirus genome", "PROBLEM", 12, 34], ["small RNA viruses", "PROBLEM", 112, 129], ["nsp14", "TEST", 145, 150], ["an exoribonuclease", "TEST", 154, 172], ["guanine N7-methyltransferase (N7-MTase)", "TREATMENT", 177, 216], ["nsp15", "TEST", 240, 245], ["a nidovirus", "TEST", 249, 260], ["IntroductionEukaryotic", "TREATMENT", 293, 315], ["most viral mRNAs", "PROBLEM", 320, 336], ["an N7-methyl-guanine moiety", "TREATMENT", 383, 410], ["coronavirus genome", "OBSERVATION", 16, 34], ["RNA viruses", "OBSERVATION", 118, 129]]], ["The cap structure is essential for efficient splicing, nuclear export, translation and stability of eukaryotic mRNA [13], [14], [15], [16].", [["nuclear", "ANATOMY", 55, 62], ["nuclear", "CELLULAR_COMPONENT", 55, 62], ["efficient splicing", "PROBLEM", 35, 53], ["eukaryotic mRNA", "TEST", 100, 115], ["cap", "OBSERVATION_MODIFIER", 4, 7], ["essential for", "UNCERTAINTY", 21, 34], ["efficient splicing", "OBSERVATION", 35, 53]]], ["All viruses use the translational machinery of host cells.", [["cells", "ANATOMY", 52, 57], ["host cells", "CELL", 47, 57], ["host cells", "CELL_TYPE", 47, 57], ["viruses", "OBSERVATION", 4, 11], ["host cells", "OBSERVATION", 47, 57]]], ["With the exception of some viruses, such as picornaviruses and hepatitis C virus that circumvent the capping problem by using an internal ribosome entry site (IRES) for mRNA translation [17], [18], viruses of eukaryotes have evolved diversified strategies to cap their mRNAs that are thus translated by cap-dependent mechanisms in the manner of eukaryotic mRNAs.", [["picornaviruses and hepatitis C", "DISEASE", 44, 74], ["hepatitis C virus", "ORGANISM", 63, 80], ["internal ribosome entry site", "DNA", 129, 157], ["IRES", "DNA", 159, 163], ["mRNAs", "RNA", 269, 274], ["eukaryotic mRNAs", "RNA", 345, 361], ["hepatitis C virus", "SPECIES", 63, 80], ["hepatitis C virus", "SPECIES", 63, 80], ["some viruses", "PROBLEM", 22, 34], ["picornaviruses", "PROBLEM", 44, 58], ["hepatitis C virus", "PROBLEM", 63, 80], ["the capping problem", "TREATMENT", 97, 116], ["an internal ribosome entry site", "TREATMENT", 126, 157], ["mRNA translation", "TEST", 169, 185], ["viruses of eukaryotes", "PROBLEM", 198, 219], ["some", "OBSERVATION_MODIFIER", 22, 26], ["viruses", "OBSERVATION", 27, 34], ["picornaviruses", "OBSERVATION", 44, 58], ["hepatitis", "OBSERVATION", 63, 72], ["diversified", "OBSERVATION_MODIFIER", 233, 244], ["eukaryotic mRNAs", "OBSERVATION", 345, 361]]], ["It has been suggested for three decades that coronavirus mRNA may carry a 5\u2032-cap structure [19], [20], [21], [22], but the principal enzymes involved in coronavirus RNA capping and their biochemical mechanisms have not been characterized until recently.", [["coronavirus", "ORGANISM", 45, 56], ["[20], [21], [22]", "SIMPLE_CHEMICAL", 97, 113], ["coronavirus", "ORGANISM", 153, 164], ["coronavirus mRNA", "RNA", 45, 61], ["5\u2032", "PROTEIN", 74, 76], ["coronavirus RNA", "RNA", 153, 168], ["coronavirus", "SPECIES", 153, 164], ["coronavirus mRNA", "PROBLEM", 45, 61], ["the principal enzymes", "TEST", 119, 140], ["coronavirus RNA capping", "TREATMENT", 153, 176], ["coronavirus RNA capping", "OBSERVATION", 153, 176]]], ["Cap formation of eukaryotic and viral mRNAs requires universally three sequential enzymatic reactions.", [["Cap", "GENE_OR_GENE_PRODUCT", 0, 3], ["eukaryotic and viral mRNAs", "RNA", 17, 43], ["eukaryotic and viral mRNAs", "PROBLEM", 17, 43], ["eukaryotic", "OBSERVATION_MODIFIER", 17, 27], ["viral mRNAs", "OBSERVATION", 32, 43]]], ["First, an RNA triphosphatase (TPase) removes the \u03b3-phosphate group from the 5\u2032-triphosphate end (pppN) of the nascent mRNA chain to generate the diphosphate 5\u2032 -ppN.", [["\u03b3-phosphate", "CHEMICAL", 49, 60], ["5\u2032-triphosphate", "CHEMICAL", 76, 91], ["diphosphate", "CHEMICAL", 145, 156], ["\u03b3-phosphate", "CHEMICAL", 49, 60], ["5\u2032-triphosphate", "CHEMICAL", 76, 91], ["diphosphate", "CHEMICAL", 145, 156], ["TPase", "GENE_OR_GENE_PRODUCT", 30, 35], ["\u03b3-phosphate", "SIMPLE_CHEMICAL", 49, 60], ["diphosphate", "SIMPLE_CHEMICAL", 145, 156], ["RNA triphosphatase", "PROTEIN", 10, 28], ["TPase", "PROTEIN", 30, 35], ["\u03b3-phosphate group", "PROTEIN", 49, 66], ["5\u2032-triphosphate end", "PROTEIN", 76, 95], ["pppN", "PROTEIN", 97, 101], ["nascent mRNA chain", "PROTEIN", 110, 128], ["an RNA triphosphatase", "TEST", 7, 28], ["the diphosphate", "TEST", 141, 156]]], ["Subsequently, a RNA guanylyltransferase (GTase) transfers a GMP to the 5\u2032-diphosphate end to yield the cap core structure (GpppN).", [["GMP", "CHEMICAL", 60, 63], ["5\u2032-diphosphate", "CHEMICAL", 71, 85], ["GMP", "CHEMICAL", 60, 63], ["5\u2032-diphosphate", "CHEMICAL", 71, 85], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 20, 39], ["GTase", "GENE_OR_GENE_PRODUCT", 41, 46], ["GMP", "SIMPLE_CHEMICAL", 60, 63], ["RNA guanylyltransferase", "PROTEIN", 16, 39], ["GTase", "PROTEIN", 41, 46], ["5\u2032-diphosphate end", "DNA", 71, 89], ["cap core structure", "PROTEIN", 103, 121], ["GpppN", "PROTEIN", 123, 128], ["a RNA guanylyltransferase (GTase", "TREATMENT", 14, 46], ["a GMP", "TREATMENT", 58, 63], ["cap core", "OBSERVATION_MODIFIER", 103, 111]]], ["Then a N7-MTase methylates the capping guanylate at the N7 position to produce a cap-0 structure (m7GpppN) [13].", [["N7", "CHEMICAL", 7, 9], ["guanylate", "CHEMICAL", 39, 48], ["guanylate", "CHEMICAL", 39, 48], ["N7", "CHEMICAL", 56, 58], ["guanylate", "GENE_OR_GENE_PRODUCT", 39, 48], ["N7-MTase", "PROTEIN", 7, 15], ["N7 position", "PROTEIN", 56, 67], ["cap-0 structure", "DNA", 81, 96], ["a N7-MTase methylates the capping guanylate", "TREATMENT", 5, 48], ["cap", "OBSERVATION_MODIFIER", 81, 84]]], ["While lower eukaryotes, including yeast, employ a cap-0 structure, higher eukaryotes and viruses usually further methylate the cap-0 structure at the ribose 2\u2032-O position of the first and second nucleotide of the mRNA by a ribose 2\u2032-O MTase to form cap-1 and cap-2 structure, respectively [13].", [["nucleotide", "CHEMICAL", 195, 205], ["ribose", "CHEMICAL", 223, 229], ["ribose", "CHEMICAL", 150, 156], ["O", "CHEMICAL", 160, 161], ["nucleotide", "CHEMICAL", 195, 205], ["ribose", "CHEMICAL", 223, 229], ["cap-0", "GENE_OR_GENE_PRODUCT", 50, 55], ["cap-1", "GENE_OR_GENE_PRODUCT", 249, 254], ["cap-2", "GENE_OR_GENE_PRODUCT", 259, 264], ["cap-0 structure", "DNA", 50, 65], ["cap-0 structure", "DNA", 127, 142], ["mRNA", "RNA", 213, 217], ["ribose 2\u2032-O MTase", "PROTEIN", 223, 240], ["yeast", "SPECIES", 34, 39], ["yeast", "SPECIES", 34, 39], ["yeast", "PROBLEM", 34, 39], ["a cap", "TEST", 48, 53], ["viruses", "PROBLEM", 89, 96], ["a ribose", "TREATMENT", 221, 229], ["cap", "TEST", 249, 252], ["cap", "OBSERVATION_MODIFIER", 127, 130], ["cap", "OBSERVATION_MODIFIER", 249, 252]]], ["Very recently, it was shown that ribose 2\u2032-O-methylation of viral RNA cap provides a mechanism for viruses to escape host immune recognition [23], [24].IntroductionFor coronaviruses, several nsps have been indicated to be involved in viral RNA capping.", [["ribose", "CHEMICAL", 33, 39], ["ribose", "CHEMICAL", 33, 39], ["O", "CHEMICAL", 43, 44], ["ribose", "SIMPLE_CHEMICAL", 33, 39], ["nsps", "GENE_OR_GENE_PRODUCT", 191, 195], ["viral RNA cap", "RNA", 60, 73], ["nsps", "PROTEIN", 191, 195], ["ribose", "TEST", 33, 39], ["viral RNA cap", "TREATMENT", 60, 73], ["viruses", "PROBLEM", 99, 106], ["coronaviruses", "PROBLEM", 168, 181], ["viral RNA capping", "TREATMENT", 234, 251], ["viral RNA capping", "OBSERVATION", 234, 251]]], ["We have shown that SARS-CoV nsp14, a previously described exoribonuclease, acts as N7-MTase to generate cap-0 structure [8].", [["SARS-CoV nsp14", "GENE_OR_GENE_PRODUCT", 19, 33], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 83, 91], ["cap-0", "GENE_OR_GENE_PRODUCT", 104, 109], ["SARS-CoV nsp14", "PROTEIN", 19, 33], ["exoribonuclease", "PROTEIN", 58, 73], ["N7-MTase", "PROTEIN", 83, 91], ["SARS-CoV", "SPECIES", 19, 27], ["SARS", "PROBLEM", 19, 23]]], ["Recently, it was shown that SARS-CoV nsp16 acts as 2\u2032-O-MTase in complex with nsp10 and selectively 2\u2032-O-methylates the cap-0 structure to give rise to cap-1 structure [25].", [["SARS-CoV nsp16", "GENE_OR_GENE_PRODUCT", 28, 42], ["2\u2032-O-MTase", "GENE_OR_GENE_PRODUCT", 51, 61], ["nsp10", "GENE_OR_GENE_PRODUCT", 78, 83], ["2\u2032-O", "SIMPLE_CHEMICAL", 100, 104], ["cap-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["SARS-CoV nsp16", "PROTEIN", 28, 42], ["2\u2032-O-MTase", "PROTEIN", 51, 61], ["nsp10", "PROTEIN", 78, 83], ["cap-0 structure", "DNA", 120, 135], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32], ["nsp10", "TEST", 78, 83], ["cap", "TEST", 152, 155]]], ["Feline coronavirus (FCoV) nsp16 was also shown to bind N7-methyl guanosine cap (m7GpppAC3-6) and methylate the penultimate nucleotide at 2\u2032-O position to yield a cap-1 structure in vitro [26].", [["Feline coronavirus", "DISEASE", 0, 18], ["N7-methyl guanosine", "CHEMICAL", 55, 74], ["nucleotide", "CHEMICAL", 123, 133], ["N7-methyl guanosine", "CHEMICAL", 55, 74], ["nucleotide", "CHEMICAL", 123, 133], ["Feline coronavirus", "ORGANISM", 0, 18], ["FCoV", "GENE_OR_GENE_PRODUCT", 20, 24], ["nsp16", "GENE_OR_GENE_PRODUCT", 26, 31], ["N7-methyl guanosine cap", "SIMPLE_CHEMICAL", 55, 78], ["Feline coronavirus (FCoV) nsp16", "PROTEIN", 0, 31], ["Feline coronavirus", "SPECIES", 0, 18], ["Feline coronavirus", "SPECIES", 0, 18], ["FCoV", "SPECIES", 20, 24], ["methyl guanosine cap (m7GpppAC3", "TREATMENT", 58, 89], ["methylate the penultimate nucleotide", "TREATMENT", 97, 133], ["a cap", "TEST", 160, 165]]], ["Coronavirus nsp13 has been shown to exhibit RNA TPase activity in vitro and thus proposed to be functional in RNA capping reaction [27], [28], but a direct role for nsp13 in RNA capping still awaits experimental evidence.", [["nsp13", "CHEMICAL", 12, 17], ["nsp13", "GENE_OR_GENE_PRODUCT", 12, 17], ["TPase", "GENE_OR_GENE_PRODUCT", 48, 53], ["[28]", "SIMPLE_CHEMICAL", 137, 141], ["nsp13", "GENE_OR_GENE_PRODUCT", 165, 170], ["nsp13", "PROTEIN", 12, 17], ["TPase", "PROTEIN", 48, 53], ["nsp13", "PROTEIN", 165, 170], ["functional in RNA capping reaction", "PROBLEM", 96, 130], ["nsp13 in RNA capping", "TREATMENT", 165, 185]]], ["Currently, the RNA GTase that is essential for cap formation is completely unknown for coronaviruses.IntroductionSARS-CoV nsp16 requires nsp10 as a stimulatory factor to execute its 2\u2032-O-MTase activity [25] and this also holds true for other coronaviruses (our unpublished results).", [["cap", "ANATOMY", 47, 50], ["GTase", "GENE_OR_GENE_PRODUCT", 19, 24], ["cap", "CELLULAR_COMPONENT", 47, 50], ["coronaviruses", "ORGANISM", 87, 100], ["IntroductionSARS-CoV nsp16", "GENE_OR_GENE_PRODUCT", 101, 127], ["nsp10", "GENE_OR_GENE_PRODUCT", 137, 142], ["coronaviruses", "ORGANISM", 242, 255], ["RNA GTase", "PROTEIN", 15, 24], ["IntroductionSARS-CoV nsp16", "PROTEIN", 101, 127], ["nsp10", "PROTEIN", 137, 142], ["MTase", "PROTEIN", 187, 192], ["the RNA GTase", "TEST", 11, 24], ["cap formation", "PROBLEM", 47, 60], ["coronaviruses", "PROBLEM", 87, 100], ["IntroductionSARS", "TEST", 101, 117], ["nsp10", "TREATMENT", 137, 142], ["a stimulatory factor", "TREATMENT", 146, 166], ["other coronaviruses", "PROBLEM", 236, 255]]], ["This mechanism is unique for 2\u2032-O-MTase of coronaviruses and has not been found in any other viruses or host cells.", [["cells", "ANATOMY", 109, 114], ["2\u2032-O-MTase", "GENE_OR_GENE_PRODUCT", 29, 39], ["coronaviruses", "ORGANISM", 43, 56], ["host cells", "CELL", 104, 114], ["2\u2032-O-MTase", "PROTEIN", 29, 39], ["host cells", "CELL_TYPE", 104, 114], ["coronaviruses", "PROBLEM", 43, 56], ["viruses", "OBSERVATION", 93, 100], ["host cells", "OBSERVATION", 104, 114]]], ["However, the molecular mechanisms underlying the enzymatic activity of nsp16 and the stimulatory effect of nsp10 are unknown.", [["nsp16", "GENE_OR_GENE_PRODUCT", 71, 76], ["nsp10", "GENE_OR_GENE_PRODUCT", 107, 112], ["nsp16", "PROTEIN", 71, 76], ["nsp10", "PROTEIN", 107, 112], ["enzymatic activity", "OBSERVATION", 49, 67]]], ["Here we report the crystal structure of the heterodimer of nsp16 and nsp10 (nsp16/nsp10) with bound methyl donor SAM and biochemical characterization of the stimulation mechanisms.", [["methyl", "CHEMICAL", 100, 106], ["methyl", "CHEMICAL", 100, 106], ["nsp16", "GENE_OR_GENE_PRODUCT", 59, 64], ["nsp10", "GENE_OR_GENE_PRODUCT", 69, 74], ["methyl donor SAM", "SIMPLE_CHEMICAL", 100, 116], ["nsp16", "PROTEIN", 59, 64], ["nsp10", "PROTEIN", 69, 74], ["nsp16", "PROTEIN", 76, 81], ["nsp10", "PROTEIN", 82, 87], ["nsp16", "TEST", 59, 64], ["nsp10", "TEST", 69, 74], ["bound methyl donor SAM", "TREATMENT", 94, 116], ["biochemical characterization", "TEST", 121, 149], ["the stimulation mechanisms", "TREATMENT", 153, 179]]], ["We found that nsp10 is required for nsp16 to bind both SAM and RNA substrate, and the crystal structure shows that nsp10 may stabilize the SAM-binding pocket and extend the RNA-binding groove of nsp16.", [["nsp10", "GENE_OR_GENE_PRODUCT", 14, 19], ["nsp16", "GENE_OR_GENE_PRODUCT", 36, 41], ["SAM", "GENE_OR_GENE_PRODUCT", 55, 58], ["nsp10", "GENE_OR_GENE_PRODUCT", 115, 120], ["nsp16", "GENE_OR_GENE_PRODUCT", 195, 200], ["nsp10", "PROTEIN", 14, 19], ["nsp16", "PROTEIN", 36, 41], ["SAM", "PROTEIN", 55, 58], ["nsp10", "PROTEIN", 115, 120], ["SAM-binding pocket", "PROTEIN", 139, 157], ["nsp16", "PROTEIN", 195, 200], ["nsp16", "TREATMENT", 36, 41], ["RNA substrate", "TEST", 63, 76], ["the crystal structure", "TEST", 82, 103], ["the SAM-binding pocket", "PROBLEM", 135, 157], ["binding pocket", "OBSERVATION", 143, 157]]], ["These results have implications for designing specific anti-coronavirus drugs to control infection.Specific 2\u2032-O-methylation of GpppA-capped RNA by SARS-CoV nsp14/nsp16/nsp10 complex ::: ResultsIn our previous work, we adopted a genetic screening system and biochemical assays to identify SARS-CoV nsp14 as N7-MTase [8].", [["infection", "DISEASE", 89, 98], ["2\u2032-O-", "CHEMICAL", 108, 113], ["2\u2032-O-", "CHEMICAL", 108, 113], ["2\u2032-O-", "SIMPLE_CHEMICAL", 108, 113], ["GpppA", "SIMPLE_CHEMICAL", 128, 133], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 148, 156], ["SARS-CoV nsp14", "GENE_OR_GENE_PRODUCT", 289, 303], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 307, 315], ["GpppA-capped RNA", "RNA", 128, 144], ["SARS-CoV nsp14/nsp16/nsp10 complex", "PROTEIN", 148, 182], ["SARS-CoV nsp14", "PROTEIN", 289, 303], ["SARS-CoV", "SPECIES", 148, 156], ["SARS-CoV", "SPECIES", 289, 297], ["specific anti-coronavirus drugs", "TREATMENT", 46, 77], ["infection", "PROBLEM", 89, 98], ["GpppA", "TEST", 128, 133], ["SARS", "TEST", 148, 152], ["CoV nsp14", "TEST", 153, 162], ["a genetic screening system", "TEST", 227, 253], ["biochemical assays", "TEST", 258, 276], ["SARS", "TEST", 289, 293], ["infection", "OBSERVATION", 89, 98]]], ["However, we did not observe any 2\u2032-O-MTase activity in various biochemical assays for SARS-CoV nsp16, which was previously predicted to be 2\u2032-O-MTase [1], [29], although a low 2\u2032-O-MTase activity was demonstrated for feline coronavirus nsp16 [26].", [["SARS-CoV nsp16", "GENE_OR_GENE_PRODUCT", 86, 100], ["[29]", "SIMPLE_CHEMICAL", 155, 159], ["2\u2032-O-MTase", "SIMPLE_CHEMICAL", 176, 186], ["feline coronavirus", "ORGANISM", 217, 235], ["MTase", "PROTEIN", 37, 42], ["SARS-CoV nsp16", "PROTEIN", 86, 100], ["MTase", "PROTEIN", 144, 149], ["MTase", "PROTEIN", 181, 186], ["feline coronavirus", "SPECIES", 217, 235], ["SARS-CoV", "SPECIES", 86, 94], ["feline coronavirus", "SPECIES", 217, 235], ["various biochemical assays", "TEST", 55, 81], ["SARS", "PROBLEM", 86, 90], ["CoV nsp16", "TEST", 91, 100], ["feline coronavirus nsp16", "TEST", 217, 241]]], ["We and others showed previously that SARS-CoV nsp10 could interact with both nsp14 and nsp16 [30], [31], suggesting a role for nsp10 in the functions of nsp14 and nsp16.", [["SARS-CoV", "ORGANISM", 37, 45], ["nsp10", "GENE_OR_GENE_PRODUCT", 46, 51], ["nsp14", "GENE_OR_GENE_PRODUCT", 77, 82], ["nsp16 [30]", "GENE_OR_GENE_PRODUCT", 87, 97], ["nsp10", "GENE_OR_GENE_PRODUCT", 127, 132], ["nsp14", "GENE_OR_GENE_PRODUCT", 153, 158], ["nsp16", "GENE_OR_GENE_PRODUCT", 163, 168], ["SARS-CoV nsp10", "PROTEIN", 37, 51], ["nsp14", "PROTEIN", 77, 82], ["nsp10", "PROTEIN", 127, 132], ["nsp14", "PROTEIN", 153, 158], ["nsp16", "PROTEIN", 163, 168], ["SARS-CoV", "SPECIES", 37, 45], ["nsp10", "TREATMENT", 127, 132], ["nsp14", "TEST", 153, 158], ["nsp16", "TREATMENT", 163, 168]]], ["Therefore, we undertook to test the effects of nsp10 on the MTase activities of both nsp14 and nsp16.", [["nsp10", "GENE_OR_GENE_PRODUCT", 47, 52], ["nsp14", "GENE_OR_GENE_PRODUCT", 85, 90], ["nsp16", "GENE_OR_GENE_PRODUCT", 95, 100], ["nsp10", "PROTEIN", 47, 52], ["MTase", "PROTEIN", 60, 65], ["nsp14", "PROTEIN", 85, 90], ["nsp16", "PROTEIN", 95, 100], ["nsp10", "TREATMENT", 47, 52], ["the MTase activities", "TREATMENT", 56, 76], ["nsp16", "TREATMENT", 95, 100]]], ["As shown in Figure 1A, by using radiolabeled and unmethylated G indicates that the following phosphate was 32P labeled, and the sequence is identical with viral genomic RNA except for the second nucleotide), nsp14 alone could efficiently N7-methylate GpppA-RNA to generate cap-0 structure (m7GpppA) (Figure 1A, lane 2) and nsp10 did not significantly alter nsp14 N7-MTase activity in our testing system (Figure 1A, lane 4).", [["phosphate", "CHEMICAL", 93, 102], ["nucleotide", "CHEMICAL", 195, 205], ["nsp14", "CHEMICAL", 208, 213], ["N7", "CHEMICAL", 238, 240], ["phosphate", "CHEMICAL", 93, 102], ["nucleotide", "CHEMICAL", 195, 205], ["phosphate", "SIMPLE_CHEMICAL", 93, 102], ["32P", "SIMPLE_CHEMICAL", 107, 110], ["nsp14", "GENE_OR_GENE_PRODUCT", 208, 213], ["GpppA", "GENE_OR_GENE_PRODUCT", 251, 256], ["nsp10", "GENE_OR_GENE_PRODUCT", 323, 328], ["viral genomic RNA", "RNA", 155, 172], ["nsp14", "PROTEIN", 208, 213], ["N7-methylate GpppA-RNA", "RNA", 238, 260], ["cap-0 structure", "DNA", 273, 288], ["nsp10", "DNA", 323, 328], ["MTase", "PROTEIN", 366, 371], ["the following phosphate", "TREATMENT", 79, 102], ["the sequence", "TEST", 124, 136], ["viral genomic RNA", "PROBLEM", 155, 172], ["methylate GpppA", "TEST", 241, 256], ["cap", "TEST", 273, 276], ["7GpppA", "TEST", 291, 297], ["nsp", "TEST", 357, 360]]], ["While either nsp16 or nsp10 alone did not show any MTase activity (Figure 1A, lanes 3 and 1), the mixture of nsp10/nsp14/nsp16 gave rise to cap-1 structure (m7GpppAm) (Figure 1A, lane 7), indicating that addition of nsp10 and nsp16 rendered the complex active in the 2\u2032-O-MTase reaction.", [["O", "CHEMICAL", 270, 271], ["nsp16", "GENE_OR_GENE_PRODUCT", 13, 18], ["nsp10", "GENE_OR_GENE_PRODUCT", 22, 27], ["nsp10", "GENE_OR_GENE_PRODUCT", 109, 114], ["cap-1", "GENE_OR_GENE_PRODUCT", 140, 145], ["nsp10", "GENE_OR_GENE_PRODUCT", 216, 221], ["nsp16", "GENE_OR_GENE_PRODUCT", 226, 231], ["nsp16", "PROTEIN", 13, 18], ["nsp10", "PROTEIN", 22, 27], ["MTase", "PROTEIN", 51, 56], ["nsp10", "PROTEIN", 109, 114], ["nsp14", "PROTEIN", 115, 120], ["p16", "DNA", 123, 126], ["cap-1 structure", "DNA", 140, 155], ["nsp10", "PROTEIN", 216, 221], ["nsp16", "PROTEIN", 226, 231], ["MTase", "PROTEIN", 272, 277], ["nsp10", "TEST", 109, 114], ["cap", "TEST", 140, 143], ["nsp10", "TREATMENT", 216, 221], ["nsp16", "TREATMENT", 226, 231], ["MTase reaction", "PROBLEM", 272, 286]]], ["We then used radiolabeled m7Gm7GpppA-capped RNA (where * indicates that the methyl group was 3H labeled) while nsp10, nsp16, or nsp5 alone could not pull down the labeled RNA.", [["methyl", "CHEMICAL", 76, 82], ["methyl", "CHEMICAL", 76, 82], ["3H", "CHEMICAL", 93, 95], ["m7Gm7GpppA", "GENE_OR_GENE_PRODUCT", 26, 36], ["methyl", "SIMPLE_CHEMICAL", 76, 82], ["3H", "SIMPLE_CHEMICAL", 93, 95], ["nsp10", "GENE_OR_GENE_PRODUCT", 111, 116], ["nsp16", "GENE_OR_GENE_PRODUCT", 118, 123], ["nsp5", "GENE_OR_GENE_PRODUCT", 128, 132], ["m7Gm7GpppA", "PROTEIN", 26, 36], ["nsp10", "PROTEIN", 111, 116], ["nsp16", "PROTEIN", 118, 123], ["nsp5", "PROTEIN", 128, 132], ["labeled RNA", "RNA", 163, 174], ["radiolabeled m7Gm7GpppA-capped RNA", "TREATMENT", 13, 47]]], ["Also in this testing system, nsp16/nsp10 complex had a low binding affinity to m7GpppA and pppA-RNA, GpppG-RNA, where the * indicates that the following phosphate was radio-labeled.), and purified as previously described [8].", [["phosphate", "CHEMICAL", 153, 162], ["phosphate", "CHEMICAL", 153, 162], ["nsp16/nsp10", "GENE_OR_GENE_PRODUCT", 29, 40], ["m7GpppA", "GENE_OR_GENE_PRODUCT", 79, 86], ["pppA-RNA", "GENE_OR_GENE_PRODUCT", 91, 99], ["GpppG-RNA", "GENE_OR_GENE_PRODUCT", 101, 110], ["phosphate", "SIMPLE_CHEMICAL", 153, 162], ["nsp16/nsp10 complex", "PROTEIN", 29, 48], ["m7GpppA", "PROTEIN", 79, 86], ["pppA", "PROTEIN", 91, 95], ["GpppG", "PROTEIN", 101, 106], ["this testing system", "TEST", 8, 27], ["nsp16", "TEST", 29, 34], ["a low binding affinity", "PROBLEM", 53, 75], ["m7GpppA", "TEST", 79, 86], ["pppA", "TEST", 91, 95], ["phosphate", "TEST", 153, 162]]], ["RNAs containing 32P-labeled cap-1 structure (m7GpppA-RNA by a vaccinia virus 2\u2032-O-methyltransferase VP39 following the manufacturer's protocol (Epicentre).", [["32P", "SIMPLE_CHEMICAL", 16, 19], ["cap-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["2\u2032-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 77, 99], ["RNAs", "RNA", 0, 4], ["32P-labeled cap-1 structure", "DNA", 16, 43], ["vaccinia virus 2\u2032-O-methyltransferase VP39", "PROTEIN", 62, 104], ["vaccinia virus", "SPECIES", 62, 76], ["vaccinia virus", "SPECIES", 62, 76], ["RNAs", "TEST", 0, 4], ["cap", "TEST", 28, 31], ["7GpppA", "TEST", 46, 52], ["a vaccinia virus", "TREATMENT", 60, 76], ["methyltransferase VP39", "TREATMENT", 82, 104], ["the manufacturer's protocol", "TREATMENT", 115, 142]]], ["RNAs containing unlabeled cap structures (m7GpppA-RNA or m7GpppG-RNA) were prepared by a vaccinia virus capping enzyme following the manufacturer's protocol (Epicentre) as well as 3H-labeled cap structures (m7GpppG-RNA), except that 10 \u00b5Ci of S-adenosyl [methyl-3H] methionine (67.3 Ci/mmol, 0.5 \u00b5Ci/ul) was used as the methyl donor instead of cold SAM.", [["S-adenosyl [methyl-3H] methionine", "CHEMICAL", 243, 276], ["methyl", "CHEMICAL", 320, 326], ["3H", "CHEMICAL", 180, 182], ["S-adenosyl [methyl-3H] methionine", "CHEMICAL", 243, 276], ["methyl", "CHEMICAL", 320, 326], ["m7GpppG-RNA", "GENE_OR_GENE_PRODUCT", 57, 68], ["vaccinia virus", "ORGANISM", 89, 103], ["S-adenosyl [methyl-3H] methionine", "SIMPLE_CHEMICAL", 243, 276], ["methyl", "SIMPLE_CHEMICAL", 320, 326], ["RNAs", "RNA", 0, 4], ["m7GpppA-RNA", "RNA", 42, 53], ["m7GpppG", "DNA", 57, 64], ["vaccinia virus capping enzyme", "PROTEIN", 89, 118], ["vaccinia virus", "SPECIES", 89, 103], ["unlabeled cap structures", "TEST", 16, 40], ["7GpppA", "TEST", 43, 49], ["m7GpppG-RNA", "TREATMENT", 57, 68], ["a vaccinia virus capping enzyme", "TREATMENT", 87, 118], ["the manufacturer's protocol", "TREATMENT", 129, 156], ["3H-labeled cap structures", "TREATMENT", 180, 205], ["S-adenosyl [methyl", "TREATMENT", 243, 261], ["methionine", "TREATMENT", 266, 276], ["the methyl donor", "TREATMENT", 316, 332]]], ["The 32P-labeled cap analogue (m7GpppG) and 3H-labeled cap analogue (m7GpppG) were digested from m7GpppG-RNA and m7GpppG-RNA by nuclease P1 (Sigma) in 10 mM Tris-HCl, pH 7.5, 1 mM ZnCl2 at 50\u00b0C for 30 min.", [["Tris-HCl", "CHEMICAL", 156, 164], ["ZnCl2", "CHEMICAL", 179, 184], ["3H", "CHEMICAL", 43, 45], ["Tris-HCl", "CHEMICAL", 156, 164], ["ZnCl2", "CHEMICAL", 179, 184], ["32P-labeled cap analogue", "SIMPLE_CHEMICAL", 4, 28], ["m7GpppG", "SIMPLE_CHEMICAL", 30, 37], ["3H-labeled cap analogue", "SIMPLE_CHEMICAL", 43, 66], ["m7GpppG", "SIMPLE_CHEMICAL", 68, 75], ["m7GpppG", "GENE_OR_GENE_PRODUCT", 96, 103], ["Tris-HCl", "SIMPLE_CHEMICAL", 156, 164], ["ZnCl2", "SIMPLE_CHEMICAL", 179, 184], ["m7GpppG-RNA and m7GpppG-RNA", "RNA", 96, 123], ["nuclease P1", "PROTEIN", 127, 138], ["3H-labeled cap analogue", "TREATMENT", 43, 66], ["Tris", "TEST", 156, 160], ["pH", "TEST", 166, 168], ["1 mM ZnCl2", "TREATMENT", 174, 184]]], ["All the RNA substrates were extracted with phenol-chloroform and precipitated with ethanol.", [["phenol-chloroform", "CHEMICAL", 43, 60], ["ethanol", "CHEMICAL", 83, 90], ["phenol", "CHEMICAL", 43, 49], ["chloroform", "CHEMICAL", 50, 60], ["ethanol", "CHEMICAL", 83, 90], ["phenol-chloroform", "SIMPLE_CHEMICAL", 43, 60], ["ethanol", "SIMPLE_CHEMICAL", 83, 90], ["phenol-chloroform", "TREATMENT", 43, 60], ["ethanol", "TREATMENT", 83, 90]]], ["The unlabeled cap analogues (m7GpppA, GpppA, and m7GpppG) were purchased from New England BioLabs.Biochemical assays for MTase activity ::: Materials and MethodsPurified recombinant or mutant proteins (0.5 \u00b5g) and 2\u00d7103 cpm of 32P-labeled m7GpppA-RNA substrates were added to 8.5 \u00b5L reaction mixture [40 mM Tris-HCl (pH 7.5 or 8.0), 2 mM MgCl2, 2 mM DTT, 10 units RNase inhibitor, 0.2 mM SAM] and incubated at 37\u00b0C for 1.5 h.", [["Tris-HCl", "CHEMICAL", 307, 315], ["MgCl2", "CHEMICAL", 338, 343], ["Tris-HCl", "CHEMICAL", 307, 315], ["MgCl2", "CHEMICAL", 338, 343], ["DTT", "CHEMICAL", 350, 353], ["SAM", "CHEMICAL", 388, 391], ["cap analogues", "SIMPLE_CHEMICAL", 14, 27], ["m7GpppA", "GENE_OR_GENE_PRODUCT", 29, 36], ["GpppA", "GENE_OR_GENE_PRODUCT", 38, 43], ["m7GpppG", "GENE_OR_GENE_PRODUCT", 49, 56], ["BioLabs", "GENE_OR_GENE_PRODUCT", 90, 97], ["MTase", "GENE_OR_GENE_PRODUCT", 121, 126], ["32P", "SIMPLE_CHEMICAL", 227, 230], ["m7GpppA", "SIMPLE_CHEMICAL", 239, 246], ["Tris-HCl", "SIMPLE_CHEMICAL", 307, 315], ["MgCl2", "SIMPLE_CHEMICAL", 338, 343], ["DTT", "SIMPLE_CHEMICAL", 350, 353], ["RNase", "GENE_OR_GENE_PRODUCT", 364, 369], ["GpppA", "PROTEIN", 38, 43], ["m7GpppG", "PROTEIN", 49, 56], ["MTase", "PROTEIN", 121, 126], ["MethodsPurified recombinant", "PROTEIN", 154, 181], ["mutant proteins", "PROTEIN", 185, 200], ["m7GpppA", "PROTEIN", 239, 246], ["The unlabeled cap analogues", "TEST", 0, 27], ["m7GpppA", "TEST", 29, 36], ["GpppA", "TEST", 38, 43], ["Biochemical assays", "TEST", 98, 116], ["mutant proteins", "TEST", 185, 200], ["32P", "TEST", 227, 230], ["m7GpppA-RNA substrates", "TREATMENT", 239, 261], ["Tris", "TEST", 307, 311], ["HCl", "TEST", 312, 315], ["pH", "TEST", 317, 319], ["MgCl2", "TEST", 338, 343], ["DTT", "TEST", 350, 353], ["RNase inhibitor", "TREATMENT", 364, 379]]], ["RNA cap structures were liberated with 5 \u00b5g of nuclease P1 (Sigma), then spotted onto polyethyleneimine cellulose-F plates (Merck) for TLC, and developed in 0.4 M ammonium sulfate.", [["polyethyleneimine cellulose", "CHEMICAL", 86, 113], ["ammonium sulfate", "CHEMICAL", 163, 179], ["polyethyleneimine", "CHEMICAL", 86, 103], ["ammonium sulfate", "CHEMICAL", 163, 179], ["polyethyleneimine cellulose-F plates", "SIMPLE_CHEMICAL", 86, 122], ["Merck", "SIMPLE_CHEMICAL", 124, 129], ["ammonium sulfate", "SIMPLE_CHEMICAL", 163, 179], ["nuclease P1", "PROTEIN", 47, 58], ["RNA cap structures", "TEST", 0, 18], ["nuclease P1", "TREATMENT", 47, 58], ["polyethyleneimine cellulose-F plates", "TREATMENT", 86, 122], ["TLC", "TEST", 135, 138], ["0.4 M ammonium sulfate", "TREATMENT", 157, 179], ["cap", "OBSERVATION_MODIFIER", 4, 7]]], ["The extent of 32P-labeled cap was determined by scanning the chromatogram with a PhosphorImager [8].Biochemical assays for MTase activity ::: Materials and MethodsMTase activity assays were carried out in 30 \u00b5L reaction mixture [40 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 2 mM DTT, 40 units RNase inhibitor, 0.01 mM SAM], with 1 \u00b5Ci of S-adenosyl [methyl-3H] methionine (67.3 Ci/mmol, 0.5 \u00b5Ci/\u00b5l), 1 \u00b5g of purified proteins or mutant proteins, and 3 \u00b5g of m7GpppA/m7GpppG-RNA substrates or other RNA substrates (2 mM m7GpppA/GpppA/m7GpppG cap analogue or 15 mM NTPs) at 37\u00b0C for 1.5 h.", [["Tris-HCl", "CHEMICAL", 235, 243], ["MgCl2", "CHEMICAL", 259, 264], ["S-adenosyl [methyl-3H] methionine", "CHEMICAL", 330, 363], ["32P", "CHEMICAL", 14, 17], ["Tris-HCl", "CHEMICAL", 235, 243], ["MgCl2", "CHEMICAL", 259, 264], ["DTT", "CHEMICAL", 271, 274], ["SAM", "CHEMICAL", 310, 313], ["S-adenosyl [methyl-3H] methionine", "CHEMICAL", 330, 363], ["NTPs", "CHEMICAL", 555, 559], ["32P", "SIMPLE_CHEMICAL", 14, 17], ["MTase", "GENE_OR_GENE_PRODUCT", 123, 128], ["Tris-HCl", "SIMPLE_CHEMICAL", 235, 243], ["MgCl2", "SIMPLE_CHEMICAL", 259, 264], ["DTT", "SIMPLE_CHEMICAL", 271, 274], ["RNase", "GENE_OR_GENE_PRODUCT", 285, 290], ["S-adenosyl [methyl-3H] methionine", "SIMPLE_CHEMICAL", 330, 363], ["m7GpppA", "GENE_OR_GENE_PRODUCT", 450, 457], ["m7GpppG", "GENE_OR_GENE_PRODUCT", 458, 465], ["MTase", "PROTEIN", 123, 128], ["purified proteins", "PROTEIN", 400, 417], ["mutant proteins", "PROTEIN", 421, 436], ["m7GpppA", "PROTEIN", 450, 457], ["m7GpppG", "PROTEIN", 458, 465], ["GpppA", "PROTEIN", 519, 524], ["32P-labeled cap", "TEST", 14, 29], ["scanning the chromatogram", "TEST", 48, 73], ["a PhosphorImager", "TREATMENT", 79, 95], ["Biochemical assays", "TEST", 100, 118], ["MethodsMTase activity assays", "TEST", 156, 184], ["Tris", "TEST", 235, 239], ["pH", "TEST", 245, 247], ["MgCl2", "TEST", 259, 264], ["DTT", "TEST", 271, 274], ["RNase inhibitor", "TREATMENT", 285, 300], ["S-adenosyl [methyl", "TREATMENT", 330, 348], ["methionine", "TREATMENT", 353, 363], ["mutant proteins", "TEST", 421, 436], ["m7GpppA", "TREATMENT", 450, 457], ["m7GpppG", "TREATMENT", 458, 465], ["RNA substrates", "TREATMENT", 466, 480], ["other RNA substrates", "TREATMENT", 484, 504], ["2 mM m7GpppA/GpppA/m7GpppG cap analogue", "TREATMENT", 506, 545], ["15 mM NTPs", "TREATMENT", 549, 559]]], ["3H-labeled product was isolated in small DEAE-Sephadex columns and quantitated by liquid scintillation [68].SAM binding assay ::: Materials and Methods25 \u00b5L reaction mixtures [40 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 2 mM DTT] containing 1 \u00b5g of purified proteins and 1 \u00b5Ci of S-adenosyl [methyl-3H] methionine (67.3 Ci/mmol, 0.5 \u00b5Ci/\u00b5l) were pipetted into wells of a microtiter plate.", [["3H", "CHEMICAL", 0, 2], ["Tris-HCl", "CHEMICAL", 182, 190], ["MgCl2", "CHEMICAL", 206, 211], ["S-adenosyl [methyl-3H] methionine", "CHEMICAL", 273, 306], ["3H", "CHEMICAL", 0, 2], ["Tris-HCl", "CHEMICAL", 182, 190], ["MgCl2", "CHEMICAL", 206, 211], ["DTT", "CHEMICAL", 218, 221], ["S-adenosyl [methyl-3H] methionine", "CHEMICAL", 273, 306], ["3H", "SIMPLE_CHEMICAL", 0, 2], ["Tris-HCl", "SIMPLE_CHEMICAL", 182, 190], ["MgCl2", "SIMPLE_CHEMICAL", 206, 211], ["DTT", "SIMPLE_CHEMICAL", 218, 221], ["S-adenosyl [methyl-3H] methionine", "SIMPLE_CHEMICAL", 273, 306], ["3H-labeled product", "TREATMENT", 0, 18], ["small DEAE-Sephadex columns", "TREATMENT", 35, 62], ["Materials", "TEST", 130, 139], ["Methods25", "TEST", 144, 153], ["mixtures", "TEST", 166, 174], ["Tris", "TEST", 182, 186], ["HCl", "TEST", 187, 190], ["pH", "TEST", 192, 194], ["DTT", "TEST", 218, 221], ["purified proteins", "TEST", 242, 259], ["S-adenosyl [methyl", "TREATMENT", 273, 291], ["methionine", "TREATMENT", 296, 306], ["\u00b5Ci/\u00b5l)", "TREATMENT", 326, 333], ["a microtiter plate", "TREATMENT", 362, 380]]], ["The reaction mixtures were incubated on ice and irradiated with 254-nm UV light in a Hoefer UVC500 cross-linking oven for 30 min.", [["The reaction mixtures", "PROBLEM", 0, 21]]], ["The distance of samples from the UV tubes was 4 cm.", [["samples", "ANATOMY", 16, 23], ["the UV tubes", "TREATMENT", 29, 41], ["distance", "OBSERVATION_MODIFIER", 4, 12], ["UV tubes", "OBSERVATION", 33, 41], ["4 cm", "OBSERVATION_MODIFIER", 46, 50]]], ["The samples were then analyzed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).", [["samples", "ANATOMY", 4, 11], ["sodium dodecyl sulfate", "CHEMICAL", 38, 60], ["sodium dodecyl sulfate", "CHEMICAL", 38, 60], ["polyacrylamide", "CHEMICAL", 61, 75], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 38, 60], ["The samples", "TEST", 0, 11], ["12% sodium dodecyl sulfate", "TREATMENT", 34, 60], ["polyacrylamide gel electrophoresis", "TREATMENT", 61, 95]]], ["The gels were soaked in Enlightning Solution (PerkinElmer) and used for fluorography [68].Gel shift assay ::: Materials and MethodsThe gel shift assay provides a simple and rapid method for detecting RNA-binding proteins.", [["RNA-binding proteins", "GENE_OR_GENE_PRODUCT", 200, 220], ["RNA-binding proteins", "PROTEIN", 200, 220], ["The gels", "TREATMENT", 0, 8], ["Enlightning Solution (PerkinElmer)", "TREATMENT", 24, 58], ["fluorography", "TEST", 72, 84], ["Methods", "TREATMENT", 124, 131], ["The gel shift assay", "TEST", 131, 150], ["RNA-binding proteins", "PROBLEM", 200, 220]]], ["This method has been widely used in the study of sequence-specific RNA-binding proteins.", [["RNA-binding proteins", "GENE_OR_GENE_PRODUCT", 67, 87], ["RNA-binding proteins", "PROTEIN", 67, 87], ["This method", "TREATMENT", 0, 11], ["the study", "TEST", 36, 45], ["sequence", "TEST", 49, 57]]], ["In this assay, 1 \u00b5g of purified proteins and 4\u00d7103 cpm of 32P-labeled RNA substrates (m7GpppG-RNA, m7GpppG cap analogue) were added to 20 \u00b5L reaction mixtures [40 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 2 mM DTT].", [["Tris-HCl", "CHEMICAL", 166, 174], ["Tris-HCl", "CHEMICAL", 166, 174], ["MgCl2", "CHEMICAL", 190, 195], ["DTT", "CHEMICAL", 202, 205], ["32P", "SIMPLE_CHEMICAL", 58, 61], ["Tris-HCl", "SIMPLE_CHEMICAL", 166, 174], ["DTT", "SIMPLE_CHEMICAL", 202, 205], ["purified proteins", "PROTEIN", 23, 40], ["32P-labeled RNA substrates", "RNA", 58, 84], ["purified proteins", "TEST", 23, 40], ["cpm", "TEST", 51, 54], ["32P", "TEST", 58, 61], ["RNA substrates", "TEST", 70, 84], ["7GpppG-RNA", "TREATMENT", 87, 97], ["m7GpppG cap analogue", "TREATMENT", 99, 119], ["Tris", "TEST", 166, 170], ["pH", "TEST", 176, 178]]], ["The reactions were incubated at room temperature for 25 min, and separated by nondenaturing polyacrylamide gel (N-PAGE).", [["N-PAGE", "CHEMICAL", 112, 118], ["polyacrylamide", "CHEMICAL", 92, 106], ["The reactions", "PROBLEM", 0, 13], ["nondenaturing polyacrylamide gel", "TREATMENT", 78, 110]]], ["The RNA substrate bands were quantitated by scanning the gels with a PhosphorImager.RNA binding assay ::: Materials and MethodsIn each set of RNA binding assay, 3 \u00b5g of freshly prepared 3H-labeled RNA substrates (m7GpppG-RNA, m7GpppG cap analogue) and 4 \u00b5g of purified His6-proteins were mixed in 100 \u00b5L binding buffer [40 mM Tris-HCl (pH 7.5), 2 mM MgCl2].", [["3H", "CHEMICAL", 186, 188], ["Tris-HCl", "CHEMICAL", 326, 334], ["MgCl2", "CHEMICAL", 350, 355], ["3H", "CHEMICAL", 186, 188], ["Tris-HCl", "CHEMICAL", 326, 334], ["MgCl2", "CHEMICAL", 350, 355], ["3H", "SIMPLE_CHEMICAL", 186, 188], ["His6", "GENE_OR_GENE_PRODUCT", 269, 273], ["Tris-HCl", "SIMPLE_CHEMICAL", 326, 334], ["3H-labeled RNA substrates", "RNA", 186, 211], ["His6", "PROTEIN", 269, 273], ["The RNA substrate bands", "PROBLEM", 0, 23], ["a PhosphorImager", "TREATMENT", 67, 83], ["RNA binding assay", "TEST", 142, 159], ["RNA substrates", "TEST", 197, 211], ["m7GpppG cap analogue", "TREATMENT", 226, 246], ["Tris", "TEST", 326, 330], ["pH", "TEST", 336, 338], ["RNA", "OBSERVATION_MODIFIER", 4, 7], ["substrate bands", "OBSERVATION", 8, 23]]], ["The binding reactions were shaken at 4\u00b0C over night.", [["The binding reactions", "PROBLEM", 0, 21]]], ["20 \u00b5L high affinity Ni-NTA resin (50% slurry, GenScript), equilibrated with binding buffer, were added to binding reactions and mixed gently for 30 min at 4\u00b0C. The complex of 3H-labeled-RNA-His6 and Ni-NTA-bound protein was pelleted by centrifugation for 20 s at 1000 g, and washed twice with binding buffer to remove free 3H-labeled RNA substrates.", [["Ni-NTA", "CHEMICAL", 20, 26], ["3H", "CHEMICAL", 175, 177], ["Ni-NTA", "CHEMICAL", 20, 26], ["3H", "CHEMICAL", 175, 177], ["3H", "CHEMICAL", 323, 325], ["Ni-NTA", "SIMPLE_CHEMICAL", 20, 26], ["3H", "SIMPLE_CHEMICAL", 175, 177], ["His6", "GENE_OR_GENE_PRODUCT", 190, 194], ["Ni-NTA", "SIMPLE_CHEMICAL", 199, 205], ["His6", "PROTEIN", 190, 194], ["Ni-NTA-bound protein", "PROTEIN", 199, 219], ["\u00b5L high affinity Ni-NTA resin", "TREATMENT", 3, 32], ["binding buffer", "TREATMENT", 76, 90], ["RNA", "TEST", 186, 189], ["Ni-NTA-bound protein", "TREATMENT", 199, 219], ["binding buffer", "TREATMENT", 293, 307]]], ["The complex was finally resuspended in 100 \u00b5L of binding buffer, and a 30 \u00b5L aliquot was analyzed by Western Blotting analysis with anti-His-tag antibody.", [["anti-His-tag antibody", "PROTEIN", 132, 153], ["binding buffer", "TREATMENT", 49, 63], ["a 30 \u00b5L aliquot", "TREATMENT", 69, 84], ["Blotting analysis", "TEST", 109, 126], ["anti-His-tag antibody", "TREATMENT", 132, 153]]], ["The remaining 70 \u00b5L was quantitated by liquid scintillation.Isothermal Titration Calorimetry ::: Materials and MethodsITC experiments on the interaction of SAM with nsp16, nsp10, and nsp16/nsp10 complex of SARS-CoV in the absence of DTT were carried out at 25\u00b0C using a VP-ITC titration calorimeter (MicroCal, Northampton, MA).", [["VP-ITC", "CHEMICAL", 270, 276], ["SAM", "CHEMICAL", 156, 159], ["DTT", "CHEMICAL", 233, 236], ["SAM", "GENE_OR_GENE_PRODUCT", 156, 159], ["nsp16", "GENE_OR_GENE_PRODUCT", 165, 170], ["nsp10", "GENE_OR_GENE_PRODUCT", 172, 177], ["nsp16", "GENE_OR_GENE_PRODUCT", 183, 188], ["nsp10", "GENE_OR_GENE_PRODUCT", 189, 194], ["SARS-CoV", "ORGANISM", 206, 214], ["DTT", "SIMPLE_CHEMICAL", 233, 236], ["SAM", "PROTEIN", 156, 159], ["nsp16", "PROTEIN", 165, 170], ["nsp10", "PROTEIN", 172, 177], ["nsp16", "PROTEIN", 183, 188], ["nsp10 complex", "PROTEIN", 189, 202], ["SARS-CoV", "PROTEIN", 206, 214], ["SARS-CoV", "SPECIES", 206, 214], ["liquid scintillation", "TREATMENT", 39, 59], ["nsp16", "TEST", 165, 170], ["nsp10", "TEST", 172, 177], ["SARS", "PROBLEM", 206, 210], ["DTT", "TEST", 233, 236], ["a VP-ITC titration calorimeter", "TREATMENT", 268, 298], ["liquid scintillation", "OBSERVATION", 39, 59]]], ["Freshly purified nsp16 and nsp10 proteins were mixed, and their final concentrations were 10 \u00b5M and 80 \u00b5M, respectively.", [["nsp16", "GENE_OR_GENE_PRODUCT", 17, 22], ["nsp10", "GENE_OR_GENE_PRODUCT", 27, 32], ["nsp16", "PROTEIN", 17, 22], ["nsp10 proteins", "PROTEIN", 27, 41], ["nsp10 proteins", "TEST", 27, 41], ["mixed", "OBSERVATION_MODIFIER", 47, 52]]], ["Then nsp16, nsp10, and nsp16/nsp10 complex were dialyzed against 40 mM Tris-HCl buffer (pH 8.0) containing 50 mM NaCl, over night at 4\u00b0C, extensively to remove glycerol and DTT.", [["Tris-HCl", "CHEMICAL", 71, 79], ["NaCl", "CHEMICAL", 113, 117], ["glycerol", "CHEMICAL", 160, 168], ["DTT", "CHEMICAL", 173, 176], ["Tris-HCl", "CHEMICAL", 71, 79], ["NaCl", "CHEMICAL", 113, 117], ["glycerol", "CHEMICAL", 160, 168], ["DTT", "CHEMICAL", 173, 176], ["nsp16", "GENE_OR_GENE_PRODUCT", 5, 10], ["nsp10", "GENE_OR_GENE_PRODUCT", 12, 17], ["nsp16", "GENE_OR_GENE_PRODUCT", 23, 28], ["Tris-HCl", "SIMPLE_CHEMICAL", 71, 79], ["glycerol", "SIMPLE_CHEMICAL", 160, 168], ["DTT", "SIMPLE_CHEMICAL", 173, 176], ["nsp16, nsp10, and nsp16/nsp10 complex", "PROTEIN", 5, 42], ["nsp16", "TEST", 5, 10], ["nsp10", "TEST", 12, 17], ["nsp16", "TEST", 23, 28], ["pH", "TEST", 88, 90], ["50 mM NaCl", "TREATMENT", 107, 117], ["glycerol", "TREATMENT", 160, 168], ["DTT", "TREATMENT", 173, 176]]], ["A solution of nsp16, nsp10, or nsp16/nsp10 complex was loaded into the sample cell (1.43 mL), and a solution of 150 \u00b5M SAM was placed in the injection syringe (300 \u00b5L).", [["sample cell", "ANATOMY", 71, 82], ["nsp16", "GENE_OR_GENE_PRODUCT", 14, 19], ["nsp10", "GENE_OR_GENE_PRODUCT", 21, 26], ["cell", "CELL", 78, 82], ["nsp16", "PROTEIN", 14, 19], ["nsp10", "PROTEIN", 21, 26], ["nsp16/nsp10 complex", "PROTEIN", 31, 50], ["A solution of nsp16", "TREATMENT", 0, 19], ["nsp10", "TREATMENT", 21, 26], ["nsp16/nsp", "TREATMENT", 31, 40], ["a solution of 150 \u00b5M SAM", "TREATMENT", 98, 122], ["the injection syringe", "TREATMENT", 137, 158]]], ["The first injection (5 \u00b5L) was followed by 29 injections of 10 \u00b5L.", [["The first injection", "TREATMENT", 0, 19]]], ["Dilution heats of SAM were measured by injecting SAM solution into buffer alone and were subtracted from the experimental curves prior to data analysis.Isothermal Titration Calorimetry ::: Materials and MethodsThe interaction of nsp16, nsp10, and nsp16/nsp10 complex of SARS-CoV with m7GpppA-capped RNA in the absence of DTT were carried out at 25\u00b0C using an ITC200 titration calorimeter (MicroCal, Northampton, MA), which has higher sensitivity than the equipment adopted for analyzing protein-SAM binding as described above.", [["SAM", "CHEMICAL", 49, 52], ["DTT", "CHEMICAL", 321, 324], ["SAM", "SIMPLE_CHEMICAL", 18, 21], ["nsp16", "GENE_OR_GENE_PRODUCT", 229, 234], ["nsp10", "GENE_OR_GENE_PRODUCT", 236, 241], ["nsp16", "GENE_OR_GENE_PRODUCT", 247, 252], ["nsp10", "GENE_OR_GENE_PRODUCT", 253, 258], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 270, 278], ["m7GpppA", "GENE_OR_GENE_PRODUCT", 284, 291], ["DTT", "SIMPLE_CHEMICAL", 321, 324], ["nsp16", "PROTEIN", 229, 234], ["nsp10", "PROTEIN", 236, 241], ["nsp16", "PROTEIN", 247, 252], ["nsp10 complex", "PROTEIN", 253, 266], ["m7GpppA", "PROTEIN", 284, 291], ["capped RNA", "RNA", 292, 302], ["SARS-CoV", "SPECIES", 270, 278], ["Dilution heats of SAM", "TREATMENT", 0, 21], ["data analysis", "TEST", 138, 151], ["Isothermal Titration Calorimetry", "TREATMENT", 152, 184], ["nsp16", "TEST", 229, 234], ["nsp10", "TEST", 236, 241], ["nsp16", "TEST", 247, 252], ["SARS", "PROBLEM", 270, 274], ["m7GpppA-capped RNA", "TREATMENT", 284, 302], ["DTT", "TEST", 321, 324], ["an ITC200 titration calorimeter", "TREATMENT", 356, 387], ["the equipment", "TREATMENT", 451, 464], ["analyzing protein-SAM binding", "PROBLEM", 477, 506], ["SAM binding", "OBSERVATION", 495, 506]]], ["A solution of m7GpppA-capped RNA (7 \u00b5M) was loaded into the sample cell (500 \u00b5L), and a solution of 100 \u00b5M purified proteins were placed in the injection syringe (40 \u00b5L).", [["sample cell", "ANATOMY", 60, 71], ["m7GpppA", "CHEMICAL", 14, 21], ["m7GpppA", "SIMPLE_CHEMICAL", 14, 21], ["cell", "CELL", 67, 71], ["m7GpppA", "PROTEIN", 14, 21], ["A solution of m7GpppA-capped RNA (7 \u00b5M)", "TREATMENT", 0, 39], ["a solution of 100 \u00b5M purified proteins", "TREATMENT", 86, 124], ["the injection syringe", "TREATMENT", 140, 161]]], ["Dilution heats of purified proteins were measured by injecting purified proteins solution into buffer alone and were subtracted from the experimental curves prior to data analysis.Isothermal Titration Calorimetry ::: Materials and MethodsThe resulting data were fitted to a single set of identical sites model using MicroCal ORIGIN software supplied with the instrument, and the binding stoichiometry, N, the standard molar enthalpy change for the binding, , and the dissociation constant, Kd, were thus obtained.", [["purified proteins", "PROTEIN", 18, 35], ["Dilution heats of purified proteins", "TREATMENT", 0, 35], ["purified proteins solution", "TREATMENT", 63, 89], ["the experimental curves", "TEST", 133, 156], ["data analysis", "TEST", 166, 179], ["the binding stoichiometry", "TEST", 375, 400], ["the standard molar enthalpy change", "TREATMENT", 405, 439], ["molar enthalpy", "OBSERVATION", 418, 432]]], ["The standard molar free energy change, , and the standard molar entropy change, , for the binding reaction were calculated by the fundamental equations of thermodynamics: = ; = (-)/T.Accession numbers ::: Materials and MethodsThe GenBank accession numbers for genes and proteins mentioned in the text are as follow: SARS coronavirus nsp3 unique domain (SUD), JN247391; SARS coronavirus nonstructural protein nsp5, JN247392; SARS coronavirus nonstructural protein nsp10, JN247393; SARS coronavirus nsp10-nsp11 fusion protein, JN247394; SARS coronavirus nsp12 N-terminal domain (nsp12N), JN247395; SARS coronavirus nonstructural protein nsp14, JN247396; SARS coronavirus nonstructural protein nsp16, JN247397.", [["SARS coronavirus", "ORGANISM", 369, 385], ["nsp5", "GENE_OR_GENE_PRODUCT", 408, 412], ["SARS coronavirus", "ORGANISM", 424, 440], ["nsp10", "GENE_OR_GENE_PRODUCT", 463, 468], ["SARS coronavirus", "ORGANISM", 480, 496], ["nsp10", "GENE_OR_GENE_PRODUCT", 497, 502], ["nsp11", "GENE_OR_GENE_PRODUCT", 503, 508], ["nsp12N", "GENE_OR_GENE_PRODUCT", 577, 583], ["SARS coronavirus", "ORGANISM", 596, 612], ["nsp14", "GENE_OR_GENE_PRODUCT", 635, 640], ["SARS coronavirus", "ORGANISM", 652, 668], ["SARS coronavirus nsp3 unique domain", "PROTEIN", 316, 351], ["SUD", "PROTEIN", 353, 356], ["SARS coronavirus nonstructural protein nsp5", "PROTEIN", 369, 412], ["JN247392", "PROTEIN", 414, 422], ["SARS coronavirus nonstructural protein", "PROTEIN", 424, 462], ["nsp10", "PROTEIN", 463, 468], ["JN247393", "PROTEIN", 470, 478], ["SARS coronavirus nsp10-nsp11 fusion protein", "PROTEIN", 480, 523], ["JN247394", "PROTEIN", 525, 533], ["SARS coronavirus nsp12 N-terminal domain", "PROTEIN", 535, 575], ["nsp12N", "PROTEIN", 577, 583], ["JN247395", "PROTEIN", 586, 594], ["SARS coronavirus nonstructural protein", "PROTEIN", 596, 634], ["nsp14", "PROTEIN", 635, 640], ["JN247396", "PROTEIN", 642, 650], ["SARS coronavirus nonstructural protein", "PROTEIN", 652, 690], ["nsp16", "PROTEIN", 691, 696], ["JN247397", "PROTEIN", 698, 706], ["coronavirus", "SPECIES", 374, 385], ["coronavirus", "SPECIES", 429, 440], ["coronavirus", "SPECIES", 485, 496], ["coronavirus", "SPECIES", 540, 551], ["coronavirus", "SPECIES", 601, 612], ["coronavirus", "SPECIES", 657, 668], ["SARS coronavirus", "SPECIES", 316, 332], ["SARS coronavirus", "SPECIES", 369, 385], ["SARS coronavirus", "SPECIES", 424, 440], ["SARS coronavirus", "SPECIES", 480, 496], ["SARS coronavirus", "SPECIES", 535, 551], ["SARS coronavirus", "SPECIES", 596, 612], ["SARS coronavirus", "SPECIES", 652, 668], ["The standard molar free energy change", "PROBLEM", 0, 37], ["the standard molar entropy change", "TREATMENT", 45, 78], ["the binding reaction", "PROBLEM", 86, 106], ["genes and proteins", "PROBLEM", 260, 278], ["SARS coronavirus nonstructural protein", "TEST", 369, 407], ["nsp5", "TEST", 408, 412], ["JN247392", "TEST", 414, 422], ["SARS coronavirus", "TEST", 424, 440], ["nonstructural protein", "TEST", 441, 462], ["nsp10", "TEST", 463, 468], ["JN247393", "TEST", 470, 478], ["SARS coronavirus", "TEST", 480, 496], ["nsp10", "TEST", 497, 502], ["fusion protein", "TEST", 509, 523], ["JN247394", "TEST", 525, 533], ["SARS coronavirus nsp", "TEST", 535, 555], ["N-terminal domain", "TEST", 558, 575], ["nsp12N", "TEST", 577, 583], ["SARS coronavirus nonstructural protein nsp14", "TEST", 596, 640], ["JN247396", "TEST", 642, 650], ["SARS coronavirus nonstructural protein nsp16", "TEST", 652, 696], ["molar", "OBSERVATION_MODIFIER", 13, 18], ["free", "OBSERVATION_MODIFIER", 19, 23], ["energy change", "OBSERVATION", 24, 37]]]]}